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SUMMARY 
 
Prostate carcinoma (PCa) is the most incident neoplasia in men and the second 
leading cancer-related cause of death. PCa is a heterogeneous disease and current 
therapeutic strategies are dependent on TNM staging, Gleason scoring, PSA levels and 
overall health status. Primary treatment consists mainly of radical prostatectomy and/or 
radiation therapy, which may be supplemented with androgen ablation. Although many 
patients are identified with local, surgically curable, disease, there is a subset of patients 
that progress or show metastatic prostate cancer, where the gold standard therapy is 
androgen ablation. Moreover, recurrence is frequent, and many patients develop 
metastatic disease, for which chemotherapy is only moderately effective. A better 
understanding of the genetics and molecular pathways involved in prostate 
carcinogenesis should contribute to the current challenge of identifying promising 
molecular targets involved in PCa progression.  
Genomic rearrangements involving members of the ETS family of transcription 
factors are recurrently found in PCa, with ERG and ETV1 being reported in 50% and 10% 
of the cases, respectively. These aberrant alterations are also present in precursor lesions 
of PCa, suggesting a role in the early events that ultimately led to a prostate carcinoma. 
ETS members have generally been associated with the regulation of cell growth, 
proliferation, differentiation, and apoptosis, through activation or repression of target 
genes. Therapeutic targeting of ETS and other transcription factors has been challenging 
due to their nuclear localization and molecular embedding in DNA–protein and protein–
protein complexes. Consequently, it has been of utmost importance to identify and to 
characterize the downstream molecular targets of ETS rearrangements, as some of them 
could potentially be more amenable to targeted therapy. 
In a previous work, using a genome-wide scale and exon-level expression 
microarray platform on a clinical series of PCa enriched for ERG and ETV1 
rearrangements, we have shown that ERG and ETV1 regulate both specific and shared 
target genes in PCa. Our group reported a list of 27 target genes shared by ERG and 
ETV1 rearrangements. Our results, using VCaP and LNCaP knockdown cell line models, 
clearly validate KCNH8, TMEM45B and GRPR as downstream targets of both ERG and 
ETV1, as also indicated by our demonstration of direct binding of ERG to the promoter of 
these genes using ERG-immunoprecipitated chromatin from VCaP cells. GRPR encodes 
the gastrin-releasing peptide receptor and has been described as overexpressed in 
several cancer types, including PCa. Considering the overexpression of GRPR in a high 
proportion of PCa that harbor either ERG or ETV1 rearrangements, the cellular 
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localization of its protein product, the relevance of its function, the availability of blocking 
agents, and the several previous reports on its oncogenic activity, makes it a promising 
therapeutic target for these particular molecular subtypes of PCa. 
In Paper I, we have shown that effective knockdown of GRPR in LNCaP and VCaP 
cells attenuates their malignant phenotype by decreasing proliferation, invasion and 
anchorage-independent growth, while increasing apoptosis. Besides validating GRPR as 
a potential target gene of both ERG and ETV1 transcription factors, our data revealed the 
activation of different intermediate players of GRPR/ETS in in vitro-mediated 
proliferation/apoptosis and invasion/ anchorage-independent growth, associated with 
disease aggressiveness. Considering what is known concerning the activity of these 
intermediates and the data shown here, we propose a model for GRPR signaling under an 
ETS-rearrangement cellular context, where TYK2, MST1 and p-Akt may constitute 
promising therapeutic targets that should be explored in combination with GRPR inhibitors 
for treating this particular subtype of prostate cancer.  
TYK2 overexpression has been observed in several malignancies including breast 
cancer cell lines, prostate cancer and squamous cervical carcinomas (Übel et al. 2013) 
and some studies have described the involvement of this tyrosine kinase in mediating 
prostate cancer invasion. Considering the oncogenic role of TYK2 in prostate 
carcinogenesis and its overexpression in tumors harboring ETS rearrangements, a 
combined therapy of a GRPR antagonist and a TYK2 inhibitor in prostate carcinomas with 
ETS rearrangements was evaluated in Paper II. Our data provides further evidence to 
sustain a therapeutic effect of dual GRPR/TYK2 blockade in prostate carcinogenesis, 
since in vitro treatment with GRPR antagonist in combination with a tyrosine kinase 
inhibitor targeting TYK2, drastically reduces the tumorigenic behavior of LNCaP and 
VCaP cell lines. Additional in vitro and in vivo ongoing studies will be crucial to further test 
the possible therapeutic potential of dual GRPR/TYK2 blockade in the molecular PCa 
subtype characterized by rearrangements of the ETS transcription factors.  
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RESUMO 
 
Os carcinomas da próstata (PCa) são uma das neoplasias mais incidentes em 
homens e a segunda causa de morte relacionada com cancro. Os tumores da próstata 
são bastante heterogéneos e a terapia utilizada actualmente depende do estadio TMN, 
do score de Gleason, dos níveis de PSA no sangue e do estado de saúde em geral. O 
tratamento primário neste tipo de neoplasias é a prostatectomia radical e/ou radioterapia, 
eventualmente suplementada com ablação androgénica.  
A maioria dos pacientes apresentam doença localizada potencialmente curável 
através de cirurgia, mas existe um subgrupo de pacientes cuja doença progride ou que 
apresentam metastização. Adicionalmente, a recorrência de doenca é frequente e muitos 
doentes desenvolvem doença metastática, para a qual o tratamento por quimioterapia é 
apenas moderadamente eficaz. O estudo e compreensão da genética e das vias 
moleculares envolvidas na carcinógenese da prostata poderá contribuir para a 
identificação de alvos moleculares involvidos na progressão do PCa. 
Rearranjos genómicos envolvendo membros da família dos factores de 
transcrição ETS são frequentemente observados em PCa, com maior frequência para os 
genes ERG e ETV1 (50% e 10% dos casos, respectivamente). Estas alterações foram 
também identificadas em lesões precursoras de PCa, sugerindo um papel como eventos 
iniciais da carcinógenese prostática. Os membros da família ETS têm vindo a ser 
associados com a regulação do crescimento celular, da proliferação, da diferenciação e 
da apoptose através da activação e repressão de genes alvo. Contudo, a terapia dirigida 
aos ETS e a outros factores de transcrição tem vindo a ser um desafio devido à sua 
localização nuclear e aos complexos DNA-proteína e proteína-proteína. 
Consequentemente, é de extrema importância identificar e caracterizar alvos moleculares 
dos rearranjos ETS que poderão ser alvos de terapia dirigida. 
Num estudo prévio, utilizando uma plataforma de microarrays de expressão génica 
e exónica global numa série clínica de PCa enriquecida para casos com presença de 
rearranjos ERG e ETV1, demonstramos que os genes ERG e ETV1 regulam genes alvo 
quer específicos, quer comuns. O nosso grupo descreveu uma lista de 27 genes-alvo 
partilhados em casos de rearranjos ERG ou ETV1. Os nossos resultados utilizando linhas 
celulares VCaP and LNCaP silenciadas para os ETS em questão validaram os genes 
KCNH8, TMEM45B e GRPR como alvos do ERG e ETV1, tal como demonstrado pela 
ligação directa do ERG ao promotor desses genes utilizando immunoprecipitação da 
cromatina para o ERG em células VCaP. O gene GRPR codifica o receptor do péptido 
libertador de gastrina e tem sido descrito como sobrexpresso em diversos tumores, entre 
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os quais PCa. A sobrexpressão de GRPR numa grande proporção de PCa com 
rearranjos do ERG ou ETV1, a localização celular do seu produto protéico, a relevância 
da sua função, a disponibilidade de fármacos antagonistas e diversos trabalhos 
demonstrando a sua actividade oncogénica, torna este receptor um promissor alvo 
terapêutico neste subgrupo particular de PCa. 
Na publicaçao I, demonstrámos que o silenciamento do gene GRPR nas linhas 
celulares LNCaP e VCaP atenua o seu fenótipo maligno através da diminuição da 
proliferação, invasão e crescimento independente de ancoragem, e do aumento dos 
níveis de apoptose. Para além de validarmos o gene GRPR como potencial alvo 
terapêutico de ambos os factores de transcriçao ERG e ETV1, os nosos resultados 
revelaram a activação de diferentes intermediários da proliferação/apoptose e invasão/ 
crescimento independente de ancoragem mediado pela sinalização GRPR/ETS in vitro. 
Considerando aquilo que estava descrito na literatura relativamente à actividade destes 
intermediários, propomos um modelo de sinalização celular desencadeado pelo GRPR no 
contexto ETS, onde TYK2, MST1 e p-Akt poderão constituir promissores alvos 
terapêuticos que deverão ser explorados em combinação com inibidores GRPR para o 
tratamento deste subgrupo particular de PCa.  
A sobreexpressão de TYK2 tem vindo a ser observada em diversas neoplasias, 
incluindo linhas celulares de cancro da mama, PCa e carcinomas cervicais escamosos, e 
alguns estudos descrevem o seu envolvimento na mediação da invasão de PCa. Deste 
modo, e considerando  o papel oncogénico de TYK2 na carcinógenese prostática e a sua 
sobrexpressão em tumores com rearranjos ETS, foi avaliado na publicação II uma 
terapia combinada de um antagonista GRPR e de um inibidor TYK2 em PCa com 
rearranjos ETS. Os nossos dados revelaram o efeito terapêutico do duplo bloqueio 
GRPR/TYK2 na carcinógenese prostática, onde o tratamento com um antagonista do 
GRPR em combinação com um inibidor do TYK2 levou à diminuição drástica das 
características tumorigénicas das linhas celulares LNCaP e VCaP. Estudos adicionais in 
vitro e in vivo em curso serão cruciais para melhor avaliar o potencial terapêutico da 
dupla inibição GRPR/TYK2 no subtipo molecular de PCa caracterizado por rearranjos dos 
factores de transcrição ETS. 
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1. ANATOMY OF THE PROSTATE GLAND 
 
The prostate gland is an exocrine walnut-shaped organ of the male reproductive 
system, whose main function is to secrete a thin, slightly alkaline fluid that forms a portion 
of the seminal fluid (DeVita et al. 2008, Shen and Abate-Shen 2010). The prostate is 
enclosed by a capsule composed of collagen, elastin and large amounts of smooth 
muscle and it is located in the pelvic region, posterior to the lower portion of the 
symphysis pubis superior to the perineal membrane, anterior to the rectum, inferior to the 
urinary bladder and surrounding the urethra (DeVita et al. 2008, Bhavsar and Verma 
2014). In normal adult it reaches approximately 25 cm3 and weights about 20g (DeVita et 
al. 2008, Hricak and Scardino 2009). 
In 1969, McNeal proposed that the prostate gland was composed by four zones: 
peripheral, central, transition and the anterior fibromuscular stroma (AFMS) (Figure 1) 
(McNeal 1981, Hricak and Scardino 2009, Shen and Abate-Shen 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Zonal anatomy of the normal prostate as described by McNeal (McNeal 1988). 
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The peripheral zone is the one closest to rectum, comprises 70% of the organ, has a 
mesodermal origin and consists of the area palpable by digital rectal examination (DRE). 
About 70% of adenocarcinomas occur in this zone and chronic prostatitis and 
postinflammatory atrophy are also more common than in the other zones. The central 
zone is a cone shaped region that surrounds the ejaculatory ducts, comprises about 25% 
of the glandular tissue and only 1-5% of prostate carcinomas occur in this region. The 
transition zone has an endodermal origin that forms only 5-10% of the glandular tissue, 
and consists of two equal lobules that surround the urethra. Age-related benign prostatic 
hyperplasia (BPH) is frequently limited to this specific region and only 15% of prostate 
cancer arises from this zone. The AFMS is an anterior band composed mostly by striated 
muscle, contiguous to the bladder smooth muscle and external sphincter (DeVita et al. 
2008, Hricak and Scardino 2009). 
Histologically, the architecture of the prostate looks like a branched duct gland, each 
containing two cell layers, a luminal secretory columnar and an underlying basal cell layer. 
Additionally, rare neuroendocrine cells are observable in normal epithelium of prostate 
glands (DeVita et al. 2008, Hricak and Scardino 2009). 
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2. PROSTATE GLAND PATHOLOGY 
 
Prostate disorders are very diverse and include benign, pre-malignant and 
malignant conditions. These disorders have become a huge health concern in an aging 
world population, as they are commonly associated with increased age.  
 
2.1 BENIGN PROSTATIC HYPERPLASIA 
 
Benign prostatic hyperplasia (BPH) is one of the most common urological diseases 
in aging men, affecting around 50% of men over 50 years old (Alcaraz et al. 2009). Nearly 
90% of 80-year-old men will have histologic BPH (Bushman 2009) and about half of these 
men will develop prostatic enlargement, although this lesion is not considered to be a 
precursor of prostate cancer (Kristal 2010). BPH is characterized by a hyperplastic growth 
of epithelial and stromal cells in the prostate and occurs more frequently at the transition 
region (Hricak and Scardino 2009, Timms and Hofkamp 2011). 
 
2.2 PRE-MALIGNANT LESIONS 
 
Individuals with pre-malignant lesions present an increased risk to developed cancer 
when compared to the general population (Berney and Warren 2013). Prostatic 
intraepithelial neoplasia (PIN) is a neoplastic proliferation of the prostatic acinar cells, 
confined by the basement membrane and without invasion of the stroma (Epstein 2009, 
Berney and Warren 2013). Histologically, PIN is divided in low- and high-grade PIN 
(HGPIN), but only the last one is considered a precursor of invasive carcinomas (Epstein 
2009).  HGPIN lesions present higher levels of cellular proliferation markers and 
prominent nucleoli, which it is related with its ability to progress towards a prostate 
carcinoma. HGPIN and prostate carcinomas are both multifocal and heterogeneous, and 
there are several other features in common between both lesions: firstly, the 
epidemiologic evidence, since prostate cancer and HGPIN undergo parallel increase with 
age; topographic proximity of both lesions has been observed in about 70% of the cases; 
morphologic similarities have been described in both lesions (progressive loss of basal 
cells, atypia with increased size and nuclear irregularity) and also some genetic alterations 
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(gain or loss of specific chromosomes and expression of α-methylacel-CoA racemase 
(AMACR)) (Ramon and Denis 2007, Tewari 2013). The earliest evidence of carcinoma is 
typically an early stromal invasion, and this step occurs at sites of acinar outpouching and 
basal cell disruption in acini with PIN. This microinvasion is present in about 2% of high-
power microscopic fields of PIN, with equal distribution between all architectural patterns. 
Several studies have evaluated the predictive value of HGPIN for prostate cancer, 
concluding that HGPIN provides a higher significant risk ratio. In the era of sextant-biopy, 
has been reported a 30.2% risk of cancer in the following biopsy after one or two cores 
diagnosed with HGPIN, 40% with three cores and 75% with more than three cores (Kronz 
et al. 2001). However, in an initial 11-13 core biopsy scheme, the presence of HGPIN by 
itself is no longer an indication to repeat biopsy, as the risk of cancer in the following 
biopsy is reduced to 22% (Karakiewicz et al. 2005). 
Proliferative inflammatory atrophy (PIA) is morphologically characterized by 
glandular atrophy associated with glandular proliferation and chronic inflammatory cells, 
whose epithelial cells are intermediate between the basal and secretory cell phenotype 
(Tewari 2013). Recent studies have described that PIA is heterogeneous and subsets are 
histologically definable (DeVita et al. 2008). Proliferative inflammatory atrophy (PIA) has 
been suggested as a precursor of HGPIN, due to identification of the same genetic and 
morphologic changes among them, although its potential premalignant role is 
controversial and has yet not been fully defined (Ramon and Denis 2007). Contrarily, PIA 
is common throughout the entire prostate gland and is also present in young adults, 
whereas HGPIN and prostate carcinomas develop predominantly in the peripheral zones 
in older age groups (Tewari 2013). 
 Atypical small acinar proliferation (ASAP) is an area of glands that fulfill some of 
the cytological and architectural features of a carcinoma, although not all. This clinical 
finding typically occurs in just 5% of biopsies. Due to their similarities with prostate 
carcinomas, these lesions have been called as ―borderline for malignancy‖. Several 
studies have shown that the diagnosis of ASAP increases the risk for the later diagnosis 
of malignancy in about 35-45% (Tewari 2013, Dorin et al. 2015). Occasionally, prostate 
biopsies show both HGPIN and ASAPs, and these can happen in two distinct ways. First, 
the ASAP focus and the HGPIN are unrelated spatially, being detected in different 
biopsies or different parts of the same biopsy. Second, and the most studied entity, ASAP 
may be associated with HGPIN, frequently called PINATYP or PIN/ASAP. There are a few 
studies on PINATYP prognosis, all pointing to a higher risk of a subsequent diagnosis of 
malignant lesion, equivalent or even higher than that observed when HGPIN or ASAP are 
identified alone (Kronz et al. 2001).  
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2.3 MALIGNANT LESIONS 
 
Prostate adenocarcinoma comprises about 95% of prostatic malignant conditions. 
Other prostate malignant lesions include intralobular acinar carcinomas, ductal 
carcinomas, small cell or scirrhous pattern tumors, a rare clear cell variant resembling 
renal cell carcinomas, and mucinous carcinoma (DeVita et al. 2008). 
Prostate adenocarcinomas arise in acinar and proximal ductal epithelium. The 
peripheral zone of the prostate is affected in about 75% of cases, although transitional 
and central zone tumors occur as well in about 15% and 10% of patients, respectively 
(DeVita et al. 2008). The histopathologic diagnosis of adenocarcinoma is made on the 
basis of a combination of several histologic features (Tabela 1), grouped into primary 
(architecture of the glands) and secondary criteria (cytologic). Tertiary criteria are helpful 
and supportive of the diagnosis (Tewari 2013).  
 
Table 1 - Criteria for diagnosis of prostate cancer 
Primary criteria 
Architectural – diagnostic 
1. Small glands (microacini) 
2. Crowded glands 
3. Haphazardly arranged glands, not in lobules 
4. Fused glands 
5. Infiltrative pattern 
6. Small glands around/between benign glands 
7. Perineural invasion 
8. Mucinous fibroplasia 
9. Glomerulations 
Secondary criteria 
Cytologic – diagnostic 
7. Absence of basal cells 
8. Large nucleoli 
9. Large hyperchromatic nuclei, with an increased nucleus-cytoplasm ratio 
Terciary criteria 
Cytoplasmic/luminal – supportive 
1. Luminal blue mucin 
2. Luminal pink amorphous secretions 
3. Crystalloids 
4. Sharp/rigid luminal borders 
5. Amphophilic or foamy cytoplasm 
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Adenocarcinomas range from clinically indolent to extremely aggressive neoplasms 
(Hricak and Scardino 2009), and the high degree of PCa heterogeneity is potentially 
relevant to understand these different states. Although PCa is described as a disease of 
older men, studies of prostate specimens from healthy men with ages of 20 to 40 years, 
frequently showed presence of histologic foci of prostate cancer. This data suggests that 
cancer initiation has already taken place at a relatively early age (Shen and Abate-Shen 
2010). 
Multifocal adenocarcinoma of the prostate is present in more than 85% of the cases, 
which supports the idea that prostate gland can present multiple neoplastic transformation 
events, many of these giving rise to latent and clinically undetectable disease (Shen and 
Abate-Shen 2010). The basal cell layer is lost progressively from BPH, to HGPIN and 
finally PCa, suggesting a relationship between these lesions (Figure 2) (Chrisofos et al. 
2007, Shen and Abate-Shen 2010). Therefore, there is still a lot to be understood on how 
prostate cancer evolves and if this potential relationship presents a real chain of events. 
 
 
 
Figure 2. Progression pathway in prostate cancer (adapted from (Shen and Abate-Shen 
2010). 
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3. PROSTATE CANCER  
3.1 EPIDEMIOLOGY 
 
The incidence and mortality rate of prostate cancer varies worldwide. PCa is the 
thirst most common neoplasia among men, with 1,094,916 cases in the year 2012. This 
represents 14.8% of all cancer cases in men (68% in developed countries and 32% in 
developing countries) (Ferlay J 2012). Incidence rates vary by more than 25-fold 
worldwide, with the highest rates found in the developed countries of Oceania, Europe 
and North America (Jemal et al. 2011). Incidence variance could be explained by 
differences in age-structure between populations of different regions, since PCa is 
associated with advancing age. Other reasons for this difference are genetic susceptibility, 
exposure to unknown external risk factor or differences in the detection techniques 
implemented and screening programs, such as the prostate-specific antigen (PSA) test 
(Crawford 2003, Ramon and Denis 2007). PCa is a less prominent cause of death from 
cancer, counting 307,481 deaths in 2012 (6.6% of cancer deaths in men) (Ferlay J 2012). 
Associated with the high incidence rate and relatively low mortality rate, PCa became the 
most prevalent form of cancer in men. Likewise, prostate cancer mortality varies 
worldwide, with highest rates in Caribbean and Scandinavia and the lowest in China, 
Japan and countries of the former Soviet Union. Again, this difference probably occurs 
due to different age-structure in populations from these countries or genetic susceptibility 
(Jemal et al. 2011) (Figure 3). 
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Figure 3. International variation in age-standardized prostate cancer incidence (a) and 
mortality (b) rates by world area (adapted from GLOBOCAN 2012). Rate per 100000. 
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Among European men, PCa is the second most incident neoplasm and is the fourth 
leading cause of cancer-related death. In Portugal, 6,622 new PCa patients were 
diagnosed in 2012, being the second most frequent neoplasia detected among men 
(23.3% of total) and ranking fourth in cancer mortality (11.1% of total cancer cases) 
(Figure 4)(Ferlay J 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cancer incidence in Europe and Portugal in males (adapted from Globocan 
2012). 
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3.2 RISK FACTORS 
 
PCa risk has been related to several factors including diet, environmental exposures 
and obesity. However, there are only three well-established risk factors for this particular 
cancer: family history, ethnicity and age. 
Family history of PCa increases risk of developing the disease. Indeed, having a first 
degree relative affected by PCa more than doubles the risk of developing this malignant 
disease, and the risk is much higher for men with several affected relatives (Brawley 
2012, Albright et al. 2015). This could be explained not only by genetic predisposition, but 
also by the exposure to the same environmental factor within a family (Brawley 2012). 
Other well-established risk factor is race, as it has been observed an unbalanced 
incidence between ethnic groups. When compared with Caucasians, African American 
men have higher incidence and, besides being diagnosed earlier, have higher tumor 
burdens within each stage category, a 1.5-fold higher frequency of metastatic disease at 
presentation, and lower survival rates (Chornokur et al. 2011, Siegel et al. 2015). Asians 
have lower prostate cancer incidence rates both in the United States and in Asia (DeVita 
et al. 2008). It is uncertain why some populations have higher incidence than others, 
although genetic susceptibility, exposure to environmental factors, culture and 
socioeconomic differences may play a role in this observation (Brawley 2012). 
Age is the most important risk factor for PCa incidence and mortality. It is well 
established that PCa is age-related. Indeed, PCa rarely occurs until the age of 49, but the 
incidence rate increases thereafter. Men with up 49 years of age have a probability of 
developing PCa of 0.3% (1 in 304), but this probability increases to 2.3% (1 in 44) for men 
with 50 to 59, 6.3% (1 in 16) for men with 60 to 69 and 10.9% (1 in 9) for men who are 70 
years old or older (Siegel et al. 2015). 
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4. DIAGNOSIS OF PROSTATE CANCER 
 
PCa is normally asymptomatic until invasion occurs, at which point curative therapy 
is unusual, demanding the need for implementation of screening methods on a population 
basis. Several studies have concluded that there is no evidence for introducing 
widespread screening for PCa (Ilic et al. 2013). However, early detection should be 
offered to well-informed men (Heidenreich et al. 2014). Diagnostic tools to diagnose PCa 
include digital rectal examination (DRE), serum concentration of PSA, and transrectal 
ultrasound (TRUS)–guided biopsies. 
 
4.1 DIGITAL RECTAL EXAMINATION  
 
DRE is critical to establish the clinical stage of PCa. In fact, this exam provides 
information about location, size, and extent of the primary cancer and is essential for 
prognostic and treatment planning. The sensitivity of DRE for PCa diagnosis depend both 
on the stage of the tumor and the experience of the examiner. While DRE is of limited 
value in detecting tumors confined to the prostate gland, it remains a useful adjunct to 
PSA testing to identify higher-risk cancer when PSA levels are low (Tewari 2013). In fact, 
twenty percent (20%) of tumors detected by DRE when the PSA is less than 2 ng/ml are 
not organ confined (Okotie et al. 2007).  
 
4.2 PROSTATE-SPECIFIC ANTIGEN  
 
PSA screening test was first implemented in 1987 and in subsequent years 
incidence rates raised significantly in the United States (Barry 2001). PSA is a 
glycoprotein with protease activity produced by epithelial cells surrounding prostate acini 
and ducts. This protein is secreted in the lumina of these ducts and is normally present in 
low concentration in the plasma but in some prostate disorders, such as inflammation, 
HBP or cancer, its concentration increases (Ramon and Denis 2007). PSA expression is 
prostate specific rather than prostate cancer specific, which makes it a test with reduced 
accuracy (Crawford 2003). Nevertheless, the PSA test has been an outstanding help for 
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PCa management by clinicians, although its nonspecificity has led to overdiagnosis and 
overtreatment of indolent tumors (Duffy 2011). 
Conventionally, a patient with PSA above 4 ng/ml is purposed to have a prostate 
biopsy, since approximately 70% of cancers will be detected using this cutoff (Catalona et 
al. 1994). About 30% of men with PSA in the range of 4–10 ng/ml will have PCa on biopsy 
(Gann et al. 1995), but it has been reported a high prevalence of PCa among men with a 
PSA ≤4 ng/ml and that at these PSA levels several men can harbor clinically significant 
disease. Indeed, in men with PSA test between 3.1-4.0 ng/ml, 26.9% had PCa and of 
these 25% were high-grade tumors (Thompson et al. 2004). 
To improve the specificity of PSA in early detection of PCa, several modifications of 
serum PSA value have been described, including PSA density, PSA density of the 
transition zone, age-specific reference ranges, and PSA molecular forms (Heidenreich et 
al. 2014). 
Screening for prostate cancer is primarily performed using DRE and PSA test, yet 
the specificity and sensitivity of both of these modalities are not ideal (Holmström et al. 
2009). However, DRE and PSA together as early detection tools have allowed diminishing 
stage at detection in recent years, as 70-80% of PCa now diagnosed are organ confined 
and with increased chances of cure (DeVita et al. 2008). According to international 
guidance, screening must start at age of 50 and it must be regular throughout the years 
until the seventh decade of life (Wolf et al. 2010). 
 
4.3 TRANSRECTAL ULTRASONOGRAPHY  
 
The transrectal ultrasound probe was introduced by Watanabe and colleagues in 
1968 and the first report of the diagnostic procedure were led by Holm and Gammelgard 
in 1981 (Tewari 2013). Transrectal ultrasonography (TRUS) has become the standard 
imaging tool used by urologists to assess the prostate and assist guidance of needles for 
directed tissue biopsies to obtain material for histopathologic examination. Patients with 
high levels of PSA and/or an inconclusive and suspicious DRE are submitted to TRUS, to 
determine presence of PCa. The number of collected cores must be adapted depending 
on patient’s age, PSA level and prostate volume. European guidelines suggest that in a 
30-40 mg organ, eight cores must be obtained at least (Heidenreich et al. 2014). Patient 
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age, potential comorbidities, and the therapeutic consequences should also be considered 
(Heidenreich et al. 2014). 
TRUS is also useful in assessing prostate volume and calculating PSA density. 
Limitations of this imaging modality include the difficulty to characterize the integrity of 
prostatic capsule and to visualize early extra capsular extension or seminal vesicle 
involvement (DeVita et al. 2008).  
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5. GRADING AND STAGING OF PROSTATE ADENOCARCINOMAS  
 
5.1 HISTOLOGICAL GRADING: GLEASON SCORE 
 
Histological grading has been proven to be one of the main predictors of prostate 
adenocarcinomas outcome. Gleason grading was firstly developed in 1966 by Donald 
Gleason and his colleagues, and has recently been updated to meet the needs of daily 
diagnostic practice (Lotan and Epstein 2010). Gleason grading score has become the 
strongest prognostic factor for clinical behavior and treatment response, including 
recurrence risk after radical prostatectomy or radiotherapy. The Gleason grading system 
is based entirely on the histological pattern evaluated at low magnification in H&E-stained 
prostatic tissue sections. This grading system is based on the degree of differentiation of 
the two most common patterns (Figure 5). The grade of the most common pattern is 
added to the grade of the second most common pattern (both ranging from 1 to 5) with 
pattern 1 being the most differentiated and 5 the most poorly differentiated. The sum of 
the primary and secondary patterns is called Gleason score (GS), ranging from 2 to 10 
(Ramon and Denis 2007, DeVita et al. 2008). The Gleason score is reported with both 
primary and secondary patterns. The 2005 ISUP consensus update also demands that if a 
tertiary pattern 5 is observed on needle biopsy, it should be reported in place of the 
secondary pattern, to reflect the prognostic impact of Gleason pattern 5 adenocarcinoma 
and the uncertainty about possible sampling error. An example, a positive core with 
Gleason patterns 4 + 3 and tertiary pattern 5 on needle biopsy, should be diagnosed as 
GS 9 (4 + 5). However, in prostatectomies, when the entire carcinoma is available, the 
consensus is to grade such tumor as Gleason score 7 (4 + 3) and include additionally the 
tertiary pattern 5 (Epstein 2010). 
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2005 ISUP Modified Gleason System 
Gleason pattern 1  
- Completely circumscribed nodule of tightly 
packed but separate, uniform, rounded to oval, 
medium-sized acini 
Gleason pattern 2  
- Circumscribed nodule of small acini, with some 
variation in size, which are less tightly packed 
than in pattern 1 and may show minimal 
peripheral invasion into stroma but never into 
benign lobules  
Gleason pattern 3  
- Discrete glandular units, frequently with irregular 
contours 
- Infiltrates in and amongst non-neoplastic prostate 
acini 
- Marked variation in size and shape. 
- Smoothy circumscribe small cribiform nodules of 
tumor 
Gleason pattern 4  
- Fused microacinar glands  
- Ill-defined glands with poorly formed glandular 
lumina 
- Cribriform glands with na irregular border 
- Hypernephromatoid 
Gleason pattern 5  
- Glandular architecture is completely lost, 
composed of  single cells, cords or solid sheets 
- Comedocarcinoma with central necrosis 
surrounded by papillary, cribriform or solid 
masses 
 
 
Figure 5. Modified Gleason score system for histological grading of PCa (adapted from 
(Epstein et al. 2005). 
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5.2 TUMOR STAGING 
 
An accurate staging is critical for prognosis assessment and treatment planning for 
PCa. In the earlier 1950s, staging systems for solid tumors began to consider the tumor, 
lymph node and metastasis to categorize prognosis (Hricak and Scardino 2009). A unified 
TNM (tumor, lymph node, metastasis) staging system for prostatic carcinoma was first 
introduced only in 1992, by the American Joint Committee on Cancer (AJCC) and the 
International Union Against Cancer (UICC) (Cheng et al. 2012). Since them, several 
revisions have been undertaken to optimize the prognostic accuracy. At this time, the 
2010 TNM staging system revision of the AJCC/UICC is the most widely used.  
The TNM staging system consists on the evaluation of the extension of the primary 
tumor (T), presence and extension of involved lymph nodes (N) and distant metastases 
(M). Within each category of TNM, there are different sublevels (Table 2) based on tumor 
volume or extent (T1–T4), amount and/or size of lymph node metastases (N0–N1), and 
distant metastases (M0–M1) (Cheng et al. 2012). This system comprises two types of 
staging considering timing of data collection, namely clinical and pathological staging. 
Clinical staging reports to any information on cancer extension before definitive treatment 
and is established by DRE examination, TRUS, magnetic resonance imaging (MRI) and 
also serum PSA level (Falzarano and Magi-Galluzzi 2011). Pathologic staging is obtained 
after radical prostatectomy (RP) and is centered in macro and microscopic examination of 
the surgical specimen and dissected regional lymph nodes (Falzarano and Magi-Galluzzi 
2011, Cheng et al. 2012). Considering extent of disease outside the prostate, N-staging is 
assessed by pelvic lymphadenectomy, while M-staging is obtained by bone scan (Edge 
and Compton 2010). Agreement between clinical and pathological stages would simplify 
assessment of patient prognosis and guide appropriate therapy. However, clinical staging 
is an inaccurate tool to predict the final pathological stage (Cheng et al. 2012). 
Furthermore, over 80% of PCa are multifocal, which makes accurate clinical staging even 
more difficult and uncertain (Andreoiu and Cheng 2010). Clinical tumor understaging has 
consistently been shown to range from 40% to 60% (Campbell et al. 2001, Heidenreich et 
al. 2014). This is evidently associated to the multifocal and histologically heterogeneous 
nature of prostatic carcinomas. 
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Table 2. Clinical and pathologic classification of PCa by the The American Joint 
Committee on Cancer (adapted from (Cheng et al. 2012)). 
Primary Tumor – Clinical (T) 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1  Clinically inapparent tumor neither palpable nor visible by imaging 
T1a  Tumor incidental histologic finding in 5% or less of tissue resected 
T1b  Tumor incidental histologic finding in more than 5% of tissue resected 
T1c  Tumor identified by needle biopsy (e.g., because of elevated PSA) 
T2  Tumor confined within prostate* 
T2a  Tumor involves one-half of one lobe or less 
T2b  Tumor involves more than one-half of one lobe but not both lobes 
T2c  Tumor involves both lobes 
T3  Tumor extends through the prostate capsule 
T3a  Extracapsular extension (unilateral or bilateral) 
T3b  Tumor invades seminal vesicle(s) 
T4  Tumor is fixed or invades adjacent structures other than seminal 
vesicles such as external sphincter, rectum, bladder, levator muscles, 
and/or pelvic wall 
Primary Tumor - Pathologic (pT) 
pT2 Organ confined 
pT2a Unilateral, one-half of one side or less 
pT2b Unilateral, involving more than one-half of side but not both sides 
pT2c Bilateral disease 
pT3 Extraprostatic extension 
pT3a Extraprostatic extension or microscopic invasion of bladder neck 
pT3b Seminal vesicle invasion 
pT4 Invasion of rectum, levator muscles, and /or pelvic wall 
Regional Limph Nodes - Clinical (N) 
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Regional Limph Nodes - Pathologic (pN)  
pNX Regional nodes not sampled 
pN0 No positive regional nodes 
pN1 Metastases in regional node(s) 
Distant metastasis - Clinical (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Nonregional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
Distant metastasis - Pathologic (pM) 
pM0 No distant metastasis 
pM1 Distant metastasis 
pM1a Non-regional lymph node(s) 
pM1b Bone(s) 
pM1c 
 
Other site(s) with or without bone disease. When more than one site of 
metastasis is present, the most advanced category is used. pM1c is 
most advanced 
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6. TREATMENT OF PROSTATE CANCER 
 
Considering the complexity and heterogeneity of PCa, it is difficult to determine a 
standard treatment option for all patients. Selecting the optimal therapeutic approach from 
an array of choices requires individualization of treatment plans based on several 
features: age, life expectancy, life quality, TNM classification, GS and preoperative serum 
PSA level (Ramon and Denis 2007). For organ-confined PCa, the therapeutic options 
include active surveillance, radical prostatectomy (RP), and radiation therapy. For invasive 
or metastatic tumors, the options available include hormone and/or radiation therapy and 
chemotherapy. The present challenge is to distinguish men with aggressive local disease 
for whom treatment might be useful (DeVita et al. 2008). Concerning PCa therapeutic 
strategies, there is an urgent need to develop new and better therapeutic options. Thus, it 
is crucial to attend this goal by increasing knowledge on the biology of PCa 
carcinogenesis. 
 
6.1 ACTIVE SURVEILLANCE AND WATCHFUL WAITING 
 
Active surveillance is a strategy adopted for low-risk patients that includes active 
prostate cancer monitoring with scheduled attention to both local and PSA progression. 
With this option patients are not treated but kept under surveillance and treated only when 
risk of progression increases during follow-up (Heidenreich et al. 2014). This approach is 
a strategy to avoid overtreatment. Criteria to select PCa patients to this procedure are: 
clinically confined PCa, GS equal or less than 6 and low PSA serum level (less than 
10ng/mL) (Heidenreich et al. 2014). The follow-up of these patients consists in frequent 
PSA evaluation and prostatic biopsies at 2, 5 and 10 years (Ramon and Denis 2007). On 
the other hand, the watchful waiting is a less intensive type of follow-up that means fewer 
tests and relay more on changes in a man’s symtoms to decide if treatment is needed 
(Heidenreich et al. 2014) 
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6.2 RADICAL PROSTATECTOMY 
 
Radical prostatectomy (RP) is a surgical procedure that removes the entire prostate 
gland and both seminal vesicles and is frequently accompanied by bilateral pelvic lymph 
node dissection (Heidenreich and Pfister 2014). This treatment is offered to men with 
localized PCa (cT1a–T2b, Gleason score 2–7 and PSA inferior to 20 ng/mL), life 
expectancy of 10 or more years and its intent is to totally eradicate disease (Ramon and 
Denis 2007, Heidenreich and Pfister 2014).  
 
6.3 RADIOTHERAPY 
 
Radiation therapy has played a significant role in management of PCa over the 
years.  There are two main types of radiation therapy: external-beam radiotherapy and 
brachytherapy. Regarding efficiency in patient survival, radiation therapy has achieved 
rates of disease-free survival similar to those obtained by RP (Jani and Hellman 2003). 
External-beam radiotherapy (EBRT) is the procedure with lower morbidity rates, which 
enables its application to broad range of PCa patients, whom do not tolerate RP or 
brachytherapy (Jani and Hellman 2003). Brachytherapy consists in the placement of a 
small radioactive source into or near the tumor, allowing a more localized distribution of 
radiation and resulting in fewer side effects than external-beam radiotherapy (Jani and 
Hellman 2003). Brachytherapy is typically administrated in patients harboring localized 
PCa, with low-volume and low-grade (Jani and Hellman 2003). Moreover combined use of 
external-beam therapy and brachytherapy is frequent in patients with intermediate to high-
risk disease, leading to good survival rates (Ramon and Denis 2007). 
 
6.4 HORMONOTHERAPY 
 
The benefits of surgical castration and estrogen treatment on prostate size and 
symptoms in metastatic PCa were firstly reported in 1941 by Huggins and Hodges. These 
effects showed that PCa were androgen dependent (Hammerer and Madersbacher 2012), 
indeed, androgens are essential for the growth and perpetuation of tumor cells (Walsh 
1975). Prostate is a hormone-responsive gland and androgen deprivation can be 
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achieved by suppressing the secretion of testicular androgens by surgical (orchiectomy) 
or chemical castration (luteinizing hormone-releasing hormone (LHRH) agonists or 
antagonists) or by inhibiting its action using competing compounds at the level of their 
receptor (anti-androgens) (Hammerer and Madersbacher 2012). Thus, androgen ablation 
has been the first therapeutic approach for patients with advanced PCa. It has previously 
been demonstrated that hormonal therapy combined with external beam-radiotherapy 
administered to local PCa presents high cure rates (Jani and Hellman 2003). These 
therapeutic approaches achieve a symptom relief in 70-80% of patients, although virtually 
all the patients will develop castration-resistant PCa (CRPC) after 18 to 24 months of 
hormone treatment (Felici et al. 2012). 
 
6.5 CYTOTOXIC CHEMOTHERAPY 
 
Since 1990’s, the field of cytotoxic chemotherapy has significantly improved survival 
and life quality in patients with metastatic castration-resistant prostate cancer (mCRPC) 
and has become a standard of care in this disease (Sonpavde et al. 2014). In 1999, the 
combination of mitoxantrone and prednisone became the first line therapy to show clinical 
benefit in mCRPC (Tannock et al. 1996). Interestingly, it was approved based on palliative 
benefits, despite no improvement in overall survival. In 2004, a phase III trial showed that 
docetaxel, a taxane microtubule inhibitor, conferred a survival benefit in mCRPC and was 
approved for the first-line treatment of these PCa. Since 2010, multiple cytotoxic agents 
have been included to the chemotherapy resource, such as sipuleucel-T, cabazitaxel, 
abiraterone acetate plus prednisone and radium-223 (Kantoff et al. 2010, De Bono et al. 
2011, Cabot et al. 2012, Fizazi et al. 2012, Parker et al. 2013). There is no accepted 
standard sequence of cytotoxic agents and the choice is dependent of several patient 
characteristics, such as presence of symptoms, sites of metastasis, previous docetaxel 
exposure, comorbidities, patient preference, and the cost and availability of different 
treatments (Sonpavde et al. 2014).  
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7. GENETIC CHANGES IN PROSTATE CANCER 
 
Prostate carcinoma is a multifactorial disease influenced by both environmental and 
genetic factors. Besides advancing age and ethnic background, the strongest 
epidemiological risk factor for PCa is a positive family history. Over the past 20 years, 
much has been done in the field of gene abnormalities associated with prostate cancer 
risk, including familial aggregation studies, twin studies, family-based linkage studies, 
mutation screening and molecular epidemiological studies (Alberti 2010). The increasing 
knowledge in understanding the molecular basis of PCa will be crucial to establish 
efficient biomarkers for early detection, distinguish between indolent and aggressive PCa, 
and also to develop new and more effective therapies.  
 
7.1 GERMLINE MUTATIONS 
 
PCa can be divided into three groups: sporadic (up to 85%), hereditary (5%) and 
familial (10%) (Kral et al. 2011). Hereditary PCa has been defined as families that meet at 
least one of the following three criteria: three or more first-degree relatives affected with 
PCa in any nuclear family; occurrence of PCa in each of three successive generations in 
either of the proband’s paternal or maternal lineages; or at least two relatives, both 
affected with PCa diagnosed before age 55 (Carter et al. 1993). Cases that do not fulfill 
the reported criteria but have at least two affected relatives are defined as familial forms. 
The clinicopathologic characteristics and tumor progression features are similar between 
hereditary and sporadic PCa, except in the age at diagnosis that commonly arises 6 years 
earlier in hereditary PCa. Recent studies suggest that hereditary PCa is a complex 
disease, involving multiple susceptibility genes with variable phenotypic expression. 
Family-based studies have identified strong candidate susceptibility genes involved in the 
hereditary form of prostate cancer, including RNaseL, ElaC2, MSR1 and HOXB13 and 
additional weak candidate susceptibility loci have been suggested to be involved in 
hereditary PCa (Table 3). 
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Table 3. Genes involved in prostate cancer development 
Gene 
localization 
Candidate 
gene/locus 
Gene Function 
Strong candidates for susceptibility genes 
1q25.3 RNaseL/HPC1 Antiviral and pro-apoptotic 
17p11 ELaC2/HPC2 Induces tRNA maturation 
8p22-23 MSR1 Involved in arterial wall deposition of 
cholesterol and in endocytosis of low density 
lipoproteins 
17q21-23 HOXB13 Transcription factor  
Weak candidates for susceptibility genes (low-risk alleles) 
Xq27-28 HPCX  
20q13 HPC20  
17q21 BRCA1 Regulation of cell cycle progression and DNA 
repair 
13q12-13 BRCA2 DNA recombination and repair 
1q42-43 PCAP  
 
 
In 1996, the first prostate cancer susceptibility locus was identified. Termed HPC1 
locus and located in chromosome 1q24–25, it was subsequently identified as the RNaseL 
gene. RNaseL codifies an important enzyme in immune response to viral infection, 
induction of apoptosis and cell cycle, and cell differentiation regulation. Germ-line 
mutations in RNaseL gene have been reported in up to 13 % of all familial prostate cancer 
cases (Casey et al. 2002). 
Other strong candidate for susceptibility in PCa is the ELAC2 gene. This gene is 
located on 17p11 and codifies an essential enzyme for tRNA biosynthesis. Mutations in 
this gene increase 2%–5% the risk of PCa. However, germ-line HPC2/ELaC2 mutations 
are rare in hereditary prostate cancer, indicating that this gene plays a limited role in 
genetic susceptibility to this disease (Wang et al. 2001). 
The MSR1 gene has also been implicated as a candidate gene to hereditary 
prostate cancer. This gene is located at the 8p22 chromosome region and encodes the 
macrophage scavenger receptor type A, involved in several cell functions such as the 
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modulation of interaction between foreign cells and macrophages, cell adhesion and 
phagocytosis. Several studies have described MSR1 mutations linked to prostate cancer 
and, in fact, a specific region was characterized as linked to an increased risk of prostate 
cancer in Caucasian population (Xu et al. 2002, Beuten et al. 2010). 
Finally, HOXB13 encodes for an important transcription factor in prostate 
development. Recently, Ewing and collaborators identified a recurrent germ-line mutation 
(G84E) in HOXB13, in a previously recognized region of linkage at 17q21–22, as 
harboring an increased risk for familial prostate cancer (Ewing et al. 2012). Importantly, 
despite being a rare mutation in prostate cancer families (about 5%), HOXB13 G84E 
mutation is significantly associated with predisposition to PCa (Xu et al. 2013). 
 
7.2 EPIGENETIC CHANGES 
 
Epigenetics is defined as the study of mechanisms that initiate and maintain 
patterns of gene function and regulation in a heritable manner without affecting DNA 
sequence. Epigenetic alterations include: DNA methylation, histone modifications and 
non-coding RNAs, specially microRNAs (Sandoval and Esteller 2012). These alterations 
arise early and have been associated also with PCa progression. In addition, there are 
many studies describing the application of epigenetic alterations for biomarker 
development and also the developing of inhibitors to block epigenetic mechanisms of 
carcinogenesis. 
DNA methylation occurs by addition of a methyl group at the 5’ position of a cytosine 
ring inside CpG dinucleotides. Gene promoter regions are frequently enriched with CpG 
dinucleotides, and these stretches are commonly known as CpG islands (Jones 2012). 
GSTP1 is one of the best-known genes hypermethylated in PCa. GSTP1 encodes an 
enzyme involved in oxidative damage response and protect cells from DNA damage and 
cancer initiation. Promoter hypermethylation of GSTP1, and subsequently loss of 
expression, was frequently found in PCa (over 90%), as well as in HGPIN. These 
observations support that promoter hypermethylation is an early event in tumorigenesis. 
Since it can be detected in tumor tissues and body fluids, extensive work has been done 
in an attempt to make methylation of GSTP1 a useful biomarker to PCa (Jerónimo et al. 
2001, Nakayama et al. 2004). 
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DNA hypomethylation has also been observed in PCa. This aberrant DNA 
methylation was the first cancer-related epigenetic alteration reported. A well-studied 
example is the hypomethylation of LINE1 in around 50% of all PCa samples. Several 
other genes were observed as upregulated due to promoter hypomethylation in PCa, 
including CAGE, CYP1B1, HPDSE, PLAU, CRIP1, S100P and WNT5A (Jerónimo et al. 
2011). 
Histone modifications are changes of basic amino acid residues (such as lysine, 
arginine and serine) on histone tails, including acetylation, phosphorylation, methylation, 
ubiquitylation, sumoylation, citrullination, and ADP ribosylation (Bannister and Kouzarides 
2011). These modifications disturb the affinity to DNA, change the chromatin structure, 
and subsequently influence gene expression. The study of histone modifications in PCa 
progression presents a huge challenge due to the complexities of this field. Several 
histone-modifying enzymes have been described as affected in PCa, including HDACs, 
HMTs and HDMs (Bannister and Kouzarides 2011). Among these, the best studied is the 
enhancer of zeste homolog 2 (EZH2). This histone methyltransferase is responsible for 
the trimethylation of H3K27 (H3K27me3) and subsequently gene silencing (Cao et al. 
2002). Physically it interacts with DNMTs and helps to their binding at EZH2 target 
promoters (Viré et al. 2006). Overexpression of EZH2 has been associated with high 
proliferation rate and tumor aggressiveness in PCa (Bachmann et al. 2006). 
MicroRNAs (miRNA/miR) are small noncoding RNAs (18–25 nucleotides in length) 
that can regulate the expression of multiple genes by binding with complementary mRNA 
sequences and altering their expression through a RNA-induced silencing complex (Catto 
et al. 2011). Each miRNA frequently regulates multiple mRNAs, and each mRNA can be 
targeted by multiple miRNAs (Catto et al. 2011). MicroRNA expression is often altered in 
cancer and can act as oncogenes (when overexpressed) or tumor suppressors (via 
downregulation), depending on their expression status and specific targets. Several 
reports have implicated the deregulation of miRNA in PCa with alterations in important 
pathways of cell growth and disease development (Table 4) (Catto et al. 2011). In fact, 
miRNA deregulation in PCa affects epigenetic reprogramming, blockade of apoptosis, 
promotion of cell cycle, migration, and invasion, and is an alternative mechanism 
sustaining androgen-independent growth (Coppola et al. 2010). Therefore, miRNAs, as 
modulators of gene expression frequently altered in PCa, might potentially be used as 
biomarkers or novel therapeutic targets. 
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Table 4. Summary of miRNAs with altered expression in PCa, including their targeted 
messenger RNAs and pathways (adapted from (Catto et al. 2011). 
miRNA Expression miRNA target Pathway 
miR-20a up E2F1-3 Apoptosis 
miR-21 up PTEN, AKT, androgen 
pathway 
Apoptosis, mTOR, androgen 
independence 
miR-24 up FAF1 Apoptosis 
miR-32 up BCL2L11 (Bim) Apoptosis 
miR-106b up P21, E2F1 Cell cycle control/apoptosis and 
proliferation 
miR-125b up P53, BBC3 (Puma), 
BAK1 
Apoptosis 
miR148a up CAND1 Cell cycle control 
miR-221 up P27(kip1) Cell cycle control and androgen 
independence 
miR-222 up P27(kip1) Cell cycle control and androgen 
independence 
miR-521 up Cockayne syndrome 
protein A 
DNA repair 
miR-1 down Exportin-6, tyrosine 
kinase 9 
Gene expression 
miR-7 down ERBB-2 (EGFR, HER2) Signal transduction 
miR-15a-16 
cluster 
down CCND1 and WNT3a Cell cycle regulation, apoptosis and 
proliferation 
miR-34a down HuR/Bcl2/SIRT1 Apoptosis and drug resistance 
miR-34c down E2F3, bcl2 Apoptosis and proliferation 
miR-101 down EZH2 Gene expression 
miR-107 down Granulin Proliferation 
miR-143 down MYO6, ERK5 Cell migration, proliferation 
miR-145 down MYO6, BNIP3L, CCNA2, 
TNFSF10 
Cell migration, apoptosis, cell cycle 
control 
miR-146a down ROCK1 - 
miR-148a down MSK1 Proliferation, stress response and 
drug resistance 
miR-205 down IL-24 and IL-32, Cepsilon Cell growth and invasion, EMT 
miR-331-3P down ERBB-2, CDCA5, KIF23 Signal transduction, cell cycle control 
miR-449a down HDAC-1 Gene expression 
miR-1296 down MCM family DNA replication 
Let-7a down E2F2 and CCND2 Cell cycle control and proliferation 
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7.3 COPY NUMBER ALTERATIONS 
 
Extensive genomic analyses of prostate cancer have identified copy number 
alterations and chromosomal rearrangements associated with prostate carcinogenesis. 
Important somatic alterations have been identified by comparative genomic hybridization 
(CGH), such as gains or losses of chromosomal regions (Boyd et al. 2012). Global 
analyses of copy number profiles of primary PCa tumors and metastases have identified 
recurrent aberrations, including gains at 1q, 3q, 7q and 8q and losses at 1p, 6q, 8p, 9p, 
13q, and 16p (Boyd et al. 2012). Importantly, numerous of these genetic alterations have 
also been identified in PIN and PIA lesions, which have further suggested these lesions as 
precursors to PCa. Focal amplifications, containing key regulatory genes, have been 
frequently observed in PCa, including androgen receptor at Xq12 and MYC at 8q24 
((Demichelis et al. 2009, Taylor et al. 2010, Lonigro et al. 2011, Barbieri et al. 2013). 
Several studies have demonstrated that the number of copy number alterations is 
correlated with features of PCa progression, such as Gleason grade, advanced tumor 
stage, and other poor prognostic features. Indeed, a genetic model of prostate 
carcinogenesis based on genomic imbalances detected by CGH has been proposed 
(Figure 6). This model shows that losses of 8p and 13q are independent initiating events, 
followed by intermediate events (8q gain and 6q, 16q and 18q losses) and finally a cluster 
of events that includes both gains and losses of chromosomal regions (Ribeiro et al. 
2006). 
 
 
Figure 6. Genetic model of PCa progression based on genomic imbalances detected by 
comparative genomic hybridization (adapted from (Ribeiro et al. 2006). 
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7.4 GENES COMMONLY ALTERED 
 
There are several molecular events that are believed to occur frequently in PCa. 
Even though each event has been associated with a possible role in cancer initiation or 
progression, it is unclear if there is a temporal sequence associated with these events, or 
whether there is a causal relationship between them. 
Loss-of-heterozygosity (LOH) at 8p21.2 is present in up to 85% of high-grade PIN 
lesions and adenocarcinomas (Swalwell et al. 2002, Bethel et al. 2006). This region 
includes NKX3.1, a homeobox gene that has been observed down-regulated in PCa. 
Such alteration is an initial event of the prostate carcinogenesis and is involved in multiple 
important pathways (Abate‐Shen et al. 2008). Although LOH of 8p21 progressively 
increases in frequency with cancer grade, NKX3.1 mRNA expression did not correlate 
with copy-number loss, suggesting the possibility of alternative tumor suppressors in this 
region (Taylor et al. 2010). 
MYC (v-myc myelocytomatosis viral oncogene homolog) at chromosome 8q24 is 
frequently amplified in prostate cancer (Taylor et al. 2010); however, this often involves 
amplification of the entire arm of chromosome 8, leading to the possibility of other 
oncogenes in the region. MYC encodes a transcription factor (c-Myc) with multiple 
downstream target genes, leading to cell cycle progression, cell survival, and 
tumorigenesis. Recent studies have suggested a role for MYC overexpression in cancer 
initiation, as nuclear MYC protein is up-regulated in many PIN lesions and the majority of 
carcinomas in the absence of gene amplification (Gurel et al. 2008). 
The androgen receptor (AR) gene that codifies a ligand-dependent nuclear 
transcription factor is located on Xq11–12. One of the principal functions of this protein is 
to activate the expression of target genes (Dehm and Tindall 2006). AR is essential for 
growth and differentiation of the normal prostate and is also responsible for treatment 
failure in castration-resistant metastatic disease (Chen et al. 2004, Tran et al. 2009). In 
PCa, AR has been observed with increased activation by multiple alterations, including 
gene amplification, point mutations and alterations in splicing leading to constitutively 
active variants. Recent studies point these alterations as more frequent in metastatic 
CRPC. Indeed, AR amplification was present in about 40% and mutation in 10% of 
metastatic PCa, but completely absent in primary tumors (Taylor et al. 2010). Alterations 
in the AR gene itself do not play a role in the pathogenesis of prostate cancer, but instead 
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emerge during treatment as a mechanism of resistance to therapies targeting the 
androgen axis. 
The phosphatase and tensin homologue gene (PTEN) is located on chromosomal 
region 10q23. PTEN is an essential protein in the regulation of PI3K/Akt signaling 
pathway, as its main negative regulator. This protein is also involved is several important 
cell processes including apoptosis, cell cycle progression, cell proliferation, angiogenesis, 
aging and DNA damage response (Govender and Chetty 2012). It was originally identified 
as a tumor suppressor gene, frequently mutated or deleted in many neoplasms, including 
those of the prostate (Salmena et al. 2008). Deletions at the PTEN locus occur in 
approximately 40% of primary PCa and 70-80% in advanced PCa (Squire et al. 2011). 
Loss of PTEN caused by inactivating point mutations is less frequent, about 5-10% of 
primary PCa (Grasso et al. 2012, Weischenfeldt et al. 2013). Recent studies have 
demonstrated that PTEN undergoes copy number loss as an early event in prostate 
carcinogenesis and is correlated with progression to aggressive, castration-resistant 
disease (Verhagen et al. 2006, Schmitz et al. 2007, Sircar et al. 2009, Taylor et al. 2010). 
Alteration of PTEN expression in human prostate cancer cell lines or targeted deletion of 
PTEN in PCa mouse models is sufficient for the development of castration resistance (Lin 
et al. 2004, Bertram et al. 2006, Wu et al. 2006). Whereas this could reflect the ability of 
PTEN to interact directly with AR, the mechanistic details by which PTEN loss promotes 
castration resistance remains to be resolved. 
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7.5 SIGNALING PATHWAYS IN PROSTATE CANCER 
 
The PI3K/Akt/mTOR pathway is a key oncogenic signaling pathway that has been 
linked to tumorigenesis and resistance to both conventional and targeted anticancer 
therapies in a wide variety of tumor types (McCubrey et al. 2011). This signaling pathway 
has been involved in numerous essential cell functions, including the regulation of cellular 
survival, differentiation and stem cell-like properties, growth, proliferation, metabolism, 
migration and angiogenesis (Bitting and Armstrong 2013). In prostate cancer, activation of 
the PI3K/Akt/mTOR pathway has been strongly implicated in tumor progression (Taylor et 
al. 2010). Activation of the PI3K/Akt/mTOR pathway by mutation, altered expression, or 
copy number alterations, has been reported in 42% of primary prostate tumors and 100% 
of metastatic tumors leading to prostate cancer progression (Taylor et al. 2010). Several 
studies have showed that the functional consequences of Pi3K/Akt/mTOR pathway 
activation are mostly relevant for castration-resistant prostate cancer (Majumder et al. 
2004, Uzgare and Isaacs 2004, Gao et al. 2006, Xin et al. 2006). Therefore, the 
PI3K/Akt/mTOR pathway appears to be fundamental to the metastatic potential of PCa, 
offering a strong rationale for targeting the PI3K/Akt/mTOR pathway in disease treatment. 
Since the discovery that castration of men with advanced disease eventually ends 
with cancer relapse, much have been done in the field of androgen-signaling in PCa. 
Several reports have described AR gene amplification, point mutations, and alteration in 
splicing leading to increased activity in PCa (Taylor et al. 2010). Furthermore, AR pathway 
interacts with other oncogenic signaling pathways, including PI3K/Akt signaling. Based on 
the whole genome of PCa, an interesting role for androgen signaling in driving prostate 
carcinogenesis has been proposed: as rearrangement breakpoints are more common 
near androgen receptor-binding sites, AR-mediated transcription could predispose to 
genomic rearrangements through transcriptional stress (Berger et al. 2011). Thus, 
androgen stimulation can potentially bring together the TMPRSS2 and ERG loci, 
ultimately promoting gene fusion of both genes (Haffner et al. 2010). Androgen-mediated 
transcriptional activity could act as an initial driver of many genomic rearrangements in 
PCa, and emphasize androgen signaling as a critical signaling pathway in both primary 
and advanced prostate cancer. 
The mitogen-activated protein kinase (MAPK) pathway has a critical role in many 
human neoplasias (including lung, ovary, melanoma, pancreas and GI tract); however, its 
role in PCa is not well established. Up-regulation of MAPK pathway components and 
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upstream intermediates are common and enriched in prostate cancer metastases, 
although mutations in these components are rare (Taylor et al. 2010). 
The Wnt proteins are secreted cysteine-rich proteins that have important roles in the 
developing embryo and in tissue homeostasis in adults (Clevers 2006). The Wnt/β-catenin 
signaling pathway is implicated in the maintenance of stem and progenitor cells in several 
adult tissues, including blood, intestine and skin (Wend et al. 2010). The deregulation of 
this pathway can occur in many types of cancer, such as colon, liver, skin, and prostate 
cancer (Giles et al. 2003, MacDonald et al. 2009, Kypta and Waxman 2012). An important 
feature of Wnt/β-catenin signaling is the stabilization of the transcriptional co-activator β-
catenin, which regulates the expression of many genes implicated in cancer and is also an 
essential component of cadherin cell adhesion complexes. The last feature has special 
importance for the formation and function of the prostate gland (Heuberger and 
Birchmeier 2010). The activation of the Wnt/β-catenin pathway has effects on prostate cell 
proliferation, differentiation and the epithelial–mesenchymal transition, which is thought to 
regulate the invasive behavior of tumor cells. Studies focused in the development of 
inhibitors for Wnt/β-catenin signalling have recently emerged, as their action might reduce 
the self-renewal of prostate cancer stem or progenitor cells, which could be of potential 
therapeutic benefit (Kypta and Waxman 2012). 
Hedgehog (Hh) signaling pathway genes are essential components in cell 
proliferation, differentiation and tissue polarity during embryonic development (Ingham 
1998). During prostate development, the Hedgehog signaling is required for ductal 
morphogenesis and proliferation, and its activity is relatively low in adult normal prostate 
gland (Berman et al. 2004). This pathway has been reported as deregulated in several 
human cancers, including basal cell carcinomas, medulloblastomas, small cell lung cancer 
and GI cancers (Rubin and de Sauvage 2006). Emerging studies have related the Hh 
signaling to the development and progression of PCa to a more aggressive and to 
therapy-resistant disease states (Karhadkar et al. 2004, Sheng et al. 2004, Kim et al. 
2011); however there is still a lot of controversy about how this deregulation occurs. 
Finally, the deregulated expression of oncogenic tyrosine kinases, such as Src or 
Her2/Neu, has been studied in prostate neoplasm (Mellinghoff et al. 2004, Fizazi 2007). In 
fact, SRC tyrosine kinases have been implicated in aggressive PCa, progression to 
metastasis and castration resistance (Fizazi 2007). Several studies have demonstrated 
that Src is highly expressed in PCa cell lines, as well as in the majority of prostate cancer 
specimens. Additionally, AR signaling leads to activation of Src signaling in PCa, which 
can lead to castration resistance and cellular proliferation and invasiveness (Migliaccio et 
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al. 2000, Agoulnik et al. 2005, Kraus et al. 2006). A number of experiments have proved 
that Src inhibitors decrease the oncogenic potential of prostate cancer cell lines in vitro 
(Recchia et al. 2003, Lombardo et al. 2004, Nam et al. 2005), and also reduce prostate 
cancer growth and metastasis in mouse xenograft studies (Park et al. 2008, Saad and 
Lipton 2010). However, further research regarding the optimal use of these agents in the 
clinic still needs to be performed.  
 
7.6 ETS REARRANGEMENTS IN PROSTATE CANCER  
 
Recurrent chromosomal rearrangements in prostate carcinomas were firstly 
reported by Tomlins and collaborators (Tomlins et al. 2005), through an unconventional 
bioinformatics approach termed as the ―Cancer Outlier Profile Analysis‖ (COPA) 
algorithm, used to analyze DNA microarray studies. This algorithm has allowed the 
identification of high expression genes on DNA microarrays data, and using this strategy 
in prostate cancer profiling studies two members of the ETS transcription factor family 
gene, ERG and ETV1, were identified. Then using 5’-RNA ligase-mediated rapid 
amplification of cDNA ends (5’RACE), the authors found recurrent chromosomal 
rearrangements of the 5’ ends of the ETS family member (ERG or ETV1) with sequences 
from the 5’ untranslated region of the androgen-regulated gene TMPRSS2  (Tomlins et al. 
2005). The gene fusion of TMPRSS2 with ERG or ETV1 only occurred in cases with 
overexpression of the respective ETS gene, and fusions were not detectable in benign 
prostate tissues. Using fluorescence in situ hybridization (FISH), more than 50% of a 
prostate-specific antigen (PSA)–screened cohort of prostatectomy samples had ETS 
rearrangements, confirming their existence at the chromosomal level. Analysis of 
TMPRSS2-ERG positive and TMPRSS2-ERG negative PCa cell lines showed that the 
TMPRSS2-ERG fusion resulted in androgen-regulated expression of ERG. In fact, upon 
androgen stimulation of VCaP cell line (harboring TMPRSS2-ERG) an increase of ERG 
expression occured, whereas no effect was observed in LNCaP cell line (TMPRSS2-ETS 
negative). Thus, the androgen-responsive elements that normally restrict the expression 
of TMPRSS2 to the prostate drove the aberrant overexpression of the truncated ETS 
oncogenes (Tomlins et al. 2005). Many subsequent studies have validated the ocurrence 
of ETS gene fusions in about 47% of 10,779 prostate cancer cases (Pettersson et al. 
2012). Furthermore, the identification of ETS rearrangements in about 20% of HGPIN and 
none of HBP or normal prostate tissue suggests that ETS gene fusions could be an early 
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event in prostate carcinogenesis (Cerveira et al. 2006, Perner et al. 2007, Clark et al. 
2008, Park et al. 2008, van Leenders et al. 2011). 
 
7.6.1 ETS TRANSCRIPTION FACTOR FAMILY 
 
The E26 transformation-specific (ETS) transcription factor family is one of the 
largest families of transcription regulators, composed of 28 members (Figure 7). All of 
them have an evolutionary conserved DNA-binding domain, named ETS domain, at the C-
terminal part of the protein (Seth and Watson 2005, Hollenhorst et al. 2011). The human 
ETS factors are classified into 12 subgroups based on the ETS domain sequence 
homology (Seth and Watson 2005, Watson et al. 2010, Hollenhorst et al. 2011). The ETS 
domain is a sequence of 85 amino acids forming a helix-turn-helix DNA-binding structure 
that recognizes a GGAA/T core consensus sequence (ETS binding site) in regulatory 
regions of target genes (Wei et al. 2010, Hollenhorst et al. 2011). A second conserved 
domain present in a subset of ETS factors is the pointed domain (PNT). This domain, 
presented in 11 of the 28 ETS members, codifies a 65 to 85 amino acid helix-loop-helix 
domain important in protein-protein interactions and oligomerization (Seth and Watson 
2005). Besides ETS and PNT domains, ETS proteins may also present activation and 
repression domains and, rarely, B-box and OST domains (Hollenhorst et al. 2011). 
 
7.6.2 ETS REARRANGEMENTS DIVERSITY 
  
Although gene fusions between TMPRSS2 and ERG represent the most common 
subtype of fusions found in PCa, rearrangements involving other ETS family members 
have been described (Tomlins et al. 2009). In fact, ETV1 fusion products are present in 
approximately 10% of PCa, and this gene can be rearranged with the 5’ untranslated 
region of several other genes besides TMPRSS2 (TMRSS2-ETV1 is present in only 1% of 
PCa). Thereafter, the screening of microarrays datasets for ETS gene outlier expression 
led to the identification of fusion genes involving the ETS variant 4 and 5 genes, ETV4 
and ETV5 (Tomlins et al. 2006, Helgeson et al. 2008). The ongoing effort to screen PCa 
patients for gene fusions, in combination with the recent technological advances, has 
resulted in a comprehensive gene fusion landscape. Several other novel 5′ promoter or 
other upstream sequences of androgen-inducible genes (HERV_K22q11.23, SLC45A3, 
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C15orf21, HNRPA2B1, KLK2, CANT1) have been identified (Tomlins et al. 2008) (Table 
5). ETS gene fusions in prostate cancer seem mutually exclusive, but in multifocal disease 
more than one fusion event can be found (Mehra et al. 2007, Furusato et al. 2008, Paulo 
et al. 2012).  
 
 
Figure 7. Structural and functional domains of the ETS family of transcription factors. 
Nomenclature (HUGO) and domain organization of the 28 human ETS proteins. Boxes 
identify the DNA-binding ETS domain (red), PNT domain (green), OST domain (blue), and 
B-box (magenta) of the ETS factors. (adapted from Hollenhorst et al. 2011). 
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Table 5. Known ETS genes and 5’ partners involved in gene fusions. 
Translocation 
partner 
Locus Androgen 
response 
Structure of 
encoded 
protein 
Gene function 
ERG     
TMPRSS2 21q22 Up-regulated NTT; Fusion 
(5aa); WT 
Transmembrane 
serine protease 
SLC45A3 1q32 Up-regulated NS Solute carrier protein 
HERPUD1 16q13 Up-regulated Fusion (49aa) Multipass membrane 
protein – Ubiquitin-
dependent 
degradation 
NDRG1 8q24.3 Up-regulated  Alfa/beta hydrolase 
ETV1     
TMPRSS2 21q22 Up-regulated NTT; Fusion 
(5aa) 
Transmembrane 
serine protease 
SLC45A3 1q32 Up-regulated NTT Solute carrier protein 
ACSL3 2q36.1 Up-regulated NTT Acetyl-CoA 
synthetase 
HERV-K22 22q11.23 Up-regulated NTT Endogenous 
retrovirus 
HERV-K17 17q13.1 Up-regulated NTT Endogenous 
retrovirus 
FOXP1 3p13 Up-regulated Fusion (19aa) Transcriptional 
repressor 
EST14 14q21.1 Up-regulated NTT; Fusion 
(5aa) 
Non-coding RNA 
Chromosome 
14 
14q13.3-
21.1 
Up-regulated WT NA 
C15orf21 15q21.1 Down-
regulated 
NTT Unidentified open 
reading frame 
HNRPA2B1 7p15 No effect Fusion (2aa) Ribonuclear protein – 
pre-mRNA 
processing  
ETV4     
TMPRSS2 21q22 Up-regulated NTT; Fusion 
(5aa) 
Transmembrane 
serine protease 
KLK2 19q13.33 Up-regulated NTT Kallikrein peptidase - 
serine protease 
CANT1 17q25.3 Up-regulated NTT calcium activated  
nucleotidase 
DDX5 17q24.1 No effect Fusion (102aa) RNA helicase 
ETV5     
TMPRSS2 21q22 Up-regulated Fusion (84aa); 
WT 
Transmembrane 
serine protease 
SLC45A3 1q32 Up-regulated NTT Solute carrier protein 
NTT, N-terminal truncated; WT, wild type; NS, not specified; NA, not applicable 
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Besides the diversity of fusion partners described, an additional level of complexity 
is introduced by both rearrangements mechanism and the multiple fusion-transcript 
isoforms. Both TMPRSS2 and ERG are located less than 3 megabases (Mb) apart on 
chromosome 21, and the gene fusion TMPRSS2-ERG can occur either through 
interchromosomal insertion (Teixeira 2008) or through deletion of the intervening region 
on chromosome 21. Moreover, the most common TMPRSS2-ERG fusion transcript 
isoform involves the exon 1 of TMPRSS2 and exon 4 of ERG, although more than 20 
TMPRSS2-ERG different transcripts have been described. The majority of TMPRSS2-
ERG rearrangements linked exon 1 of TMPRSS2 with different exons of ERG, resulting in 
overexpression of N-terminal truncated (NTT) ERG proteins (Wang et al. 2006, Clark et al. 
2007, Liu et al. 2007, Hu et al. 2008). This is also observed for other ETS transcription 
factors involved in rearrangements, in which the majority of the 5’ partners contribute to 
the fusion transcripts with untranslated exons. Whereas ETV1 and ETV4 have frequently 
lost part of the 5’ translated region, ETV5 has its wildtype (WT) protein overexpressed 
(Tomlins et al. 2007).  
 
7.6.3 PROGNOSTIC VALUE OF ETS REARRANGEMENTS 
 
Owing to the high frequency of PCa harboring ETS rearrangements, several studies 
have investigated the effect of TMPRSS2-ERG rearrangement on prognosis of PCa 
patients. However, the conclusions are contradictory, ERG rearrangements have been 
reported as associated with both more aggressive and more indolent disease, due to 
several variables such as heterogeneity of study cohorts and management, the impact of 
sampling, multifocality and intraprostate molecular heterogeneity, and the variability of 
measured outcomes (Clark and Cooper 2009). Population-based studies focused on non-
PSA screened populations with PCa diagnosed by transurethral resection of the prostate 
(TURP) and conservatively management (watchful waiting) have shown a significant 
association between ETS fusions and poor prognosis (Demichelis et al. 2007, Attard et al. 
2010), while retrospective radical prostatectomy series studies have produced 
inconsistent results regarding aggressiveness and prognosis of ETS fusion-positive PCa 
(Clark and Cooper 2009). With the lower frequency of ETV1 rearrangements, it is more 
difficult to evaluate an association of ETV1 rearrangement and clinicopathological 
variables. Attard and collaborators have analyzed 22 PCa samples harboring ETV1 
rearrangement and did not show an association with survival (Attard et al. 2008). More 
recently, Baena and colaborators have associated ETV1-regulated pathways with higher 
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Gleason score and metastasis (Baena et al. 2013), supporting previous reports (Shin et 
al. 2009). 
 
7.6.4 ETS TARGET GENES 
 
Cancer results from a multi-step sequence of genetic and epigenetic changes that 
lead to crucial alterations in cell physiology, such as loss of growth controls and normal 
apoptotic response, as well as sustained angiogenesis, invasion, and metastasis 
(Hanahan and Weinberg 2011). The ETS transcription factors are able to act as positive 
or negative regulators of gene expression of crucial elements that are involved in those 
important biological pathways. Consequently, ETS have been associated to cellular 
proliferation, differentiation, apoptosis, tissue remodeling, angiogenesis, metastasis and 
transformation. In the last years, several studies have made significant efforts in 
identification of ETS target genes. Among ETS target genes validated so far are genes 
associated with cell proliferation control (cyclins and cdks), motility (HGF), invasion (uPA, 
PAI, MMPs, TIMPs), extravasation (MMPS, integrins), micro-metastasis (Osteopontin; 
BSP and Osteonectin), and establishment and maintenance of distant site metastasis and 
angiogenesis (integrin b3, VEGF, Flt-1/KDR, Tie2) (Sementchenko and Watson 2000, 
Hsu et al. 2004). As stated above, a significant proportion of PCa carry ETS 
rearrangements leading to overexpression of the ETS transcription factor involved. In vitro 
studies have revealed that ERG activates plasminogen and Wnt pathways to promote 
degradation of the extracellular matrix and decrease cell adhesion, but very few genes 
have been validated as direct ERG targets (Tomlins et al. 2008, Gupta et al. 2010, 
Mohamed et al. 2011).  Regarding ETV1 rearrangements, there are some in vitro and in 
vivo models linking overexpression of ETV1 with the invasion potential of cancer cells by 
activation of matrix metalloproteinase MMP1 and ITGB3 integrin (Cai et al. 2007, Tomlins 
et al. 2007, Hermans et al. 2008). 
Therapeutic targeting of ETS and other transcription factors has been challenging 
due to their nuclear localization and molecular embedding in DNA–protein and protein–
protein complexes (Konstantinopoulos and Papavassiliou 2011, Findlay et al. 2013). 
Consequently, it has been of utmost importance to identify and to characterize the 
downstream molecular targets of ETS rearrangements, as potentially some of them could 
be more amenable to targeted therapy. 
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In our previous work, and using a genome-wide scale and exon-level expression 
microarray platform on a clinical series of PCa enriched for ERG and ETV1 
rearrangements, we have shown that ERG and ETV1 regulate both specific and shared 
target genes in PCa (Paulo et al. 2012). Our group reported a list of 57 ERG-associated 
genes in primary PCa, which 8 were also deregulated in VCaP cells with the TMPRSS2-
ERG fusion (SH3RF1, TMBIM1, PLA1A, CACNA1D, ATP8A2, HLA-DMB, PDE3B, and 
TDRD1). Of the 15 genes highly associated with tumors harboring ETV1 rearrangements, 
only 2 genes were shown to have the expected overexpression in the LNCaP cell line 
harboring an ETV1 rearrangement (FKBP10 and GLYATL2). We also reported a list of 27 
target genes shared by ERG and ETV1 rearrangements. Our results, using the VCaP and 
LNCaP knockdown cell line models, clearly validate KCNH8, TMEM45B and GRPR as 
downstream targets of both ERG and ETV1, as also indicated by our demonstration of 
direct binding of ERG to the promoter of these genes using ERG-immunoprecipitated 
chromatin from VCaP cells (Paulo et al. 2012). KCNH8 have been previously associated 
with tumors harboring ERG rearrangements (Glinsky et al. 2004, Jhavar et al. 2008, 
Jhavar et al. 2009). TMEM45B encodes a putative membrane protein with unknown 
function, so its role in prostate carcinogenesis might be worth exploring. Finally, GRPR 
encodes the gastrin-releasing peptide receptor and has been described as overexpressed 
in several cancer types, including PCa (Cornelio et al. 2007, Beer et al. 2012). 
Considering the overexpression of GRPR in a high proportion of PCa that harbor either 
ERG or ETV1 rearrangements, the cellular membrane localization of its protein product, 
the relevance of its function, the availability of blocking agents, and the several previous 
reports on its oncogenic activity, makes it a promising therapeutic target for these 
particular molecular subtypes of PCa. 
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8. GASTRIN-RELEASING PROTEIN RECEPTOR  
 
The Gastrin-releasing protein receptor (GRPR) is a member of the G-protein 
coupled receptor superfamily (GPCR). GPCR superfamily is the largest family of cell-
surface molecules involved in signal transmission that regulate many cell functions, 
including cell proliferation, survival and motility, and have lately arisen as crucial players in 
tumor growth, angiogenesis and metastasis. The aberrant overexpression of GPCR 
members and their activation by specific agonists represents the most frequent form used 
by cancer cells to stimulate GPCRs signaling networks (Dorsam and Gutkind 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Some oncogenic signaling pathways associated to gastrin-releasing peptide 
receptor activation (adapted from (Dorsam and Gutkind 2007). 
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The expression of GRPR in normal tissues is restricted to gastric, respiratory, 
endocrine, muscle and nervous systems (Xiao et al. 2001).  The activation of this receptor 
is mediated by its specific ligand GRP (gastrin-releasing peptide). GRP belongs to the 
regulatory peptide family, involved in several modulatory roles in distinct regions of the 
human body, including brain, gastrointestinal tract, vascular and endocrine systems. 
Several signaling mechanisms are activated through the binding of GRPR, including 
phospholipases (A2, B1, B3 and D), cAMP, PKC, cyclooxygenase, and protein kinase 
cascades (among them the Raf/MEK/ERK kinase cascade) (Figure 8) (Hohla and Schally 
2010). Generally, regulatory peptides and their receptors are present at low 
concentrations in physiologically organs, although the receptors are often highly 
expressed in human cancers. In fact, GRPR is known to be overexpressed in several 
human malignancies, including neuroblastoma, lung, breast, pancreatic, colorectal, 
gastric, esophageal, and prostatic cancer (Cornelio et al. 2007). GRPR activation by GRP 
ligation lead to the regulation of many functions of the gastrointestinal and central nervous 
systems, including the release of gastrointestinal hormones, contraction of smooth 
musculature in the gastrointestinal and urogenital tract, hormone release from the 
pancreas, stomach and other endocrine organs, and proliferation of epithelial cells (Mansi 
et al. 2013).  
GRPR overexpression in prostate tumors has been identified in radical 
prostatectomy at both mRNA and protein level (Bartholdi et al. 1998, Markwalder and 
Reubi 1999, Sun et al. 2000, Weber 2009). Markwalder and Reubi detected that primary 
prostatic carcinomas express GRPR at much higher levels than non-neoplastic prostate 
glands, and this protein was also detected at higher levels in high-grade prostatic 
intraepithelial neoplasia (HGPIN), usually considered a tumor precursor lesion 
(Markwalder and Reubi 1999). The discovery of GRPR overexpression in several cancer 
cells led to approaches to inhibit the autocrine growth effect of GRP peptides on tumor 
growth, including receptor antagonists, monoclonal antibodies (mAbs) against GRP, 
antisense oligonucleotides (ASOs), and bispecific molecules (BsMol). Additionally, GRP 
analogues for imaging were also developed (Hohla and Schally 2010).  
The three main GRPR antagonists’ options are the nonradioactive bombesin 
analogues for long-term antiproliferation treatment, the radioactive bombesin analogues 
for targeted radiotherapy, and the cytotoxic bombesin analogues for targeted cytotoxic 
therapy (Mansi et al. 2013). Concerning GRPR nonradioactive analogues, a large number 
of compounds have been synthesized and several studies have reported the 
antiproliferative effect of GRPR antagonists in vitro and in vivo in distinct tumor models 
(Schally et al. 2001, Hohla and Schally 2010). Although the mechanisms involved in the 
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tumor growth inhibition by GRPR antagonists are not completely understood, it is already 
known that it includes reduction of epidermal growth factor receptor levels (Bajo et al. 
2002), inhibition of neovascularization, and the decrease of oncogene expression (Schally 
et al. 2001, Jensen et al. 2008). Among GRPR antagonists, the compound RC-3095 [D-
Tpi6,Leu13Ψ(CH2NH) Leu
14]bombesin(6-14) showed strong inhibitory effect on several 
experimental cancers in vitro and in vivo (Hohla and Schally 2010). In fact, several reports 
have described the effect of selective GRPR antagonists on inhibition of tumor growth in 
numerous models, including prostate cancer cell lines (PC-3, DU-145, MDA-PCa-2b) 
(Stangelberger et al. 2005a, Stangelberger et al. 2005b, Stangelberger et al. 2005c), 
although the associated mechanisms are not yet fully understood. The tumor-inhibitory 
mechanism of GRP antagonists appears to be more complex than a simple competitive 
action on the receptor, although the main mechanism of tumor inhibitory action of RC-
3095 appears to involve the reduction in levels of key members of oncogenic signaling 
(Mansi et al. 2013). Considering the impressive preclinical antitumor activity of RC-3095, a 
phase I clinical trial was conducted in which RC-3095 was administered to 25 patients 
with different advanced solid malignancies, including six with PCa. According to this initial 
study, no side effects were observed, but the tumor-reducing effects were not convincing. 
However, maximal doses could not be reached by the methods used, despite dose 
escalation (Schwartsmann et al. 2006). Our recent study concerning the connection 
between GRPR overexpression and ERG and ETV1 rearrangements (Paulo et al. 2012) 
may help understand how the expression of this molecule is regulated and the potential 
use of GRPR as a therapeutic target for this particular subset of prostate carcinomas 
harboring ETS rearrangements. 
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Chapter 2 
 
 
 
AIMS 
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The aims of this thesis were: 
 
1. To perform technical and biological validation of the differential RNA 
expression of the gastrin-releasing peptide receptor (GRPR) between non-
malignant prostate samples and prostate carcinomas with and without the 
ETS rearrangements; 
 
2. To study the phenotypic impact of in vitro silencing of GRPR using prostate 
cancer cell lines that show the same pattern of RNA and protein expression 
as those identified in primary tumors;  
 
3. To characterize the downstream pathway effects of GRPR silencing and to 
identify the most promising therapeutic targets; 
 
4. To evaluate the potential of an anti-oncogenic therapy targeting GRPR and 
its downstream targets using prostate cancer cell line models with ETS 
rearrangements. 
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No. Antibody 
Codes 
Target 
Protein 
Name 
Phosp
ho Site (Human) 
Full Target Protein Name Refseq Uniprot Link 
1 NN001 14-3-3 z Pan-specific 14-3-3 protein zeta (cross-reacts with other 
isoforms) 
NP_003397   P63104 
2 NN166 4E-BP1 Pan-specific Eukaryotic translation initiation factor 4E binding 
protein 1 (PHAS1) 
NP_004086 Q13541 
3 PN001 4E-BP1 S65 Eukaryotic translation initiation factor 4E binding 
protein 1 (PHAS1) 
NP_004086 Q13541 
4 PN114 4E-BP1 T45 Eukaryotic translation initiation factor 4E binding 
protein 1 (PHAS1) 
NP_004086 Q13541 
5 PN128 4E-BP1 T70 Eukaryotic translation initiation factor 4E binding 
protein 1 (PHAS1) 
NP_004086 Q13541 
6 NK001 Abl Pan-specific Abelson proto-oncogene-encoded protein-
tyrosine kinase 
NP_005148  P00519 
7 PN002 AcCoA 
carboxylas
e 
S80 Acetyl coenzyme A carboxylase NP_000655 Q13085 
8 NN135-1 Acetylated 
Lysine 
Pan-specific Acetylated Lysine NA NA 
9 NN135-2 Acetylated 
Lysine 
Pan-specific Acetylated Lysine NA NA 
10 NK002 ACK1 Pan-specific Activated p21cdc42Hs protein-serine kinase NP_005772 Q07912 
11 PN003-
PN004 
Adducin a S726 Adducin alpha (ADD1) NP_058432 P35611 
12 NN002 AIF Pan-specific Apoptosis inducing factor (programed cell death 
protein 8 (PDCD8)) 
NP_004199 O95831 
13 NN003 AK2 Pan-specific Adenylate kinase 2 NP_001616 P54819 
14 NK003 ALK Pan-specific Anaplastic lymphoma kinase NP_004295.2 Q9UM73 
15 NK004 ALS2CR7 
(PFTAIRE
2) 
Pan-specific Amyotrophic lateral sclerosis 2 chromosomal 
region candidate gene protein-serine kinase 7 
NP_631897 Q96Q40 
16 PK002 AMPKa1/2 T183 5'-AMP-activated protein kinase subunit alpha 
1/2 
NP_006242 Q13131 
17 NK006 ANKRD3 Pan-specific Ankyrin repeat domain protein-serine kinase 3 
(RIPK4, DIK) 
NP_065690  P57078 
18 NN004 APG1 Pan-specific Hsp 70-related heat shock protein 1 (osmotic 
stress protein 94 (OSP94)) 
NP_055093 O95757 
19 NN122 APG2 Pan-specific Hsp 70-related heat shock protein 4 (HSP70RY) NP_002145.3 P34932 
20 PN189 APP T668 Amyloid beta A4 protein NP_000475.1 P05067 
21 NN121 Arrestin b1 Pan-specific Arrestin beta 1 NP_004032 P49407 
22 PN133 Arrestin b1 S412 Arrestin beta 1 NP_004032  P49407 
23 NK007 ASK1 
(MAP3K5) 
Pan-specific Apoptosis signal regulating protein-serine kinase NP_005914  Q99683 
24 NK007-2 ASK1 
(MAP3K5) 
Pan-specific Apoptosis signal regulating protein-serine kinase NP_005914  Q99683 
25 PK143 ASK1 
(MAP3K5) 
S966 Apoptosis signal regulating protein-serine kinase NP_005914  Q99683 
26 NN160 ATF2 Pan-specific Activating transcription factor 2 (CRE-BP1) NP_001871  P15336 
27 PN006-1 ATF2 T69 + T71 Activating transcription factor 2 (CRE-BP1) NP_001871  P15336 
28 PN115 ATF2 S112 Activating transcription factor 2 (CRE-BP1) NP_001871  P15336 
29 NK008-2 Aurora A 
(AIK) 
Pan-specific Aurora Kinase A (serine/threonine protein 
kinase 6) 
NP_940835 O14965 
30 NK193 Aurora B 
(AIM-1) 
Pan-specific Aurora Kinase B (serine/threonine protein 
kinase 12) 
NP_004208 Q96GD4 
31 NK009 Aurora C 
(AIK3) 
Pan-specific Aurora Kinase C (serine/threonine-protein 
kinase 13) 
NP_003151 Q9UQB9 
32 NK010 Axl Pan-specific Axl proto-oncogene-encoded protein-tyrosine 
kinase 
NP_001690 P30530 
33 PN008 B23 (NPM) T199 B23 (nucleophosmin, numatrin, nucleolar protein 
NO38) 
NP_002511 P06748 
34 PN008-2 B23 (NPM) T199 B23 (nucleophosmin, numatrin, nucleolar protein 
NO38) 
NP_002511 P06748 
35 PN009 B23 (NPM) T234/T237 B23 (nucleophosmin, numatrin, nucleolar protein 
NO38) 
NP_002511 P06748 
36 PN012-1 Bad S99 Bcl2-antagonist of cell death protein NP_004313 Q92934 
37 NN000 Bak Pan-specific Bcl2 homologous antagonist/killer (BCK2L7) NP_001179 Q16611 
38 NN005 Bax Pan-specific Apoptosis regulator Bcl2-associated X protein NP_620116 Q07812 
39 NN006 Bcl2 Pan-specific B-cell lymphoma protein 2 alpha NP_000624  P10415 
40 NN006-1 Bcl2 Pan-specific B-cell lymphoma protein 2 alpha NP_000624  P10415 
41 NN007 Bcl-xL Pan-specific Bcl2-like protein 1 NP_612815 Q07817 
42 NN008 Bcl-xS/L Pan-specific Bcl2-like protein 1 NP_612815 Q07817 
43 PK164 Bcr Y177 Breakpoint cluster region protein NP_004318.3 P11274 
44 NN009 Bid Pan-specific BH3 interacting domain death agonist NP_001187  P55957 
45 NK011 BLK Pan-specific B lymphoid tyrosine kinase NP_001706 P51451 
46 PN013 BLNK Y84 B-cell linker protein NP_037446 O75498 
47 NK012 BMX (Etk) Pan-specific Bone marrow X protein-tyrosine kinase NP_001712 P51813 
48 PK003 BMX (Etk) Y40 Bone marrow X protein-tyrosine kinase NP_001712 P51813 
49 PN014 BRCA1 S1497 Breast cancer type 1 susceptibility protein NP_009225 P38398 
50 PN116 BRCA1 S1423 Breast cancer type 1 susceptibility protein NP_009225 P38398 
51 NK013 BRD2 Pan-specific Bromodomain-containing protein-serine kinase 2 NP_005095 P25440 
52 NK014 Btk Pan-specific Bruton's agammaglobulinemia tyrosine kinase NP_000052 Q06187 
53 PK004 Btk Y223 Bruton's agammaglobulinemia tyrosine kinase NP_000052 Q06187 
54 NK015 BUB1A Pan-specific BUB1 mitotic checkpoint protein-serine kinase NP_004327  O43683 
55 NN174 CA9 Pan-specific Carbonic anhydrase 9 NP_001207.2 Q16790 
56 PN015 Caldesmo
n 
S789 Caldesmon NP_004333  Q05682 
57 NN136-2 Calnexin Pan-specific Calnexin NP_001019820.1. P27824 
58 NN137-1 Calreticulin Pan-specific Calreticulin NP_004334.1. P27797 
59 NK211 CAMK1a Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 1 alpha 
NP_003647.1 Q14012 
60 NK016-1 CaMK1d Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 1 delta 
NP_003647 Q8IU85 
61 NK016-2 CaMK1d Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 1 delta 
NP_003647 Q8IU85 
62 PK005-1 CaMK2a T286 Calcium/calmodulin-dependent protein-serine 
kinase 2 alpha 
NP_741960 Q9UQM7 
63 NK018-2 CAMK2b Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 2 beta 
NP_742081 Q13554 
64 NK019-2 CAMK2d Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 2 delta 
NP_742126 Q13557 
65 NK021 CaMK4 Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 4 
NP_001735 Q16566 
66 NK021-2 CaMK4 Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 4 
NP_001735 Q16566 
67 NK021-3 CaMK4 Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase 4 
NP_001735 Q16566 
68 NK022 CaMKK 
(CaMKK1) 
Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase kinase 
NP_006540 Q8N5S9 
69 NN010 CAS Pan-specific Cellular apoptosis susceptibility protein (CSE1L) NP_001307 P55060 
70 NK023 CASK/Lin2 Pan-specific Calcium/calmodulin-dependent protein-serine 
kinase (Lin2 homolog) 
NP_001119526.1 O14936 
71 NN011 CASP1 Pan-specific Caspase 1 (Interleukin-1 beta convertase) NP_001214 P29466 
72 NN011-2 CASP1 Pan-specific Caspase 1 (Interleukin-1 beta convertase) NP_001214 P29466 
73 NN013 CASP3 Pan-specific Caspase 3 (apopain, cysteine protease CPP32) NP_004337 P42574 
74 NN013-3 CASP3 Pan-specific Caspase 3 (apopain, cysteine protease CPP32) NP_004337 P42574 
75 NN016 CASP6 Pan-specific Caspase 6 (apoptotic protease Mch2) NP_001217 P55212 
76 NN017 CASP7 Pan-specific Caspase 7 (ICE-like apoptotic protease 3 (ICE-
LAP3), Mch3) 
NP_01218 P55210 
77 NN017-2 CASP7 Pan-specific Caspase 7 (ICE-like apoptotic protease 3 (ICE-
LAP3), Mch3) 
NP_01218 P55210 
78 NN019-2 CASP9 Pan-specific Caspase 9 (ICE-like apoptotic protease 6 (ICE-
LAP6), Mch6, APAF3) 
NP_033938 P55211 
79 PN162 Catenin a S641 Catenin (cadherin-associated protein) alpha NP_001894.2 P35221 
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80 PN166 Catenin b S33 Catenin (cadherin-associated protein) beta 1 NP_001895 P35222 
81 PN167 Catenin b Y333 Catenin (cadherin-associated protein) beta 1 NP_001895 P35222 
82 NN021 Catenin b1 Pan-specific Catenin (cadherin-associated protein) beta 1 NP_001895 P35222 
83 NN021-1 Catenin b1 Pan-specific Catenin (cadherin-associated protein) beta 1 NP_001895 P35222 
84 NN167 Caveolin 1 Pan-specific Caveolin 1 NP_001744.2 Q03135 
85 PN147 Caveolin 1 Y14 Caveolin 1 NP_001744.2 Q03135 
86 NN022-1 Caveolin 2 Pan-specific Caveolin 2 NP_001224 P51636 
87 PN018 Caveolin 2 S36 Caveolin 2 NP_001224   P51636 
88 PN171 Cbl Y700 Signal transduction protein CBL NP_005179.2 P22681 
89 NP001 CD45 Pan-specific Leukocyte common antigen CD45 receptor-
tyrosine phosphatase (LCA, T200) 
NP_002829 P08575 
90 NP002 Cdc25B Pan-specific Cell division cycle 25B phosphatase NP_004349 P30305 
91 NP003 Cdc25C Pan-specific Cell division cycle 25C phosphatase NP_001781 P30307 
92 PP005 Cdc25C S216 Cell division cycle 25C phosphatase NP_002882.3 P30307 
93 NK024 CDC2L5 
(CHED) 
Pan-specific Cell division cycle 2-like protein-serine kinase 5 NP_003709  Q14004 
94 NN023 Cdc34 Pan-specific Cell division cycle 34 (ubiquitin-conjugating 
ligase) 
NP_004350 P49427 
95 NN024 Cdc42 Pan-specific Cell division control protein 42 homolog NP_001782 P60953 
96 NK025-1 CDK1 
(CDC2) 
Pan-specific Cyclin-dependent protein-serine kinase 1 NP_001777 P06493 
97 NK025-2 CDK1 
(CDC2) 
Pan-specific Cyclin-dependent protein-serine kinase 1 NP_001777 P06493 
98 NK025-3 CDK1 
(CDC2) 
Pan-specific Cyclin-dependent protein-serine kinase 1 NP_001777 P06493 
99 NK025-4 CDK1 
(CDC2) 
Pan-specific Cyclin-dependent protein-serine kinase 1 NP_001777 P06493 
100 NK025-5 CDK1 
(CDC2) 
Pan-specific Cyclin-dependent protein-serine kinase 1 NP_001777 P06493 
101 NK025-6 CDK1 
(CDC2) 
Pan-specific Cyclin-dependent protein-serine kinase 1 NP_001777 P06493 
102 PK006 CDK1/2 T14+Y15 Cyclin-dependent protein-serine kinase 1/2 NP_001777 P06493 
103 PK007-1 CDK1/2 Y15 Cyclin-dependent protein-serine kinase 1/2 NP_001777 P06493 
104 PK007-2 CDK1/2 Y15 Cyclin-dependent protein-serine kinase 1/2 NP_001777 P06493 
105 PK007-3 CDK1/2 Y15 Cyclin-dependent protein-serine kinase 1/2 NP_001777 P06493 
106 PK008 CDK1/2 T161 Cyclin-dependent protein-serine kinase 1/2 NP_001777 P06493 
107 NK033 CDK10 Pan-specific Cyclin-dependent protein-serine kinase 10 
[PISSLRE] 
NP_003665 Q15131 
108 NK026-2 CDK2 Pan-specific Cyclin-dependent protein-serine kinase 2 NP_001789 P24941 
109 NK026-3 CDK2 Pan-specific Cyclin-dependent protein-serine kinase 2 NP_001789 P24941 
110 NK026-4 CDK2 Pan-specific Cyclin-dependent protein-serine kinase 2 NP_001789 P24941 
111 NK026-5 CDK2 Pan-specific Cyclin-dependent protein-serine kinase 2 NP_001789 P24941 
112 NK026-6 CDK2 Pan-specific Cyclin-dependent protein-serine kinase 2 NP_001789 P24941 
113 NK026-7 CDK2 Pan-specific Cyclin-dependent protein-serine kinase 2 NP_001789 P24941 
114 NK027 CDK4 Pan-specific Cyclin-dependent protein-serine kinase 4 NP_000066 P11802 
115 NK027-2 CDK4 Pan-specific Cyclin-dependent protein-serine kinase 4 NP_000066 P11802 
116 NK028-1 CDK5 Pan-specific Cyclin-dependent protein-serine kinase 5 NP_004926 Q00535 
117 NK028-2 CDK5 Pan-specific Cyclin-dependent protein-serine kinase 5 NP_004926 Q00535 
118 NK028-4 CDK5 Pan-specific Cyclin-dependent protein-serine kinase 5 NP_004926 Q00535 
119 NK028-5 CDK5 Pan-specific Cyclin-dependent protein-serine kinase 5 NP_004926 Q00535 
120 NK029 CDK6 Pan-specific Cyclin-dependent protein-serine kinase 6 NP_001250 Q00534 
121 NK029-2 CDK6 Pan-specific Cyclin-dependent protein-serine kinase 6 NP_001250 Q00534 
122 NK029-3 CDK6 Pan-specific Cyclin-dependent protein-serine kinase 6 NP_001250 Q00534 
123 PK165 CDK6 Y13 Cyclin-dependent protein-serine kinase 6 NP_001250 Q00534 
124 NK030-2 CDK7 Pan-specific Cyclin-dependent protein-serine kinase 7 NP_001790 P50613 
125 NK030-3 CDK7 Pan-specific Cyclin-dependent protein-serine kinase 7 NP_001790 P50613 
126 NK031-2 CDK8 Pan-specific Cyclin-dependent protein-serine kinase 8 NP_001252 P49336 
127 NK031-4 CDK8 Pan-specific Cyclin-dependent protein-serine kinase 8 NP_001252 P49336 
128 NK031-5 CDK8 Pan-specific Cyclin-dependent protein-serine kinase 8 NP_001252 P49336 
129 NK032 CDK9 Pan-specific Cyclin-dependent protein-serine kinase 9 NP_001252 P50750 
130 NK199 CDKL1 Pan-specific Cyclin-dependent kinase-like 1 NP_004187.2 Q00532 
131 NK034 Chk1 Pan-specific Checkpoint protein-serine kinase 1 NP_001265 O14757 
132 NK034-2 Chk1 Pan-specific Checkpoint protein-serine kinase 1 NP_001265 O14757 
133 PK162 Chk1 S280 Checkpoint protein-serine kinase 1 NP_001265 O14757 
134 NK035 Chk2 Pan-specific Checkpoint protein-serine kinase 2 NP_009125  O96017 
135 PK119 Chk2 T68 Checkpoint protein-serine kinase 2 NP_009125  O96017 
136 NN025 c-IAP1 Pan-specific Cellular inhibitor of apoptosis protein 1 
(baculoviral IAP repeat-containing protein 3, 
apoptosis inhibitor 2 (API2)) 
NP_001156 Q13490 
137 NK036 CK1d Pan-specific Casein protein-serine kinase 1 delta NP_001884 P48730 
138 NK037-1 CK1e Pan-specific Casein protein-serine kinase 1 epsilon NP_001885 P49674 
139 NK198 CK1g Pan-specific Casein kinase I gamma 1 isoform NP_071331 Q9HCP0  
140 NK040 CK1g2 Pan-specific Casein protein-serine kinase 1 gamma 2 NP_001310 P78368 
141 NK041 CK2a Pan-specific Casein protein-serine kinase 2 alpha/ alpha 
prime 
NP_001887 P68400 
142 PK167 CK2a T360/S362 Casein protein-serine kinase 2 alpha/ alpha 
prime 
NP_001887 P68400 
143 PN130 c-Myc T58/S62 Myc proto-oncogene protein NP_002458.2 P01106 
144 NN026 Cofilin 1 Pan-specific Cofilin 1 NP_005498 P23528 
145 PN019 Cofilin 1 S3 Cofilin 1 NP_005498   P23528 
146 PN020 Cofilin 2 S3 Cofilin 2 NP_068733 Q9Y281 
147 PN148 Connexin 
43 
S368 Gap junction alpha-1 protein NP_000156.1 P17302 
148 PN022-2 Cortactin Y466 Cortactin (amplaxin) (mouse) NP_031829 Q14247 
149 NK042 COT Pan-specific Osaka thyroid oncogene protein-serine kinase 
(Tpl2) 
NP_005195 P41279 
150 NK042-2 COT Pan-specific Osaka thyroid oncogene protein-serine kinase 
(Tpl2) 
NP_005195 P41279 
151 NN027 COX2 Pan-specific Cyclo-oxygenase 2 (prostaglandin G/H synthase 
2 precursor) 
NP_000954 P35354 
152 NK043 CPG16/Ca
MKinase 
VI 
Pan-specific Serine/threonine-protein kinase DCAMKL1 NP_004725 O15075 
153 PN023 CREB1 S129+S133 cAMP response element binding protein 1 NP_004370 P16220 
154 PN024 CREB1 S133 cAMP response element binding protein 1 NP_004370  P16220 
155 PN024-2 CREB1 S133 cAMP response element binding protein 1 NP_004370  P16220 
156 NN149-1 Crystallin 
aB 
Pan-specific Crystallin alpha B (heat-shock 20 kDa like-
protein) 
NP_001876  P02511 
157 NN149-2 Crystallin 
aB 
Pan-specific Crystallin alpha B (heat-shock 20 kDa like-
protein) 
NP_001876  P02511 
158 NN149-3 Crystallin 
aB 
Pan-specific Crystallin alpha B (heat-shock 20 kDa like-
protein) 
NP_001876  P02511 
159 PN025 Crystallin 
aB 
S19 Crystallin alpha B (heat-shock 20 kDa like-
protein) 
NP_001876  P02511 
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160 PN110 Crystallin 
aB 
S45 Crystallin alpha B (heat-shock 20 kDa like-
protein) 
NP_001876  P02511 
161 NK044 Csk Pan-specific C-terminus of Src tyrosine kinase NP_004374 P41240 
162 NK044-2 Csk Pan-specific C-terminus of Src tyrosine kinase NP_004374 P41240 
163 NN028 Cyclin A Pan-specific Cyclin A1 NP_003905 P78396 
164 NN029 Cyclin B1 Pan-specific Cyclin B1 NP_114172  P14635 
165 PN190 Cyclin B1 S147 Cyclin B1 NP_114172  P14635 
166 NN030-1 Cyclin D1 Pan-specific Cyclin D1 (PRAD1) NP_444284 P24385 
167 NN030-2 Cyclin D1 Pan-specific Cyclin D1 (PRAD1) NP_444284 P24385 
168 NN031 Cyclin E Pan-specific Cyclin E1 NP_001229 P24864 
169 PN191 Cyclin E T395 Cyclin E1 NP_001229 P24864 
170 NN032 Cyclin G1 Pan-specific Cyclin G1 NP_004051  P51959 
171 NN033 CytoC Pan-specific Cytochrome C NP_061820 P99999 
172 PN026 Dab1 Y198 Disabled homolog 1 NP_066566  O75553 
173 NK210 DAPK1 Pan-specific Death-associated protein kinase 1 NP_004929 P53355 
174 NK046 DAPK2 Pan-specific Death-associated protein kinase 2 NP_055141 Q9UIK4 
175 NN034 DAXX Pan-specific Death-associated protein 6 (BING2) NP_001341 Q9UER7 
176 NN163 DDIT3(CH
OP) 
Pan-specific DNA damage-inducible transcript 3 protein NP_001181986.1 P35639 
177 NN035-
NN126 
DFF35 Pan-specific DNA fragmentation factor alpha (ICAD) 35-kDa 
subunit 
NP_004392 O00273 
178 NK219 DGKz Pan-specific Diacylglycerol kinase zeta NP_963290 Q13574 
179 NK048 DNAPK Pan-specific DNA-activated protein-serine kinase NP_008835 P78527 
180 NK048-2 DNAPK Pan-specific DNA-activated protein-serine kinase NP_008835 P78527 
181 PN027 Dok2 Y139 Docking protein 2 NP_034201   O60496 
182 PN027-2 Dok2 Y139 Docking protein 2 NP_034201   O60496 
183 NK050 DRAK2 
(STK17B) 
Pan-specific DAP kinase-related apoptosis-inducing protein-
serine kinase 2 (STK17B) 
NP_004217 O94768 
184 NK051 eEF2K Pan-specific Elongation factor-2 protein-serine kinase NP 037434 O00418 
185 NN175 EFNA5 Pan-specific Ephrin-A5 NP_001953.1 P52803 
186 PN173 EFNB2 Y316 EPH-related receptor tyrosine kinase ligand 5 NP_004084.1 P52799 
187 NK052-1 EGFR Pan-specific Epidermal growth factor receptor-tyrosine kinase NP_005219 P00533 
188 PK010 EGFR Y1172 Epidermal growth factor receptor-tyrosine kinase NP_005219 P00533 
189 PK010-2 EGFR Y1172 Epidermal growth factor receptor-tyrosine kinase NP_005219 P00533 
190 PK011-1 EGFR Y1197 Epidermal growth factor receptor-tyrosine kinase NP_005219 P00533 
191 PK121 EGFR T693 Epidermal growth factor receptor-tyrosine kinase NP_005219 P00533 
192 PK122-1 EGFR Y1092 Epidermal growth factor receptor-tyrosine kinase NP_005219 P00533 
193 PK123 EGFR Y1110 Epidermal growth factor receptor-tyrosine kinase NP_005219 P00533 
194 NN038-1 eIF2a Pan-specific Eukaryotic translation initiation factor 2 alpha NP_004085 P05198 
195 PN028-1 eIF2a S52 Eukaryotic translation initiation factor 2 alpha NP_004085 P05198 
196 PN028-2 eIF2a S52 Eukaryotic translation initiation factor 2 alpha NP_004085 P05198 
197 PN172 eIF4B S422 Eukaryotic translation initiation factor 4B NP_001408.2 P23588 
198 NN039-1 eIF4E Pan-specific Eukaryotic translation initiation factor 4 (mRNA 
cap binding protein) 
NP_001959 P06730 
199 PN030-1 eIF4E S209 Eukaryotic translation initiation factor 4 (mRNA 
cap binding protein) 
NP_001959 P06730 
200 PN030-2 eIF4E S209 Eukaryotic translation initiation factor 4 (mRNA 
cap binding protein) 
NP_001959 P06730 
201 PN031 eIF4G S1107 Eukaryotic translation initiation factor 4 gamma 
1 
NP_004944  Q04637 
202 PN193 eIF4G S1232 Eukaryotic translation initiation factor 4 gamma 
1 
NP_004944  Q04637 
203 NN168 Elk-1 Pan-specific ETS domain-containing protein Elk-1 NP_001107595.1 P19419 
204 PN149 Elk-1 S383 ETS domain-containing protein Elk-1 NP_001107595.1 P19419 
205 PN170 Elk-1 S389 ETS domain-containing protein Elk-1 NP_001107595.1 P19419 
206 NN173 Epcam Pan-specific Epithelial cell adhesion molecule NP_002345.2 P16422 
207 NK053 EphA1 Pan-specific Ephrin type-A receptor 1 protein-tyrosine kinase NP_005223  P21709 
208 PN198 ER-alpha S104 estrogen receptor alpha NP_000116.2 P03372 
209 NK054-1 ErbB2 
(HER2) 
Pan-specific ErbB2 (Neu) receptor-tyrosine kinase NP_004439 P04626 
210 NK054-2 ErbB2 
(HER2) 
Pan-specific ErbB2 (Neu) receptor-tyrosine kinase NP_004439 P04626 
211 PK013-1 ErbB2 
(HER2) 
Y1248 ErbB2 (Neu) receptor-tyrosine kinase NP_004439 P04626 
212 PK013-2 ErbB2 
(HER2) 
Y1248 ErbB2 (Neu) receptor-tyrosine kinase NP_004439 P04626 
213 PK134 ErbB2 
(HER2) 
T686 ErbB2 (Neu) receptor-tyrosine kinase NP_004439 P04626 
214 PK163 ErbB3 Y1328 Tyrosine kinase-type cell surface receptor HER3 NP_001005915.1 P21860 
215 NK055-
NK056 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
Pan-specific Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
216 NK055-
NK056-2 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
Pan-specific Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
217 NK055-
NK056-4 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
Pan-specific Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
218 NK055-
NK056-5 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
Pan-specific Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
219 NK055-
NK056-6 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
Pan-specific Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
220 NK055-
NK056-8 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
Pan-specific Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
221 PK168-
PK169 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
Y204 Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
222 PK170-
PK171 
Erk1 
(MAPK3)+ 
Erk2 
(MAPK1) 
T202 Extracellular regulated protein-serine kinase 1 
(p44 MAP kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 MAP kinase) 
AAA36142.1, 
NP_002736 
P27361 
223 NK056 Erk2 
(MAPK1) 
Pan-specific Extracellular regulated protein-serine kinase 2 
(p42 MAP kinase) 
NP_002736 P28482 
224 NK057-2 Erk3 
(MAPK6) 
Pan-specific Extracellular regulated protein-serine kinase 3 NP_002739 Q16659 
225 NK058 Erk4 
(MAPK4) 
Pan-specific Extracellular regulated protein-serine kinase 4 NP_002738 P31152 
226 NK206-1 Erk5 
(MAPK7) 
Pan-specific Extracellular regulated protein-serine kinase 5 
(Big MAP kinase 1 (BMK1)) 
NP_620602 Q13164 
227 NK206-2 Erk5 
(MAPK7) 
Pan-specific Extracellular regulated protein-serine kinase 5 
(Big MAP kinase 1 (BMK1)) 
NP_620602 Q13164 
228 NK206-3 Erk5 
(MAPK7) 
Pan-specific Extracellular regulated protein-serine kinase 5 
(Big MAP kinase 1 (BMK1)) 
NP_620602 Q13164 
229 PK016 Erk5 
(MAPK7) 
T218+Y220 Extracellular regulated protein-serine kinase 5 
(Big MAP kinase 1 (BMK1)) 
NP_620602 Q13164 
230 PK016-3 Erk5 
(MAPK7) 
T218+Y220 Extracellular regulated protein-serine kinase 5 
(Big MAP kinase 1 (BMK1)) 
NP_620602 Q13164 
231 NN040 ERP57 Pan-specific ER protein 57 kDa (protein disulfide isomerase-
associated 3; 58 kDa glucose regulated protein) 
NP_005304 P30101 
232 NN041 ERP72 Pan-specific ER protein 72 kDa (protein disulfide isomerase-
associated 4) 
NP_004902 P13667 
233 PN174 Ezrin T567 cytovillin 2 NP_001104547.1 P15311 
234 PN175 Ezrin Y353 cytovillin 2 NP_001104547.1 P15311 
235 NK060 FAK Pan-specific Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
236 PK017 FAK Y397 Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
237 PK017-1 FAK Y397 Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
238 PK018-3 FAK Y576 Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
239 PK020 FAK S722 Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
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240 PK020-3 FAK S722 Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
241 PK021 FAK S732 Focal adhesion protein-tyrosine kinase NP_005598  Q05397 
242 PK022-2 FAK S843 Focal adhesion protein-tyrosine kinase NP_005598  Q05397 
243 PK024 FAK S910 Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
244 PK151 FAK Y576/Y577 Focal adhesion protein-tyrosine kinase NP_005598 Q05397 
245 NN042 FAS Pan-specific Tumor necrosis factor superfamily member 6 
(Apo1, CD95) 
NP_003789 P25445 
246 NN043 FasL Pan-specific Tumor necrosis factor ligand, member 6 NP_000630 P48023 
247 NK061 Fes Pan-specific Fes/Fps protein-tyrosine kinase NP_001996 P07332 
248 NN172 FHL2 Pan-specific Four and a half LIM domains protein 2 NP_001034581.1 Q14192 
249 NN127 FKBP52 Pan-specific FK506-binding protein 4 NP_002005 Q02790 
250 PN194 FKHR S256 Forkhead box protein O1 NP_002006.2 Q12778 
251 PN195 FKHR S319 Forkhead box protein O1 NP_002006.2 Q12778 
252 PN145-
PN032 
FKHRL1 T32 Forkhead-like transcription factor 1 (FOXO3A) NP_001446 O43524 
253 PN145-
PN032-
PN153 
FKHRL1 T32 Forkhead-like transcription factor 1 (FOXO3A) NP_001446 O43524 
254 NN044 Fos Pan-specific Fos-c FBJ murine osteosarcoma oncoprotein-
related transcription factor 
NP_005243 P01100 
255 PN033 Fos T232 Fos-c FBJ murine osteosarcoma oncoprotein-
related transcription factor 
NP_005243  P01100 
256 PN146 FRS2 Y348 Fibroblast growth factor receptor substrate 2 NP_001036020.1 Q8WU20 
257 NK065 Fyn Pan-specific Fyn proto-oncogene-encoded protein-tyrosine 
kinase 
NP_002028 P06241 
258 PN192 Gab1 Y627 GRB2-associated binder 1 NP_002030.2 Q13480 
259 PN098 GAP-43 S41 Growth associated protein 43 (Neuromodulin) NP_002036 P17677 
260 PN196 GATA1 S142 Erythroid transcription factor NP_002040.1 P15976 
261 NK066 GCK Pan-specific Germinal centre protein-serine kinase NP_004570 Q12851 
262 PN034 GFAP S8 Glial fibrillary acidic protein NP_002046  P14136 
263 PN178 GluR1 S849 Glutamate receptor 1 NP_000818.2 P42261 
264 NN045 GNB2L1 Pan-specific Guanine nucleotide-binding protein beta 
(receptor for activated C kinase 1 (RACK1)) 
NP_006089 P63244 
265 NK067 GRK2 
(BARK1) 
Pan-specific G protein-coupled receptor-serine kinase 2 NP_001610 P25098 
266 PK025 GRK2 
(BARK1) 
S670 G protein-coupled receptor-serine kinase 2 NP_001610 P25098 
267 NK068 GRK3 
(BARK2) 
Pan-specific G protein-coupled receptor-serine kinase 3 NP_005151 P35626 
268 NN046 GroEL Pan-specific GroEL homolog (may correspond to Hsp60) NP_002147 P10809 
269 NN047 Grp75 Pan-specific Glucose regulated protein 75 NP_004125 P38646 
270 NN048 Grp78 Pan-specific Glucose regulated protein 78 NP_005338 P11021 
271 NN048-2 Grp78 Pan-specific Glucose regulated protein 78 NP_005338 P11021 
272 NN049 Grp94 Pan-specific Glucose regulated protein 94 (endoplasmin) NP_003290 P14625 
273 NK069-
NK070 
GSK3a Pan-specific Glycogen synthase-serine kinase 3 alpha NP_063937 P49840 
274 NK069-
NK070-2 
GSK3a Pan-specific Glycogen synthase-serine kinase 3 alpha NP_063937 P49840 
275 PK026-
PK027-1 
GSK3a S21 Glycogen synthase-serine kinase 3 alpha NP_063937 P49840 
276 PK028-
PK029-1 
GSK3a Y279 Glycogen synthase-serine kinase 3 alpha NP_063937 P49840 
277 NK070 GSK3b Pan-specific Glycogen synthase-serine kinase 3 beta NP_002084 P49841 
278 NK070-1 GSK3b Pan-specific Glycogen synthase-serine kinase 3 beta NP_002084 P49841 
279 NK071 Haspin Pan-specific Haploid germ cell-specific nuclear protein-serine 
kinase 
NP_114171 Q8TF76 
280 NN169 HDAC4 Pan-specific Histone deacetylase 4 NP_006028.2 P56524 
281 PN179-
PN180-
PN181 
HDAC4 S246 Histone deacetylase 4 NP_006028.2 P56524 
282 PN188 HDAC5 S498 Histone deacetylase 5 NP_001015053.1 Q9UQL6 
283 NN050 hHR23B Pan-specific UV excison repair protein RAD23 homolog B NP_002865 P54727 
284 NN051 Hip Pan-specific Hsp70/Hsc70 interacting protein (ST13) NP_003923 P50502 
285 PN035 Histone H1 phospho CDK1 sites Histone H1 phosphorylated NP_005316 Q02539 
286 PN036 Histone 
H2A.X 
S140 Histone H2A variant X NP_002096  P16104 
287 PN037 Histone 
H2B 
S15 Histone H2B NP_778225 P33778 
288 PN038 Histone H3 S11 Histone H3.3 NP_003521 P84243 
289 PN039 Histone H3 S29 Histone H3.3 NP_003521 P84243 
290 PN100 Histone H3 T12 Histone H3.3 NP_003521 P84243 
291 PN101 Histone H3 T4 Histone H3.3 NP_003521 P84243 
292 PN101-2 Histone H3 T4 Histone H3.3 NP_003521 P84243 
293 NN052 HO1 Pan-specific Heme oxygenase 1 NP_002124 P09601 
294 NN053 HO2 Pan-specific Heme oxygenase 2 NP_002125 P30519 
295 NK072 Hpk1 
(MAP4K1) 
Pan-specific Hematopoetic progenitor protein-serine kinase 1 NP_009112 Q92918 
296 NN054 Hsc70 Pan-specific Heat shock 70 kDa protein 8 NP_006588 P11142 
297 NN054-2 Hsc70 Pan-specific Heat shock 70 kDa protein 8 NP_006588 P11142 
298 NN055 HSF4 Pan-specific Heat shock transcription factor 4 NP_001529 Q9ULV5  
299 NN062 Hsp105 Pan-specific Heat shock 105 kDa protein NP_006635 Q92598 
300 NN152-1 Hsp27 Pan-specific Heat shock 27 kDa protein beta 1 (HspB1) NP_001531 P04792 
301 PN040-1 Hsp27 S15 Heat shock 27 kDa protein beta 1 (HspB1) NP_001531 P04792 
302 PN040-2 Hsp27 S15 Heat shock 27 kDa protein beta 1 (HspB1) NP_001531 P04792 
303 PN041 Hsp27 S78 Heat shock 27 kDa protein beta 1 (HspB1) NP_001531 P04792 
304 PN042-1 Hsp27 S82 Heat shock 27 kDa protein beta 1 (HspB1) NP_001531 P04792 
305 PN042-2 Hsp27 S82 Heat shock 27 kDa protein beta 1 (HspB1) NP_001531 P04792 
306 PN042-3 Hsp27 S82 Heat shock 27 kDa protein beta 1 (HspB1) NP_001531 P04792 
307 NN057 Hsp40 Pan-specific DnaJ homolog, subfamily B member 1 NP_006136 P25685 
308 NN057-2 Hsp40 Pan-specific DnaJ homolog, subfamily B member 1 NP_006136 P25685 
309 NN057-3 Hsp40 Pan-specific DnaJ homolog, subfamily B member 1 NP_006136 P25685 
310 NN058 Hsp47 Pan-specific Heat shock 47 kDa protein (collagen-binding 
protein 1, colligin 1) 
NP_001226 P29043 
311 NN059-1 Hsp60 Pan-specific Heat shock 60 kDa protein 1 (chaperonin, 
CPN60) 
NP_002147 P10809 
312 NN059-2 Hsp60 Pan-specific Heat shock 60 kDa protein 1 (chaperonin, 
CPN60) 
NP_002147 P10809 
313 NN059-3 Hsp60 Pan-specific Heat shock 60 kDa protein 1 (chaperonin, 
CPN60) 
NP_002147 P10809 
314 NN060 Hsp70 Pan-specific Heat shock 70 kDa protein 1 NP_005336 P08107 
315 NN060-2 Hsp70 Pan-specific Heat shock 70 kDa protein 1 NP_005336 P08107 
316 NN060-3 Hsp70 Pan-specific Heat shock 70 kDa protein 1 NP_005336 P08107 
317 NN164 Hsp90a Pan-specific Heat shock 90 kDa protein alpha NP_005339 P07900 
318 NN061 Hsp90a/b Pan-specific Heat shock 90 kDa protein alpha/beta NP_005339 P07900 
319 NN061-16 Hsp90a/b Pan-specific Heat shock 90 kDa protein alpha/beta NP_005339 P07900 
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320 NN061-2 Hsp90a/b Pan-specific Heat shock 90 kDa protein alpha/beta NP_005339 P07900 
321 NN061-3 Hsp90a/b Pan-specific Heat shock 90 kDa protein alpha/beta NP_005339 P07900 
322 NN061-4 Hsp90a/b Pan-specific Heat shock 90 kDa protein alpha/beta NP_005339 P07900 
323 NN165 Hsp90b Pan-specific Heat shock 90 kDa protein beta NP_031381 P08238 
324 NN165-1 Hsp90b Pan-specific Heat shock 90 kDa protein beta NP_031381 P08238 
325 PN176 Hsp90b S255 Heat shock 90 kDa protein beta NP_031381 P08238 
326 NN063 HspBP1 Pan-specific Hsp70 binding protein 1 NP_036399 Q9NZL4 
327 PN103 Huntingtin S421 Huntington's disease protein NP_002102 P42858 
328 NN130 I1PP2A Pan-specific Acidic leucine-rich nuclear phosphoprotein 32 
family member A 
NP_006296 P39687 
329 NN131 I2PP2A Pan-specific Protein SET NP_003002 Q01105 
330 NK073 ICK Pan-specific Intestinal cell protein-serine kinase (MAK-related 
kinase (MRK) 
NP_057597 Q9UPZ9 
331 NK074 IGF1R Pan-specific Insulin-like growth factor 1 receptor protein-
tyrosine kinase 
NP_000866 P08069 
332 PK152 IGF1R Y1280 Insulin-like growth factor 1 receptor protein-
tyrosine kinase 
NP_000866 P08069 
333 PK153 IGF1R Y1165/Y1166 Insulin-like growth factor 1 receptor protein-
tyrosine kinase 
NP_000866 P08069 
334 PK139 IGF1Rb/IR
b 
Y1161/Y1185 Insulin-like growth factor 1 /Insulin 
receptorreceptor beta 
NP_000866 P08069 
335 NN064 IkBa Pan-specific Inhibitor of NF-kappa-B alpha (MAD3) NP_065390 P25963 
336 NN064-2 IkBa Pan-specific Inhibitor of NF-kappa-B alpha (MAD3) NP_065390 P25963 
337 NN064-4 IkBa Pan-specific Inhibitor of NF-kappa-B alpha (MAD3) NP_065390 P25963 
338 PN164 IkBa Y42 Inhibitor of NF-kappa-B alpha (MAD3) NP_065390 P25963 
339 NN065 IkBb Pan-specific Inhibitor of NF-kappa-B beta (thyroid receptor 
interacting protein 9) 
NP_002494 Q15653 
340 PN168 IkBe S22 NF-kappa-B inhibitor epsilon NP_004547.2 O00221 
341 NK075-1 IKKa Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
342 NK075-2 IKKa Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
343 NK075-3 IKKa Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
344 NK075-4 IKKa Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
345 NK075-5 IKKa Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
346 NK075-6 IKKa Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
347 PK030-
PK031 
IKKa S180 Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
348 PK154 IKKa T23 Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
NP_001269 O15111 
349 NK076-1 IKKb Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
beta 
NP_001547 O14920 
350 NK076-2 IKKb Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
beta 
NP_001547 O14920 
351 NK076-3 IKKb Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
beta 
NP_001547 O14920 
352 NK076-4 IKKb Pan-specific Inhibitor of NF-kappa-B protein-serine kinase 
beta 
NP_001547 O14920 
353 NN161 IKKg 
(NEMO) 
Pan-specific I-kappa-B kinase gamma/NF-kappa-B essential 
modulator 
NP_003630 Q9Y6K9 
354 NK078-2 ILK1 Pan-specific Integrin-linked protein-serine kinase 1 NP_034692  Q13418 
355 NK078-3 ILK1 Pan-specific Integrin-linked protein-serine kinase 1 NP_034692  Q13418 
356 PN043 Integrin a4 S1027 Integrin alpha 4 (VLA4) NP_000876 P13612 
357 PN044 Integrin b1 S785 Integrin beta 1 (fibronectin receptor beta 
subunit, CD29 antigen) 
NP_002202   P05556 
358 NK079 IR (INSR) Pan-specific Insulin receptor beta chain NP_000199 P06213 
359 PK032-1 IR (INSR) Y999 Insulin receptor NP_000199 P06213 
360 PK033 IR/IGF1R 
(INSR) 
Y1189/Y1190 Insulin receptor / Insulin-like growth factor 1 
receptor 
NP_000866 P06213 
361 NK080 IRAK1 Pan-specific Interleukin 1 receptor-associated kinase 1 
(Pelle-like protein kinase) 
NP_001560 P51617 
362 NK080-2 IRAK1 Pan-specific Interleukin 1 receptor-associated kinase 1 
(Pelle-like protein kinase) 
NP_001560 P51617 
363 NK081 IRAK2 Pan-specific Interleukin 1 receptor-associated kinase 2 NP_001561  O43187 
364 NK081-2 IRAK2 Pan-specific Interleukin 1 receptor-associated kinase 2 NP_001561  O43187 
365 NK082 IRAK3 Pan-specific Interleukin 1 receptor-associated kinase 3 NP_009130 Q9Y616 
366 NK083-1 IRAK4 Pan-specific Interleukin 1 receptor-associated kinase 4 NP_057207 Q9NWZ3 
367 NK083-2 IRAK4 Pan-specific Interleukin 1 receptor-associated kinase 4 NP_057207 Q9NWZ3 
368 PN045 IRS1 Y612 Insulin receptor substrate 1 NP_005535 P35568 
369 PN046-2 IRS1 Y1179 Insulin receptor substrate 1 NP_005535 P35568 
370 PN117 IRS1 S312 Insulin receptor substrate 1 NP_005535 P35568 
371 PN118 IRS1 S639 Insulin receptor substrate 1 NP_005535 P35568 
372 NK084-1 JAK1 Pan-specific Janus protein-tyrosine kinase 1 NP_002218 P23458 
373 NK084-2 JAK1 Pan-specific Janus protein-tyrosine kinase 1 NP_002218 P23458 
374 PK126 JAK1 Y1034 Janus protein-tyrosine kinase 1 NP_002218 P23458 
375 NK085 JAK2 Pan-specific Janus protein-tyrosine kinase 2 NP_004963 O60674 
376 PK034-1 JAK2 Y1007+Y1008 Janus protein-tyrosine kinase 2 NP_004963 O60674 
377 PK034-2 JAK2 Y1007+Y1008 Janus protein-tyrosine kinase 2 NP_004963 O60674 
378 NK086 JAK3 Pan-specific Janus protein-tyrosine kinase 3 NP_000206 P52333 
379 NK087 TAO3 (JIK) Pan-specific STE20-like protein-serine kinase NP_057365 Q9H2K8 
380 NK217 JNK1 
(MAPK8) 
Pan-specific Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1 
NP_620637.1 P45983 
381 NK088-1 JNK1/2/3 Pan-specific Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1/2/3 
NP_002741 P45983 
382 NK088-2 JNK1/2/3 Pan-specific Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1/2/3 
NP_002741 P45983 
383 NK088-3 JNK1/2/3 Pan-specific Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1/2/3 
NP_002741 P45983 
384 PK035-1 JNK1/2/3 T183 + Y185 Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1/2/3 
NP_002741 P45983 
385 PK035-2 JNK1/2/3 T183 + Y185 Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1/2/3 
NP_002741 P45983 
386 PK035-4 JNK1/2/3 T183 + Y185 Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 1/2/3 
NP_002741 P45983 
387 NK189 JNK2 
(MAPK9) 
Pan-specific Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPK)) 2 
NP_002744 P45984 
388 NK196 JNK2/3 Pan-specific Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPKa/b)) 2/3 
NP_002743.3  P45984 
389 NK197 JNK3 
(MAPK10) 
Pan-specific Jun N-terminus protein-serine kinase (stress-
activated protein kinase (SAPKb)) 3 
NP_002744.1  P53779 
390 NN162 Jun Pan-specific Jun proto-oncogene-encoded AP1 transcription 
factor 
NP_002219 P05412 
391 PN047 Jun S63 Jun proto-oncogene-encoded AP1 transcription 
factor 
NP_002219 P05412 
392 PN048-1 Jun S73 Jun proto-oncogene-encoded AP1 transcription 
factor 
NP_002219 P05412 
393 PN048-2 Jun S73 Jun proto-oncogene-encoded AP1 transcription 
factor 
NP_002219 P05412 
394 PN154 Jun S243 Jun proto-oncogene-encoded AP1 transcription 
factor 
NP_002219 P05412 
395 PN155 Jun Y170 Jun proto-oncogene-encoded AP1 transcription 
factor 
NP_002219 P05412 
396 PN163 Jun T91 Jun proto-oncogene-encoded AP1 transcription 
factor 
NP_002219 P05412 
397 NP004 KAP Pan-specific Cyclin-dependent  kinase associated 
phosphatase (CDK inhibitor 3, CIP2) 
NP_005183 Q16667 
398 NN153 KDEL 
receptor 1 
Pan-specific ER lumen protein retaining receptor 1 NP_006792.1 P24390 
399 NK089 KHS 
(MAP4K5) 
Pan-specific Kinase homologous to SPS1/STE20  NP_006566 Q9Y4K4 
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400 PK036 Kit Y703 Kit/Steel factor receptor-tyrosine kinase NP_006566 P10721 
401 PK037 Kit Y730 Kit/Steel factor receptor-tyrosine kinase NP_006566 P10721 
402 PK038 Kit Y936 Kit/Steel factor receptor-tyrosine kinase NP_006566 P10721 
403 PK150 Kit Y721 Kit/Steel factor receptor-tyrosine kinase NP_006566 P10721 
404 NK090 Ksr1 Pan-specific Protein-serine kinase suppressor of Ras 1 NP_055053.1 Q8IVT5 
405 NK090-2 Ksr1 Pan-specific Protein-serine kinase suppressor of Ras 1 NP_055053.1 Q8IVT5 
406 NP005 LAR Pan-specific LCA antigen-related (LAR) receptor tyrosine 
phosphatase 
NP_002831 P10586 
407 NK091 LATS1 Pan-specific Large tumor suppressor 1 protein-serine kinase 
(WARTS) 
NP_004681 O95835 
408 NK092-2 Lck Pan-specific Lymphocyte-specific protein-tyrosine kinase NP_005347 P06239 
409 NK092-3 Lck Pan-specific Lymphocyte-specific protein-tyrosine kinase NP_005347 P06239 
410 PK039 Lck S158 Lymphocyte-specific protein-tyrosine kinase NP_005347 P06239 
411 PK040 Lck Y192 Lymphocyte-specific protein-tyrosine kinase NP_005347 P06239 
412 PK041 Lck Y505 Lymphocyte-specific protein-tyrosine kinase NP_005347 P06239 
413 PK149 Lck Y394 Lymphocyte-specific protein-tyrosine kinase NP_005347 P06239 
414 NK093 LIMK1 Pan-specific LIM domain kinase 1 NP_002305 P53667 
415 PK042-
PK144 
LIMK1 Y507+T508 LIM domain kinase 1 NP_002305 P53667 
416 NK095 Lyn Pan-specific Yes-related protein-tyrosine kinase NP_002341 P07948 
417 PK043 Lyn Y508 Yes-related protein-tyrosine kinase NP_002341 P07948 
418 NK096 MAK Pan-specific Male germ cell-associated protein-serine kinase NP_005897 P20794 
419 NK097 MAPKAPK
2 
Pan-specific Mitogen-activated protein kinase-activated 
protein kinase 2 
NP_116584 P49137 
420 PK044 MAPKAPK
2 
T222 Mitogen-activated protein kinase-activated 
protein kinase 2 
NP_004750 P49137 
421 PN049-
PN112-1 
MAPKAPK
2a 
T334 Mitogen-activated protein kinase-activated 
protein kinase 2 alpha 
NP_004750  P49137 
422 PN049-
PN112-2 
MAPKAPK
2a 
T334 Mitogen-activated protein kinase-activated 
protein kinase 2 alpha 
NP_004750  P49137 
423 PN050-1 MARCKS S159+S163 Myristoylated alanine-rich protein kinase C 
substrate 
NP_002347 P29966 
424 NK098 MARK Pan-specific MAP/microtubule affinity-regulating protein-
serine kinase 1 
NP_061120 Q9P0L2 
425 NN067 Mcl1 Pan-specific Myeloid cell leukemia differentiation protein 1 NP_068779  Q07820 
426 PN169 MDM2 S166 double minute 2 NP_002383.2 Q00987 
427 NN155 MEF-2 Pan-specific Myelin expression factor 2 (MYEF2) NP_057216.2 Q9P2K5  
428 NK099-1 MEK1 
(MAP2K1) 
Pan-specific MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
429 NK099-2 MEK1 
(MAP2K1) 
Pan-specific MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
430 NK099-3 MEK1 
(MAP2K1) 
Pan-specific MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
431 NK099-4 MEK1 
(MAP2K1) 
Pan-specific MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
432 NK099-5 MEK1 
(MAP2K1) 
Pan-specific MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
433 PK046-1 MEK1 
(MAP2K1) 
T292 MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
434 PK046-2 MEK1 
(MAP2K1) 
T292 MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
435 PK046-3 MEK1 
(MAP2K1) 
T292 MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
436 PK047-2 MEK1 
(MAP2K1) 
S298 MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
437 PK048-1 MEK1 
(MAP2K1) 
T386 MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
438 PK048-2 MEK1 
(MAP2K1) 
T386 MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
439 PK048-3 MEK1 
(MAP2K1) 
T386 MAPK/ERK protein-serine kinase 1 (MKK1) NP_002746 Q02750 
440 PK045-
PN007 
MEK1/2 
(MAP2K1/
2) 
S218+S222 MAPK/ERK protein-serine kinase 1/2 (MKK1/2) NP_002746 Q02750 
441 NK221 MEK1/2 
(MAP2K1/
2) 
Pan-specific MAPK/ERK protein-serine kinase 1/2 (MKK1/2) NP_002746 Q02750 
442 NK100-1 MEK2 
(MAP2K2) 
Pan-specific MAPK/ERK protein-serine kinase 2 (MKK2) AAH00471.1 P36507 
443 NK100-2 MEK2 
(MAP2K2) 
Pan-specific MAPK/ERK protein-serine kinase 2 (MKK2) AAH00471.1 P36507 
444 NK100-3 MEK2 
(MAP2K2) 
Pan-specific MAPK/ERK protein-serine kinase 2 (MKK2) AAH00471.1 P36507 
445 PK049 MEK2 
(MAP2K2) 
T394 MAPK/ERK protein-serine kinase 2 (MKK2) AAH00471.1 P36507 
446 PK049-2 MEK2 
(MAP2K2) 
T394 MAPK/ERK protein-serine kinase 2 (MKK2) AAH00471.1 P36507 
447 PK050 MEK2 
(MAP2K2) 
T394 MAPK/ERK protein-serine kinase 2 (MKK2) 
(mouse) 
NP_075627 P36507 
448 NK101 MEK3 
(MAP2K3) 
Pan-specific MAPK/ERK protein-serine kinase 3 (MKK3) NP_659732 P46734 
449 NK101-3 MEK3 
(MAP2K3) 
Pan-specific MAPK/ERK protein-serine kinase 3 (MKK3) NP_659732 P46734 
450 PK127 MEK3 
(MAP2K3) 
S218 MAPK/ERK protein-serine kinase 3 (MKK3) NP_659732 P46734 
451 PK051 MEK3/6 
(MAP2K3/
6) 
S218/S207 MAPK/ERK protein-serine kinase 3/6 (MKK3/6) NP_002747 P46734 
452 PK051-2 MEK3/6 
(MAP2K3/
6) 
S218/S207 MAPK/ERK protein-serine kinase 3/6 (MKK3/6) NP_002747 P46734 
453 PK051-3 MEK3/6 
(MAP2K3/
6) 
S218/S207 MAPK/ERK protein-serine kinase 3/6 (MKK3/6) NP_002747 P46734 
454 NK102 MEK3b 
(MAP2K3) 
Pan-specific MAPK/ERK protein-serine kinase 3 beta isoform 
(MKK3 beta) 
NP_659731 P46734 
455 NK103 MEK4 
(MAP2K4) 
Pan-specific MAPK/ERK protein-serine kinase 4 (MKK4) NP_003001 P45985 
456 NK103-2 MEK4 
(MAP2K4) 
Pan-specific MAPK/ERK protein-serine kinase 4 (MKK4) NP_003001 P45985 
457 NK103-3 MEK4 
(MAP2K4) 
Pan-specific MAPK/ERK protein-serine kinase 4 (MKK4) NP_003001 P45985 
458 PK052 MEK4 
(MAP2K4) 
S257+T261 MAPK/ERK protein-serine kinase 4 (MKK4) NP_003001  P45985 
459 PK155 MEK5 
(MAP2K5) 
S311+T315 MAPK/ERK protein-serine kinase 5 (MKK5) NP_660143 Q13163 
460 NK104 MEK5 
(MAP2K5) 
Pan-specific MAPK/ERK protein-serine kinase 5 (MKK5) NP_660143 Q13163 
461 NK104-2 MEK5 
(MAP2K5) 
Pan-specific MAPK/ERK protein-serine kinase 5 (MKK5) NP_660143 Q13163 
462 NK105-1 MEK6 
(MAP2K6) 
Pan-specific MAPK/ERK protein-serine kinase 6 (MKK6) NP_002749 P52564 
463 PK129 MEK6 
(MAP2K6) 
S207 MAPK/ERK protein-serine kinase 6 (MKK6) NP_002749 P52564 
464 NK106-2 MEK7 
(MAP2K7) 
Pan-specific MAPK/ERK protein-serine kinase 7 (MKK7) NP_005034 O14733 
465 NK107 MEKK1 
(MAP3K1) 
Pan-specific MAPK/ERK kinase kinase 1 NP_005912.1 Q13233 
466 NK107-2 MEKK1 
(MAP3K1) 
Pan-specific MAPK/ERK kinase kinase 1 NP_005912.1 Q13233 
467 NK107-3 MEKK1 
(MAP3K1) 
Pan-specific MAPK/ERK kinase kinase 1 NP_005912.1 Q13233 
468 NK107-4 MEKK1 
(MAP3K1) 
Pan-specific MAPK/ERK kinase kinase 1 NP_005912.1 Q13233 
469 NK108 MEKK2 
(MAP3K2) 
Pan-specific MAPK/ERK kinase kinase 2 NP_006600.3 Q9Y2U5  
470 NK108-2 MEKK2 
(MAP3K2) 
Pan-specific MAPK/ERK kinase kinase 2 NP_006600.3 Q9Y2U5  
471 NK109 MEKK4 
(MAP3K4) 
Pan-specific MAPK/ERK kinase kinase 4 NP_005913 Q9Y6R4  
472 PK055-1 Met Y1230+Y1234+Y1235 Hepatocyte growth factor (HGF) receptor-
tyrosine kinase 
NP_000236. P08581 
473 NP006 MKP1 Pan-specific MAP kinase phosphatase  1 ( VH1, DUSP1) NP_004408 P28562 
474 NP007 MKP2 Pan-specific MAP kinase phosphatase  2 (VH2) NP_001385 Q13115 
475 PN051-1 MLC(MLR
C2) 
S19 Myosin regulatory light chain 2, smooth muscle 
isoform 
NP_291024 P19105 
476 PN051-2 MLC(MLR
C2) 
S19 Myosin regulatory light chain 2, smooth muscle 
isoform 
NP_291024 P19105 
477 NK208 MLK3 Pan-specific Mixed-lineage protein-serine kinase 3 NP_002410 Q16584 
478 PK056 MLK3 T277+S281 Mixed-lineage protein-serine kinase 3 NP_002410 Q16584 
479 NN132 mMOB1 Pan-specific Preimplantation protein 3 NP_056202 Q9Y3A3  
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480 PK057 Mnk1 T250+T255 MAP kinase-interacting protein-serine kinase 1 
(calmodulin-activated) 
NP_003675 Q9BUB5 
481 NK111 Mnk2 Pan-specific MAP kinase-interacting protein-serine kinase 2 
(calmodulin-activated) 
NP_060042 Q9HBH9 
482 NN069 MSH2 Pan-specific DNA mismatch repair protein mutS homolog2, 
colon cancer, nonpolyposis type 1 
NP_000242 P43246 
483 PK058 Msk1 S376 Mitogen & stress-activated protein-serine kinase 
1 
NP_004746 O75582 
484 NK113-1 MST1 Pan-specific Mammalian STE20-like protein-serine kinase 1 
(KRS2) 
NP_006273 Q13043 
485 NK113-2 MST1 Pan-specific Mammalian STE20-like protein-serine kinase 1 
(KRS2) 
NP_006273 Q13043 
486 NK113-3 MST1 Pan-specific Mammalian STE20-like protein-serine kinase 1 
(KRS2) 
NP_006273 Q13043 
487 NK113-4 MST1 Pan-specific Mammalian STE20-like protein-serine kinase 1 
(KRS2) 
NP_006273 Q13043 
488 NK114 MST2 Pan-specific Mammalian STE20-like protein-serine kinase 2 
(KRS1) 
NP_006272 Q13188 
489 NK115 MST3 Pan-specific Mammalian STE20-like protein-serine kinase 3 NP_003567 Q9Y6E0 
490 PK116 mTOR 
(FRAP) 
S2448 Mammalian target of rapamycin (FRAP) NP_004949 P42345 
491 PN186 Myc S373 Myc proto-oncogene protein NP_002458.2 P01106 
492 PN199 Myc T58 Myc proto-oncogene protein NP_002458.2 P01106 
493 PN182 MyoD S200 Myoblast determination protein 1 NP_002469.2 P15172 
494 PN052 MYPT1 T696 Myosin phosphatase target 1 NP_446342 O14974 
495 PN187 NBS1 S343 Nijmegen breakage syndrome protein 1 NP_002476.2 O60934 
496 NK117-1 Nek2 Pan-specific NIMA (never-in-mitosis)-related protein-serine 
kinase 2 
NP_002488 P51955 
497 NK117-2 Nek2 Pan-specific NIMA (never-in-mitosis)-related protein-serine 
kinase 2 
NP_002488 P51955 
498 NK117-3 Nek2 Pan-specific NIMA (never-in-mitosis)-related protein-serine 
kinase 2 
NP_002488 P51955 
499 NK117-4 Nek2 Pan-specific NIMA (never-in-mitosis)-related protein-serine 
kinase 2 
NP_002488 P51955 
500 NK117-5 Nek2 Pan-specific NIMA (never-in-mitosis)-related protein-serine 
kinase 2 
NP_002488 P51955 
501 NK118 Nek4 Pan-specific NIMA (never-in-mitosis)-related protein-serine 
kinase 4 
NP_003148  P51957 
502 NK119 Nek7 Pan-specific NIMA (never-in-mitosis)-related protein-serine 
kinase 7 
NP_598001 Q8TDX7 
503 NN070 NFkappaB 
p50 
Pan-specific NF-kappa-B p50 nuclear transcription factor NP_003989 P19838 
504 NN071 NFkappaB 
p65 
Pan-specific NF-kappa-B p65 nuclear transcription factor NP_003989 Q04206 
505 PN053-1 NFkappaB 
p65 
S276 NF-kappa-B p65 nuclear transcription factor NP_003989 Q04206 
506 PN156 NFkappaB 
p65 
S529 NF-kappa-B p65 nuclear transcription factor NP_003989 Q04206 
507 PN157 NFkappaB 
p65 
S536 NF-kappa-B p65 nuclear transcription factor NP_003989 Q04206 
508 NK207 NIK 
(MAP3K14
) 
Pan-specific NF-kappa beta-inducing kinase NP_003945.2 Q99558 
509 NK212 NLK Pan-specific Serine/threonine protein kinase NLK NP_057315.3 Q9UBE8 
510 PN054 NMDAR2B Y1474 N-methyl-D-aspartate (NMDA) glutamate 
receptor 2B subunit 
NP_000825 Q13224 
511 NN074 NME7 Pan-specific Nucleotide diphosphate kinase 7 (nm23-H7) NP_037462 Q9Y5B8 
512 PN055-1 NR1 S896 N-methyl-D-aspartate (NMDA) glutamate 
receptor 1 subunit zeta 
NP_000823 Q05586 
513 NN075 NT5E Pan-specific Ecto-5'-nucleotidase (CD73 antigen) NP_002517 P21589 
514 NN083 p107 Pan-specific Retinoblastoma (Rb) protein-related p107 
(PRB1) 
NP_002886.2 P28749 
515 NN077 p18 INK4c Pan-specific p18 INK4c cyclin-dependent kinase inhibitor NP_523240 P42773 
516 NN078 p21 CDKI1 Pan-specific cyclin-dependent kinase inhibitor 1 (MDA6) NP_000380  P38936 
517 NN081-
NN120 
p25 Pan-specific CDK5 regulatory subunit p25 NP_003876.1 Q15078 
518 NN080 p27 Kip1 Pan-specific p27 cyclin-dependent kinase inhibitor 1B NP_004055  P46527 
519 PN056 p27 Kip1 T187 p27 cyclin-dependent kinase inhibitor 1B NP_004055 P46527 
520 PK060-1 p38a 
MAPK 
T180+Y182 Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
521 PK060-2 p38a 
MAPK 
T180+Y182 Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
522 PK060-3 p38a 
MAPK 
T180+Y182 Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
523 NK120-1 p38a 
MAPK 
Pan-specific Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
524 NK120-10 p38a 
MAPK 
Pan-specific Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
525 NK120-2 p38a 
MAPK 
Pan-specific Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
526 NK120-3 p38a 
MAPK 
Pan-specific Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
527 NK120-4 p38a 
MAPK 
Pan-specific Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
528 NK120-5 p38a 
MAPK 
Pan-specific Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
529 NK120-7 p38a 
MAPK 
Pan-specific Mitogen-activated protein-serine kinase p38 
alpha 
NP_001306 Q16539 
530 NK059-1 p38g 
MAPK 
(Erk6) 
Pan-specific Mitogen-activated protein-serine kinase p38 
gamma (MAPK12) 
NP_002960 P53778 
531 NK059-2 p38g 
MAPK 
(Erk6) 
Pan-specific Mitogen-activated protein-serine kinase p38 
gamma (MAPK12) 
NP_002960 P53778 
532 NN082 p53 Pan-specific Tu or suppressor protein p53 NP_000537  P04637 
533 PN057-1 p53 S392 Tumor suppressor protein p53 NP_000537 P04637 
534 PN057-2 p53 S392 Tumor suppressor protein p53 NP_000537 P04637 
535 PN057-3 p53 S392 Tumor suppressor protein p53 NP_000537 P04637 
536 PN158 p53 S33 Tumor suppressor protein p53 NP_000537 P04637 
537 PN159 p53 S37 Tumor suppressor protein p53 NP_000537 P04637 
538 PN160 p53 S6 Tumor suppressor protein p53 NP_000537 P04637 
539 NN123 p73 Pan-specific Tumor suppressor protein p73 NP_005418 O15350 
540 NP008 PAC1 Pan-specific Dual specificity MAP kinase protein 
phosphatase 
NP_004409 Q05923 
541 NN084 PACSIN1 Pan-specific Protein kinase C + casein kinase substrate in 
neurons protein 1 
NP_065855 Q9BY11 
542 NK122 PAK1 Pan-specific p21-activated kinase 1 (alpha)  NP_002567 Q13153 
543 NK122-2 PAK1 Pan-specific p21-activated kinase 1 (alpha)  NP_002567 Q13153 
544 NK122-4 PAK1 Pan-specific p21-activated kinase 1 (alpha)  NP_002567 Q13153 
545 PK130 PAK1 T212 p21-activated kinase 1 (alpha)  NP_002567 Q13153 
546 NK224 PAK1/2/3 Pan-specific p21-activated kinase 1/2/3  NP_002567 Q13153 
547 PK061 PAK1/2/3 S144/S141/S154 p21-activated kinase 1/2/3  NP_002567 Q13153 
548 NK200 PAK2 Pan-specific p21-activated kinase 2 (gamma) 
(serine/threonine-protein kinase PAK 2) 
NP_002568.2 Q13177 
549 NK200-2 PAK2 Pan-specific p21-activated kinase 2 (gamma) 
(serine/threonine-protein kinase PAK 2) 
NP_002568.2 Q13177 
550 NK123 PAK3 Pan-specific p21-activated kinase 3 (beta) (serine/threonine-
protein kinase PAK 3) 
NP_002569 O75914 
551 NN085-1 PARP1 Pan-specific Poly [ADP-ribose] polymerase 1 (ADPRT) NP_001609 P09874 
552 NN085-2 PARP1 Pan-specific Poly [ADP-ribose] polymerase 1 (ADPRT) NP_001609 P09874 
553 PN058 Pax2 S394 Paired box protein 2 NP_003978 Q02962 
554 NN086 Paxillin 1 Pan-specific Paxillin 1 NP_002850 P49023 
555 PN059 Paxillin 1 Y31 Paxillin 1 NP_002850 P49023 
556 PN060-1 Paxillin 1 Y118 Paxillin 1 NP_002850 P49023 
557 PN060-3 Paxillin 1 Y118 Paxillin 1 NP_002850 P49023 
558 NN087 PCNA Pan-specific Proliferating cell nuclear antigen NP_002583 P12004 
559 NK125 PCTK1 
(PCTAIRE
1) 
Pan-specific PCTAIRE-1 protein-serine kinase NP_148978 Q00536 
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560 PK063 PDGFRa Y754 Platelet-derived growth factor receptor kinase 
alpha 
NP_006197  P16234 
561 PK065 PDGFRb Y716 Platelet-derived growth factor receptor kinase 
beta 
NP_032835 P09619 
562 NN141-1 PDI Pan-specific Protein disulfide-isomerase NP_000909.2 P07237 
563 NK126-1 PDK1 Pan-specific 3-phosphoinositide-dependent protein-serine 
kinase 1 
NP_002604 O15530 
564 NK126-2 PDK1 Pan-specific 3-phosphoinositide-dependent protein-serine 
kinase 1 
NP_002604 O15530 
565 PK066 PDK1 S241 3-Phosphoinositide-dependent protein-serine 
kinase 1 
NP_002604 O15530 
566 PN061 PED15 
(PEA15) 
S116 Phosphoprotein-enriched in diabetes/astrocytes 
15 
NP_003759  Q15121 
567 NN088 PERP Pan-specific p53-induced protein PIGPC1 NP_071404 Q9H230 
568 NN089 PI3K 
p85/p55 
Pan-specific Phosphatidylinositol 3-kinase regulatory subunit 
alpha 
NP_852664 P27986 
569 PN127 PI3K 
p85/p55 
Y467/Y199 Phosphatidylinositol 3-kinase regulatory subunit 
alpha 
NP_852664 P27986 
570 NN114 PI3KR4 Pan-specific Phosphoinositide-3-kinase, regulatory subunit 4 NP_055417 Q99570 
571 NK192 PI4KCB Pan-specific phosphatidylinositol 4-kinase, catalytic, beta 
polypeptide 
NP_002642 Q5VWC1 
572 NK209 PIP5K2a Pan-specific Phosphatidylinositol 4-phosphatase 5-kinase 
type 2 alpha 
NP_005019.2 P48426 
573 NK213 PITSLRE Pan-specific PITSLRE serine/threonine-protein kinase 
CDC2L1 
NP_277021.1 P21127 
574 NK127-1 PKA Ca/b Pan-specific cAMP-dependent protein-serine kinase catalytic 
subunit alpha/beta 
NP_002721 P17612 
575 PK067 PKA Ca/b T198 cAMP-dependent protein-serine kinase catalytic 
subunit alpha/beta 
NP_002721  P17612 
576 PK068 PKA Cb S339 cAMP-dependent protein-serine kinase catalytic 
subunit beta 
NP_002722   P22694 
577 NN116 PKA R1a Pan-specific cAMP-dependent protein-serine kinase type I 
Iulatory chain 
NP_002725 P10644 
578 NK128 PKA R2a Pan-specific cAMP-dependent protein-serine kinase 
regulatory type 2 subunit alpha 
NP_004148 P13861 
579 PK069 PKA R2a S99 cAMP-dependent protein-serine kinase 
regulatory type 2 subunit alpha 
NP_523671  P13861 
580 NK129 PKBa 
(Akt1) 
Pan-specific Protein-serine kinase B alpha NP_005154 P31749 
581 NK129-2 PKBa 
(Akt1) 
Pan-specific Protein-serine kinase B alpha NP_005154 P31749 
582 PK071-2 PKBa 
(Akt1) 
T308 Protein-serine kinase B alpha NP_005154 P31749 
583 PK072-1 PKBa 
(Akt1) 
S473 Protein-serine kinase B alpha NP_005154 P31749 
584 PK072-3 PKBa 
(Akt1) 
S473 Protein-serine kinase B alpha NP_005154 P31749 
585 PK072-5 PKBa 
(Akt1) 
S473 Protein-serine kinase B alpha NP_005154 P31749 
586 PK148 PKBa 
(Akt1) 
Y474 Protein-serine kinase B alpha NP_005154 P31749 
587 NK130-1 PKBb 
(Akt2) 
Pan-specific Protein-serine kinase B beta NP_001617 P31751 
588 NK130-2 PKBb 
(Akt2) 
Pan-specific Protein-serine kinase B beta NP_001617 P31751 
589 NK130-3 PKBb 
(Akt2) 
Pan-specific Protein-serine kinase B beta NP_001617 P31751 
590 NK130-5 PKBb 
(Akt2) 
Pan-specific Protein-serine kinase B beta NP_001617 P31751 
591 NK130-6 PKBb 
(Akt2) 
Pan-specific Protein-serine kinase B beta NP_001617 P31751 
592 NK130-7 PKBb 
(Akt2) 
Pan-specific Protein-serine kinase B beta NP_001617 P31751 
593 NK131-1 PKBg 
(Akt3) 
Pan-specific Protein-serine kinase B gamma NP_005456 Q9Y243 
594 NK131-2 PKBg 
(Akt3) 
Pan-specific Protein-serine kinase B gamma NP_005456 Q9Y243 
595 NK201 PKC Pan-specific Protein-serine kinase C alpha NP_002728 P17252 
596 NK218 PKCh Pan-specific Protein kinase C eta type NP_006246.2 P24723 
597 NK132 PKCa Pan-specific Protein-serine kinase C alpha NP_002728 P17252 
598 PK073 PKCa S657 Protein-serine kinase C alpha NP_002728 P17252 
599 PK074 PKCa/b2 T638/T641 Protein-serine kinase C alpha/beta 2 NP_002728 P17252 
600 NK133 PKCb1 Pan-specific Protein-serine kinase C beta 1 NP_002729 P05771 
601 NK133-2 PKCb1 Pan-specific Protein-serine kinase C beta 1 NP_002729 P05771 
602 PK075 PKCb1/2 T500 Protein-serine kinase C beta 1/2 NP_997700 P05771 
603 PK075-2 PKCb1/2 T500 Protein-serine kinase C beta 1/2 NP_997700 P05771 
604 NK134-2 PKCb2 Pan-specific Protein-serine kinase C beta 2 AAA60095 P05771-2 
605 PK076-2 PKCb2 T642 Protein-serine kinase C beta 2 NP_002729 P05771 
606 NK135 PKCd Pan-specific Protein-serine kinase C delta NP_006245 Q05655 
607 PK077-1 PKCd Y313 Protein-serine kinase C delta NP_006245 Q05655 
608 PK077-2 PKCd Y313 Protein-serine kinase C delta NP_006245 Q05655 
609 PK078 PKCd T507 Protein-serine kinase C delta NP_006245 Q05655 
610 PK079-1 PKCd S645 Protein-serine kinase C delta NP_006245 Q05655 
611 PK080 PKCd S664 Protein-serine kinase C delta NP_006245 Q05655 
612 NK136 PKCe Pan-specific Protein-serine kinase C epsilon NP_005391 Q02156 
613 NK136-2 PKCe Pan-specific Protein-serine kinase C epsilon NP_005391 Q02156 
614 PK081-1 PKCe S729 Protein-serine kinase C epsilon NP_005391  Q02156 
615 NK137 PKCg Pan-specific Protein-serine kinase C gamma NP_002730 P05129 
616 PK082-1 PKCg T514 Protein-serine kinase C gamma NP_002730  P05129 
617 PK082-2 PKCg T514 Protein-serine kinase C gamma NP_002730  P05129 
618 PK083 PKCg T655 Protein-serine kinase C gamma NP_002730  P05129 
619 PK084 PKCg T674 Protein-serine kinase C gamma NP_002730.1  P05129 
620 PK085 PKCh T655 Protein-serine kinase C eta NP_006246 P24723 
621 NK138-1 PKCl/i Pan-specific Protein-serine kinase C lambda/iota NP_002731 P41743 
622 PK087 PKCl/i T564 Protein-serine kinase C lambda/iota NP_002731  P41743 
623 NK142 PKCm 
(PKD) 
Pan-specific Protein-serine kinase C mu (Protein kinase D) NP_002733 Q15139 
624 PK092 PKCm 
(PKD) 
S738+S742 Protein-serine kinase C mu (Protein kinase D) NP_002733 Q15139 
625 PK093-1 PKCm 
(PKD) 
S910 Protein-serine kinase C mu (Protein kinase D) NP_002733 Q15139 
626 PK093-2 PKCm 
(PKD) 
S910 Protein-serine kinase C mu (Protein kinase D) NP_002733 Q15139 
627 NK140 PKCq Pan-specific Protein-serine kinase C theta NP_006248 Q04759 
628 PK088 PKCq T538 Protein-serine kinase C theta NP_006248 Q04759 
629 PK089-1 PKCq S676 Protein-serine kinase C theta NP_006248 Q04759 
630 PK090-1 PKCq S695 Protein-serine kinase C theta NP_006248 Q04759 
631 NK141 PKCz Pan-specific Protein-serine kinase C zeta NP_002735 Q05513 
632 PK091 PKCz/l T410/T412 Protein-serine kinase C zeta/lambda NP_002735 Q05513 
633 NK143 PKG1 Pan-specific Protein-serine kinase G1 (cGMP-dependent 
protein kinase) 
NP_006249 Q13976 
634 NK202 PKG1a Pan-specific cGMP-dependent protein kinase 1, alpha 
isozyme 
NP_006249 Q13976 
635 NK203 PKG1b Pan-specific cGMP-dependent protein kinase 1, beta 
isozyme 
NP_006249.1 P14619 
636 NN115 PKM2 Pan-specific Pyruvate kinase, isozymes M1/M2 NP_872270 P14618 
637 NK144-1 PKR1 Pan-specific Double-stranded RNA-dependent protein-serine 
kinase (EIF2AK2) 
NP_002750 P19525 
638 PK132 PKR1 T446 Double-stranded RNA-dependent protein-serine 
kinase (EIF2AK2) 
NP_002750 P19525 
639 NN156 PLC 
R(PLCg2) 
Pan-specific 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-2 
NP_002652.2 P16885 
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640 PN144 PLCg1 Y783 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-1 
NP_877963.1 P19174 
641 PN165 PLCg1 Y771 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-1 
NP_877963.1 P19174 
642 PN143 PLC 
R(PLCg2) 
Y753 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase gamma-2 
NP_002652.2 P16885 
643 NK145 Plk1 Pan-specific Polo-like protein-serine kinase 1 NP_005021 P53350 
644 PK117 Plk1 T210 Polo-like protein-serine kinase 1 NP_005021 P53350 
645 NK146 Plk2 Pan-specific Polo-like protein kinase 2 (SNK) NP_006613  Q9NYY3 
646 NK146-2 Plk2 Pan-specific Polo-like protein kinase 2 (SNK) NP_006613  Q9NYY3 
647 NK147 Plk3 Pan-specific Polo-like protein kinase 3 (CNK) NP_004064 Q9H4B4 
648 NP009 PP1/Ca Pan-specific Protein-serine phosphatase 1 alpha NP_002699 P62136 
649 NP009-2 PP1/Ca Pan-specific Protein-serine phosphatase 1 alpha NP_002699 P62136 
650 PP001 PP1/Ca T320 Protein-serine phosphatase 1 aphfa NP_002699 P62136 
651 NP010 PP1/Cb Pan-specific Protein-serine phosphatase 1 beta NP_002700 P62140 
652 NP010-2 PP1/Cb Pan-specific Protein-serine phosphatase 1 beta NP_002700 P62140 
653 NP011 PP1/Cg Pan-specific Protein-serine phosphatase 1 gama NP_002701 P36873 
654 NP033 PP2A B' 
(B56) 
Pan-specific Protein-serine phosphatase 2A subunit - B56 
alpha isoform 
NP_001186685.1 Q15172 
655 NP012 PP2A/Aa/b Pan-specific Protein-serine phosphatase 2A - subunit - alpha 
and beta isoforms 
NP_002707 P30153 
656 NP035 PP2A/Bb Pan-specific Protein-serine phosphatase 2A - B regulatory 
subunit - beta isoform 
NP_001120853.1 Q00005 
657 NP032 PP2A/Bg2 Pan-specific Protein-serine phosphatase 2A - B regulatory 
subunit - gamma isoform 
NP_001193923.1 Q9Y2T4 
658 NP013-
NP014 
PP2A/Ca Pan-specific Protein-serine phosphatase 2A alpha isoform NP_002706 P67775 
659 NP015 PP2B/Aa Pan-specific Protein-serine phosphatase 2B alpha isoform NP_000935 Q08209 
660 NP016-
NP031 
PP2Ca Pan-specific Protein-serine phosphatase 2C alpha NP_066283 P35813 
661 NP012-2 PP2A/Aa/b Pan-specific Protein-serine phosphatase 2A alpha and beta 
isoforms 
NP_002707 P30153 
662 NP018 PP2Cd Pan-specific Protein-serine phosphatase 2C delta isoform NP_110395 O15297 
663 NP019 PP4/A’2 Pan-specific Protein-serine phosphatase 4 subunit (PPX/A'2) NP_005125 Q8TF05 
664 NP020 PP4C Pan-specific Protein-serine phosphatase X - catalytic subunit 
(PPX/C) 
 NP_002711 P60510 
665 NP020-2 PP4C Pan-specific Protein-serine phosphatase X - catalytic subunit 
(PPX/C) 
 NP_002711 P60510 
666 NP021 PP5C Pan-specific Protein-serine phosphatase 5  - catalytic subunit 
(PPT) 
NP_006238 P53041 
667 NP021-2 PP5C Pan-specific Protein-serine phosphatase 5  - catalytic subunit 
(PPT) 
NP_006238 P53041 
668 NP022 PP6C Pan-specific Protein-serine phosphatase 6  - catalytic subunit 
(PPVC) 
NP_002712 O00743 
669 PN062 PRAS40 T246 Proline-rich Akt substrate 40 kDa (Akt1S1) NP_115751  Q96B36 
670 NK148 PRK1 
(PKN1) 
Pan-specific Protein kinase C-related protein-serine kinase 1 NP_002732 Q16512 
671 PK095-
PK096 
PRK1 
(PKN1) 
T774 Protein kinase C-related protein-serine kinase 1 NP_002732 Q16512 
672 NK149 PRK2 
(PKN2) 
Pan-specific Protein kinase C-related protein-serine kinase 2 NP_006247 Q16513 
673 NK149-2 PRK2 
(PKN2) 
Pan-specific Protein kinase C-related protein-serine kinase 2 NP_006247 Q16513 
674 NK150 PRKAB1 Pan-specific 5'-AMP-activated protein kinase (AMPK), beta-1 
regulatory subunit 
NP_006244  Q9Y478 
675 NK151 WNK4 
(PRKWNK
4) 
Pan-specific Putative protein-serine kinase WNK4 NP_115763 Q96J92 
676 PN104 Progestero
ne 
Receptor 
S294 Progesterone receptor NP_000917 P06401 
677 NK152 PRP4K Pan-specific Protein-serine kinase PRP4 homolog NP_003904  Q13523 
678 NN142 PSD-95 Pan-specific Disks large homolog 4 NP_001356.1 P78352 
679 NK204 PSTAIRE Pan-specific PSTAIRE NA NA 
680 NP023 PTEN Pan-specific Phosphatidylinositol-3,4,5-trisphosphate 
homolog deleted on chromosome 10 
NP_000305 P60484 
681 NP023-2 PTEN Pan-specific Phosphatidylinositol-3,4,5-trisphosphate 
hosphatase and protein phosphatase and tensin 
homolog deleted on chromosome 10 
NP_000305 P60484 
682 PP003 PTEN S380+T382+S385 Phosphatidylinositol-3,4,5-trisphosphate 
phosphatase and protein phosphatase and 
tensin homolog deleted on chromosome 10 
NP_000305   P60484 
683 PP006 PTEN S380+T382+T383 Phosphatidylinositol-3,4,5-trisphosphate 
phosphatase and protein phosphatase and 
tensin homolog deleted on chromosome 10 
NP_000305   P60484 
684 PP006-1 PTEN S380+T382+T383 Phosphatidylinositol-3,4,5-trisphosphate 
phosphatase and protein phosphatase and 
tensin homolog deleted on chromosome 10 
NP_000305   P60484 
685 NP024 PTP1B Pan-specific Protein-tyrosine phosphatase 1B (PTPN1) NP_002818 P18031 
686 NP025 PTP1C Pan-specific Protein-tyrosine phosphatase 1C 
(SHP1SHPTP1, PTPN6) 
NP_002822 P29350 
687 NP026 PTP1D Pan-specific Protein-tyrosine phosphatase 1D NP_002825 Q06124 
688 NP026-2 PTP1D Pan-specific Protein-tyrosine phosphatase 1D NP_002825 Q06124 
689 PP004 PTP1D S580 Protein-tyrosine phosphatase 1D NP_002825 Q06124 
690 NP036 PTPD1 Pan-specific Protein-tyrosine phosphatase non-receptor type 
21 
NP_008970.2 Q16825 
691 NP027 PTP-PEST Pan-specific Protein tyrosine phosphatase, non-receptor type 
12 
NP_001124480.1 Q05209 
692 NK153 PyDK2 
(PDHK2) 
Pan-specific Pyruvate dehydrogenase kinase isoform 2 NP_002602  Q15119 
693 NK154 Pyk2 Pan-specific Protein-tyrosine kinase 2 NP_004094 Q14289 
694 PK097-3 Pyk2 Y579 Protein-tyrosine kinase 2 NP_004094 Q14289 
695 NN150 Rab5 Pan-specific Ras-related protein Rab-5A NP_004153.2. P20339 
696 NN092-1 Rac1 Pan-specific Ras-related C3 botulinum toxin substrate 1 NP_001782 P63000 
697 PN063 Rac1 S71 Ras-related C3 botulinum toxin substrate 1 NP_008839   P63000 
698 PN064 Rad17 S656 Rad17 homolog NP_579921 O75943 
699 NK155-2 Raf1 Pan-specific Raf1 proto-oncogene-encoded protein-serine 
kinase 
NP_002871 P04049 
700 NK155-3 Raf1 Pan-specific Raf1 proto-oncogene-encoded protein-serine 
kinase 
NP_002871 P04049 
701 NK155-4 Raf1 Pan-specific Raf1 proto-oncogene-encoded protein-serine 
kinase 
NP_002871 P04049 
702 PK098 Raf1 S259 Raf1 proto-oncogene-encoded protein-serine 
kinase 
NP_002871 P04049 
703 NK205 RafA (Araf) Pan-specific A-Raf proto-oncogene serine/threonine-protein 
kinase 
NP_001645.1   P10398 
704 NK205-2 RafA (Araf) Pan-specific A-Raf proto-oncogene serine/threonine-protein 
kinase 
NP_001645.1   P10398 
705 NK156 RafB (Braf) Pan-specific RafB proto-oncogene-encoded protein-serine 
kinase 
NP_004324 P15056 
706 NK156-2 RafB (Braf) Pan-specific RafB proto-oncogene-encoded protein-serine 
kinase 
NP_004324 P15056 
707 NN093 Rb Pan-specific Retinoblastoma-associated protein 1 NP_000312  P06400 
708 PN065 Rb T356 Retinoblastoma-associated protein 1 NP_000312 P06400 
709 PN066 Rb S612 Retinoblastoma-associated protein 1 NP_000312 P06400 
710 PN067 Rb S780 Retinoblastoma-associated protein 1 NP_000312 P06400 
711 PN068 Rb S807 Retinoblastoma-associated protein 1 NP_000312 P06400 
712 PN069 Rb S807+S811 Retinoblastoma-associated protein 1 NP_000312 P06400 
713 PN070 Rb T821 Retinoblastoma-associated protein 1 NP_000312 P06400 
714 PN071 Rb T826 Retinoblastoma-associated protein 1 NP_000312 P06400 
715 PN113 Rb S608 Retinoblastoma-associated protein 1 NP_000312 P06400 
716 PN131-1 Rb S795 Retinoblastoma-associated protein 1 NP_000312  P06400 
717 NN170 RelB Pan-specific Transcription factor RelB NP_006500.2 Q01201 
718 PN151 RelB S573 Transcription factor RelB NP_006500.2 Q01201 
719 NK157 RIP2/RICK Pan-specific Receptor-interacting serine/threonine-protein 
kinase 2 (RIPK2) 
NP_003812 O43353 
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720 NK158 RIPK1 Pan-specific Receptor-interacting protein-serine kinase 1 NP_003795 Q13546 
721 NK159-1 ROKa 
(ROCK2) 
Pan-specific RhoA protein-serine kinase alpha NP_004841 O75116 
722 NK159-2 ROKa 
(ROCK2) 
Pan-specific RhoA protein-serine kinase alpha NP_004841 O75116 
723 NK160 ROKb 
(ROCK1) 
Pan-specific RhoA protein-serine kinase beta NP_005397 Q13464 
724 NK161 RONa Pan-specific Macrophage-stimulating protein receptor alpha 
chain 
NP_002438 Q04912 
725 NK162 ROR2 Pan-specific ROR2 neurotrophic receptor-tyrosine kinase NP_004551 Q01974 
726 NK163 ROS Pan-specific Orosomucoid 1 receptor-tyrosine kinase NP_002935 P08922 
727 NK164 RSK1 Pan-specific Ribosomal S6 protein-serine kinase 1 NP_002944 Q15418 
728 NK164-2 RSK1 Pan-specific Ribosomal S6 protein-serine kinase 1 NP_002944 Q15418 
729 PK157 RSK1 S363 Ribosomal S6 protein-serine kinase 1 NP_002944 Q15418 
730 PK158 RSK1 T348 Ribosomal S6 protein-serine kinase 1 NP_002944 Q15418 
731 PK099 RSK1/2 S221/S227 Ribosomal S6 protein-serine kinase 1/2 NP_002944  Q15418 
732 PK100 RSK1/2 S363/S369 Ribosomal S6 protein-serine kinase 1/2 NP_002944  Q15418 
733 PK100-2 RSK1/2 S363/S369 Ribosomal S6 protein-serine kinase 1/2 NP_002944  Q15418 
734 PK101-1 RSK1/2 S380/S386 Ribosomal S6 protein-serine kinase 1/2 NP_002944  Q15418 
735 PK101-2 RSK1/2 S380/S386 Ribosomal S6 protein-serine kinase 1/2 NP_002944  Q15418 
736 PK102 RSK1/2/3 T573/T577/T570 Ribosomal S6 protein-serine kinase 1/2/3 NP_002944 Q15418 
737 PK103 RSK1/3 T359+S363/T356+S360 Ribosomal S6 protein-serine kinase 1/3 NP_002944 Q15418 
738 NK165 RSK2 Pan-specific Ribosomal S6 protein-serine kinase 2 NP_004577 P51812 
739 NK167 RYK Pan-specific RYK tyrosine-protein kinase NP_001005861.1 P34925 
740 PN073 S6 S235 40S ribosomal protein S6 NP_001001 P62753 
741 PK156 S6K S424 p70 ribosomal protein-serine S6 kinase NP_003152 P23443 
742 PK166 S6K S411 p70 ribosomal protein-serine S6 kinase NP_003152 P23443 
743 NK223 S6Kb1 Pan-specific Ribosomal protein-serine S6 kinase beta 1 NP_003152 P23443 
744 NK223-1 S6Kb1 Pan-specific Ribosomal protein-serine S6 kinase beta 1 NP_003152 P23443 
745 NK223-2 S6Kb1 Pan-specific Ribosomal protein-serine S6 kinase beta 1 NP_003152 P23443 
746 PK145 S6Kb1 T252 Ribosomal protein serine S6 kinase beta 1 NP_003152  P23443 
747 PK146 S6Kb1 T444+S447 Ribosomal protein serine S6 kinase beta 1 NP_003152 P23443 
748 PK147 S6Kb1 T412 Ribosomal protein serine S6 kinase beta 1 NP_003152 P23443 
749 NK222 S6Kb2 Pan-specific Ribosomal protein-serine S6 kinase beta 2 NP_003943 Q9UBS0  
750 NN133 SG2NA Pan-specific Striatin-3 NP_001077362.1 Q13033 
751 PN074 Shc1 Y349+Y350 SH2 domain-containing transforming protein 1 NP_003020 P29353 
752 PN161 Shc1 Y349 SH2 domain-containing transforming protein 1 NP_003020 P29353 
753 NN095 Smac/DIA
BLO 
Pan-specific 2nd mitochondria-derived activator of caspase NP_620308 Q9NR28  
754 PN183 Smad1 S465 Mothers against decapentaplegic homolog 1 NP_005891 Q15797 
755 PN075 Smad1/5/8 S463+S465/S463+S465/S465+
S467 
Mothers against decapentaplegic homologs 
1/5/8 
NP_005891 Q15797 
756 PN184 Smad2 S467 Mothers against decapentaplegic homolog 2 NP_005891 Q15796 
757 PN185 Smad2 T200 Mothers against decapentaplegic homolog 2 NP_005891 Q15796 
758 NN096 Smad2/3 Pan-specific SMA- and mothers against decapentaplegic 
homolog 2/3 
NP_005892 Q15796 
759 PN125 SMC1 S957 Structural maintenance of chromosomes protein 
1A 
NP_006297.2. Q14683 
760 PN177 SNCA Y136 Alpha-synuclein NP_000336.1 P37840 
761 PN197 SNCA S129 Alpha-synuclein NP_000336.1 P37840 
762 NN145 SOCS2 Pan-specific Suppressor of cytokine signaling 2 NP_003868.1. O14508 
763 NN097 SOCS4 Pan-specific Suppressor of cytokine signalling 4 (SOCS7) NP_543143 Q8WXH5 
764 NN098 SOD 
(Cu/Zn) 
Pan-specific Superoxide dismutase 1 NP_000445 P00441 
765 NN068 SOD (Mn) Pan-specific Superoxide dismutase [Mn] NP_000627 P04179 
766 NN068-1 SOD (Mn) Pan-specific Superoxide dismutase [Mn] NP_000627 P04179 
767 NN099 SODD Pan-specific Silencer of death domains (Bcl2 associated 
athanogene 4 (BAG4)) 
NP_004865 O95429 
768 PN077 SOX9 S181 SRY (sex determining region Y)-box 9 
(campomelic dysplasia, autosomal sex-reversal) 
NP_000337  P48436 
769 NN100 SPHK1 Pan-specific Sphingosine kinase 1 NP_892010 Q9NYA1  
770 NN101 SPHK2 Pan-specific Sphingosine kinase 2 NP_064511 Q9NRA0  
771 NK172 Src Pan-specific Src proto-oncogene-encoded protein-tyrosine 
kinase 
NP_005408 P12931 
772 NK172-2 Src Pan-specific Src proto-oncogene-encoded protein-tyrosine 
kinase 
NP_005408 P12931 
773 NK172-3 Src Pan-specific Src proto-oncogene-encoded protein-tyrosine 
kinase 
NP_005408 P12931 
774 NK172-4 Src Pan-specific Src proto-oncogene-encoded protein-tyrosine 
kinase 
NP_005408 P12931 
775 PK107 Src Y419 Src proto-oncogene-encoded protein-tyrosine 
kinase 
NP_005408 P12931 
776 PK108 Src Y530 Src proto-oncogene-encoded protein-tyrosine 
kinase 
NP_005408 P12931 
777 NN102-
NN124 
STAT1a Pan-specific Signal transducer and activator of transcription 1 
alpha 
NP_009330 P42224 
778 NN102-
NN124-2 
STAT1a Pan-specific Signal transducer and activator of transcription 1 
alpha 
NP_009330 P42224 
779 NN139 STAT1a Pan-specific Signal transducer and activator of transcription 1 
alpha 
NP_009330 P42224 
780 PN078-
PN135 
STAT1a S727 Signal transducer and activator of transcription 1 
alpha 
NP_009330 P42224 
781 PN079-
PN136-1 
STAT1a Y701 Signal transducer and activator of transcription 1 
alpha 
NP_009330 P42224 
782 NN103 STAT2 Pan-specific Signal transducer and activator of transcription 2 NP_005410 P52630 
783 PN080 STAT2 Y690 Signal transducer and activator of transcription 2 NP_005410 P52630 
784 NN104 STAT3 Pan-specific Signal transducer and activator of transcription 3 
(acute phase response factor) 
NP_003141 P40763 
785 NN104-2 STAT3 Pan-specific Signal transducer and activator of transcription 3 
(acute phase response factor) 
NP_003141 P40763 
786 PN081-1 STAT3 S727 Signal transducer and activator of transcription 3 NP_003141 P40763 
787 PN082 STAT3 Y705 Signal transducer and activator of transcription 3 NP_003141 P40763 
788 PN082-1 STAT3 Y705 Signal transducer and activator of transcription 3 NP_003141 P40763 
789 NN117 STAT4 Pan-specific Signal transducer and activator of transcription 4 
(acute phase response factor) 
NP_003142 Q14765 
790 NN105 STAT5A Pan-specific Signal transducer and activator of transcription 
5A 
NP_003143 P42229 
791 PN083 STAT5A Y694 Signal transducer and activator of transcription 
5A 
NP_003143 P42229 
792 PN083-1 STAT5A Y694 Signal transducer and activator of transcription 
5A 
NP_003143 P42229 
793 PN119 STAT5A S780 Signal transducer and activator of transcription 
5A 
NP_003143 P42229 
794 NN106 STAT5B Pan-specific Signal transducer and activator of transcription 
5B 
NP_036580 P51692 
795 NN107 STAT6 Pan-specific Signal transducer and activator of transcription 6 NP_003144 P42226 
796 NN108 STI1 Pan-specific Stress induced phosphoprotein 1  NP_006810 P31948 
797 NK173 STK33 Pan-specific FLJ35932 protein-serine kinase NP_112168  Q8NEF5  
798 NN134 Striatin Pan-specific Striatin NP_003153.2. O43815 
799 NK174 Syk Pan-specific Spleen protein-tyrosine kinase NP_003168 P43405 
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800 PK159 Syk Y323 Spleen protein-tyrosine kinase NP_003168 P43405 
801 NN171 Synapsin 1 Pan-specific Synapsin 1 isoform Ia NP_008881 P17600 
802 PN084 Synapsin 1 S9 Synapsin 1 isoform Ia NP_008881 P17600 
803 NK175-2 TAK1 Pan-specific TGF-beta-activated protein-serine kinase 1 NP_663306 O43318 
804 NK175-3 TAK1 Pan-specific TGF-beta-activated protein-serine kinase 1 NP_663306 O43318 
805 NK175-4 TAK1 Pan-specific TGF-beta-activated protein-serine kinase 1 NP_663306 O43318 
806 NK175-5 TAK1 Pan-specific TGF-beta-activated protein-serine kinase 1 NP_663306 O43318 
807 PN085 Tau S516 Microtubule-associated protein tau NP_005901   P10636 
808 PN086 Tau S516+S519 Microtubule-associated protein tau NP_005901   P10636 
809 PN090 Tau S713 Microtubule-associated protein tau NP_005901   P10636 
810 PN090-2 Tau S713 Microtubule-associated protein tau NP_005901   P10636 
811 PN091 Tau S717 Microtubule-associated protein tau NP_005901   P10636 
812 PN092 Tau S721 Microtubule-associated protein tau NP_005901   P10636 
813 PN106 Tau S519 Microtubule-associated protein tau NP_005901   P10636 
814 PN107 Tau S739 Microtubule-associated protein tau NP_005901   P10636 
815 PN121 Tau T522 Microtubule-associated protein tau NP_005901   P10636 
816 PN122 Tau T548 Microtubule-associated protein tau NP_005901   P10636 
817 NK220-1 TBK1 Pan-specific Serine/threonine-protein kinase TBK1 NP_037386 Q9UHD2 
818 NK220-2 TBK1 Pan-specific Serine/threonine-protein kinase TBK1 NP_037386 Q9UHD2 
819 NK176 TEK (TIE2) Pan-specific Angiopoietin-1 receptor-tyrosine kinase NP_444515 Q02763 
820 NK177 Tlk1 Pan-specific Tousled-like protein-serine kinase 1 NP_036422 Q9UKI8  
821 NP034 TPIPb Pan-specific trisphosphatehosphatase TPTE2 NP_001135440.1 Q6XPS3  
822 NN110 TRADD Pan-specific Tumor necrosis factor receptor type 1 
associated DEATH domain protein 
NP_003789 Q15628 
823 NN111 Trail Pan-specific Tumor necrosis factor-related apoptosis-
inducing ligand 
NP_003801 P50591 
824 NK178 TrkA Pan-specific Nerve growth factor (NGF) receptor-tyrosine 
kinase 
NP_002520 P04629 
825 NK179 TrkB Pan-specific BNDF/NT3/4/5 receptor- tyrosine kinase NP_006171 Q16620 
826 PK160 TrkB Y706 BNDF/NT3/4/5 receptor- tyrosine kinase NP_006171 Q16620 
827 NK180 TTK Pan-specific Dual specificity protein kinase AAA61239.1 P33981 
828 NK181 Tyk2 Pan-specific Protein-tyrosine kinase 2 (Jak-related) NP_003322 P29597 
829 NK181-2 Tyk2 Pan-specific Protein-tyrosine kinase 2 (Jak-related) NP_003322 P29597 
830 NK183-1 Tyro10 
(DDR2) 
Pan-specific Neurotrophic receptor-tyrosine kinase  NP_006173  Q16832 
831 NK183-2 Tyro10 
(DDR2) 
Pan-specific Neurotrophic receptor-tyrosine kinase  NP_006173  Q16832 
832 PN093-1 Tyrosine 
Hydroxylas
e 
S70 Tyrosine hydroxylase isoform a NP_954986 P07101 
833 PN109 Tyrosine 
Hydroxylas
e 
S18 Tyrosine hydroxylase isoform a NP_954986 P07101 
834 NN176 VEGF-C Pan-specific Vascular endothelial growth factor C NP_005420.1 P49767 
835 PK161 VEGFR2 
(KDR) 
Y1059 Vascular endothelial growth factor receptor-
tyrosine kinase 2 (KDR) 
NP_002244  P35968 
836 PK133 VEGFR2 
(KDR) 
Y1214 Vascular endothelial growth factor receptor-
tyrosine kinase 2 (KDR) 
NP_002244  P35968 
837 NP030 VHR Pan-specific Dual specificity protein phosphatase 3 NP_004081 P51452 
838 PN094 Vimentin S34 Vimentin NP_003371 P08670 
839 NK184 Vrk1 Pan-specific Vaccinia related protein-serine kinase 1 NP_003375  Q99986 
840 NK185 Wee1 Pan-specific Wee1 protein-tyrosine kinase NP_003381 P30291 
841 NP037 WIP1 Pan-specific Protein phosphatase 1D NP_003611.1. O15297 
842 NK186 Yes Pan-specific Yamaguchi sarcoma proto-oncogene-encoded 
tyrosine kinase 
NP_005424 P07947 
843 NK186-2 Yes Pan-specific Yamaguchi sarcoma proto-oncogene-encoded 
tyrosine kinase 
NP_005424 P07947 
844 NK214 YSK1 Pan-specific Serine/threonine-protein kinase 25 NP_006365.2   O00506 
845 NK187 ZAP70 Pan-specific Zeta-chain (TCR) associated protein-tyrosine 
kinase, 70 kDa 
NP_003168 P43403 
846 NK187-2 ZAP70 Pan-specific Zeta-chain (TCR) associated protein-tyrosine 
kinase, 70 kDa 
NP_003168 P43403 
847 PK109 ZAP70/Syk Y319/Y352 Zeta-chain (TCR) associated protein-tyrosine 
kinase, 70 kDa/Spleen protein-tyrosine kinase 
NP_001070 P43403 
848 CN003 pThr(MmA
b) 
pThr pThr(MmAb) NA NA 
849 NK188-1 ZIPK Pan-specific ZIP kinase (death associated protein-serine 
kinase 3 (DAPK3)) 
NP_001339 O43293 
850 NK188-2 ZIPK Pan-specific ZIP kinase (death associated protein-serine 
kinase 3 (DAPK3)) 
NP_001339 O43293 
851 CN001 Actin Pan-specific Actin NP_001092.1 P60709 
852 CN002 Tubulin Pan-specific Tubulin NP_006000.2 Q71U36 
853 CN004 pThr(RpAb
) 
pThr pThr(RpAb) NA NA 
854 CN005 4G10 pTyr 4G10 NA NA 
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Supplementary Table 2A - Antibody list of proteins with significant differential expression between 
shGRPR and scrambled in LNCaP. 
No. Antibody 
Codes 
Target Protein 
Name 
Phospho 
Site 
(Human) 
Full Target Protein Name Uniprot 
Link 
Average 
Z-ratio 
89 NP001 CD45 Pan-specific Leukocyte common 
antigen CD45 receptor-
tyrosine phosphatase (LCA, 
T200) 
NA -2,12 
666 NP021 PP5C Pan-specific Protein-serine phosphatase 
5  - catalytic subunit (PPT) 
Q99683 -2,10 
87 PN018 Caveolin 2 S36 Caveolin 2 P00519 -1,92 
408 NK092-2 Lck Pan-specific Lymphocyte-specific protein-
tyrosine kinase 
Q07912 -1,83 
73 NN013 CASP3 Pan-specific Caspase 3 (apopain, cysteine 
protease CPP32) 
P63104 -1,67 
76 NN017 CASP7 Pan-specific Caspase 7 (ICE-like apoptotic 
protease 3 (ICE-LAP3), Mch3) 
Q13541 -1,58 
646 NK146-2 Plk2 Pan-specific Polo-like protein kinase 2 
(serum -inducible kinase 
(SNK)) 
P49407 -1,57 
844 NK214 YSK1 Pan-specific Serine/threonine-protein 
kinase 25 
P15336 -1,53 
442 NK100-1 MEK2 (MAP2K2) Pan-specific MAPK/ERK protein-serine 
kinase 2 (MKK2) 
Q96Q40 -1,48 
419 NK097 MAPKAPK2 Pan-specific Mitogen-activated protein 
kinase-activated protein kinase 
2 
O95831 -1,40 
422 PN049-PN112-2 MAPKAPK2a T334 Mitogen-activated protein 
kinase-activated protein kinase 
2 alpha 
P54819 -1,39 
81 PN167 Catenin b Y333 Catenin (cadherin-associated 
protein) beta 1 
Q13541 -1,38 
398 NN153 KDEL receptor 1 Pan-specific ER lumen protein retaining 
receptor 1 
NA -1,35 
88 PN171 Cbl Y700 Signal transduction protein 
CBL 
Q13085 -1,35 
658 NP013-NP014 PP2A/Ca Pan-specific Protein-serine phosphatase 2A 
- catalytic subunit - alpha 
isoform 
Q99683 -1,35 
639 NN156 PLC R(PLCg2) Pan-specific 1-phosphatidylinositol-4,5-
bisphosphate 
phosphodiesterase gamma-2 
P49407 -1,33 
828 NK181 Tyk2 Pan-specific Protein-tyrosine kinase 2 (Jak-
related) 
Q99683 -1,32 
83 NN021-1 Catenin b1 Pan-specific Catenin (cadherin-associated 
protein) beta 1 
Q13541 -1,32 
464 NK106-2 MEK7 (MAP2K7) Pan-specific MAPK/ERK protein-serine 
kinase 7 (MKK7) 
Q13131 -1,31 
615 NK137 PKCg Pan-specific Protein-serine kinase C 
gamma 
P05067 -1,27 
428 NK099-1 MEK1 (MAP2K1) Pan-specific MAPK/ERK protein-serine 
kinase 1 (MKK1) 
Q9UM73  -1,25 
412 PK041 Lck Y505 Lymphocyte-specific protein-
tyrosine kinase 
P35611 -1,22 
84 NN167 Caveolin 1 Pan-specific Caveolin 1 Q13541 -1,21 
846 NK187-2 ZAP70 Pan-specific Zeta-chain (TCR) associated 
protein-tyrosine kinase, 70 kDa 
P15336 -1,21 
584 PK072-3 PKBa (Akt1) S473 Protein-serine kinase B alpha O95757 -1,20 
612 NK136 PKCe Pan-specific Protein-serine kinase C epsilon P34932 -1,20 
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486 NK113-3 MST1 Pan-specific Mammalian STE20-like 
protein-serine kinase 1 (KRS2) 
Q13043 -1,20 
541 NN084 PACSIN1 Pan-specific Protein kinase C + casein 
kinase substrate in neurons 
protein 1 
Q9BY11  1,22 
8 NN135-1 Acetylated Lysine Pan-specific Acetylated Lysine NA 1,42 
513 NN075 NT5E Pan-specific Ecto-5'-nucleotidase (CD73 
antigen) 
P21589 1,56 
672 NK149 PRK2 (PKN2) Pan-specific Protein kinase C-related 
protein-serine kinase 2 
Q16513 1,58 
504 NN071 NFkappaB p65 Pan-specific NF-kappa-B p65 nuclear 
transcription factor 
Q04206 1,59 
508 NK207 NIK (MAP3K14) Pan-specific NF-kappa beta-inducing kinase Q99558 1,71 
512 PN055-1 NR1 S896 N-methyl-D-aspartate (NMDA) 
glutamate receptor 1 subunit 
zeta 
Q05586 1,73 
527 NK120-4 p38a MAPK Pan-specific Mitogen-activated protein-
serine kinase p38 alpha 
Q16539 1,94 
509 NK212 NLK Pan-specific Serine/threonine protein kinase 
NLK 
Q9UBE8  2,02 
530 NK059-1 p38g MAPK 
(Erk6) 
Pan-specific Mitogen-activated protein-
serine kinase p38 gamma 
(MAPK12) 
P53778 2,20 
506 PN156 NFkappaB p65 S529 NF-kappa-B p65 nuclear 
transcription factor 
Q04206 2,65 
499 NK117-4 Nek2 Pan-specific NIMA (never-in-mitosis)-
related protein-serine kinase 2 
P51955 2,79 
495 PN187 NBS1 S343 Nijmegen breakage syndrome 
protein 1 
O60934 2,96 
498 NK117-3 Nek2 Pan-specific NIMA (never-in-mitosis)-
related protein-serine kinase 2 
P51955 3,75 
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Supplementary Table 2B - Antibody list of proteins with significant differential expression between 
shGRPR and scrambled in VCaP. 
No. Antibody 
Codes 
Target Protein 
Name 
Phospho 
Site 
(Human) 
Full Target Protein Name Uniprot 
Link 
Average 
Z-ratio 
288 PN038 Histone H3 S11 Histone H3.3 P84243 -2,29 
111 NK026-5 CDK2 Pan-specific Cyclin-dependent protein-
serine kinase 2 
P24941 -2,16 
408 NK092-2 Lck Pan-specific Lymphocyte-specific protein-
tyrosine kinase 
P06239 -1,95 
630 PK090-1 PKCq S695 Protein-serine kinase C theta Q04759 -1,90 
646 NK146-2 Plk2 Pan-specific Polo-like protein kinase 2 
(serum -inducible kinase 
(SNK)) 
Q9NYY
3 
-1,90 
615 NK137 PKCg Pan-specific Protein-serine kinase C gamma P05129 -1,85 
612 NK136 PKCe Pan-specific Protein-serine kinase C epsilon Q02156 -1,81 
613 NK136-2 PKCe Pan-specific Protein-serine kinase C epsilon Q02156 -1,79 
257 NK065 Fyn Pan-specific Fyn proto-oncogene-encoded 
protein-tyrosine kinase 
P06241 -1,65 
614 PK081-1 PKCe S729 Protein-serine kinase C epsilon Q02156 -1,64 
606 NK135 PKCd Pan-specific Protein-serine kinase C delta Q05655 -1,63 
119 NK028-5 CDK5 Pan-specific Cyclin-dependent protein-
serine kinase 5 
Q00535 -1,62 
315 NN060-2 Hsp70 Pan-specific Heat shock 70 kDa protein 1 P08107 -1,61 
631 NK141 PKCz Pan-specific Protein-serine kinase C zeta Q05513 -1,56 
633 NK143 PKG1 Pan-specific Protein-serine kinase G1 
(cGMP-dependent protein 
kinase) 
Q13976 -1,56 
607 PK077-1 PKCd Y313 Protein-serine kinase C delta Q05655 -1,55 
608 PK077-2 PKCd Y313 Protein-serine kinase C delta Q05655 -1,53 
221 PK168-
PK169 
Erk1 (MAPK3)+ 
Erk2 (MAPK1) 
Y204 Extracellular regulated protein-
serine kinase 1 (p44 MAP 
kinase)+Extracellular regulated 
protein-serine kinase 2 (p42 
MAP kinase) 
P27361 -1,53 
314 NN060 Hsp70 Pan-specific Heat shock 70 kDa protein 1 P08107 -1,52 
604 NK134-2 PKCb2 Pan-specific Protein-serine kinase C beta 2 P05771-
2 
-1,51 
228 NK206-3 Erk5 (MAPK7) Pan-specific Extracellular regulated protein-
serine kinase 5 (Big MAP 
kinase 1 (BMK1)) 
Q13164 -1,48 
470 NK108-2 MEKK2 
(MAP3K2) 
Pan-specific MAPK/ERK kinase kinase 2 Q9Y2U5 -1,45 
176 NN163 DDIT3(CHOP) Pan-specific DNA damage-inducible 
transcript 3 protein 
P35639 -1,44 
478 PK056 MLK3 T277+S281 Mixed-lineage protein-serine 
kinase 3 
Q16584 -1,43 
828 NK181 Tyk2 Pan-specific Protein-tyrosine kinase 2 (Jak-
related) 
P29597 -1,41 
616 PK082-1 PKCg T514 Protein-serine kinase C gamma P05129 -1,38 
584 PK072-3 PKBa (Akt1) S473 Protein-serine kinase B alpha P31749 -1,34 
397 NP004 KAP Pan-specific Cyclin-dependent  kinase 
associated phosphatase (CDK 
inhibitor 3, CIP2) 
Q16667 -1,33 
113 NK026-7 CDK2 Pan-specific Cyclin-dependent protein-
serine kinase 2 
P24941 -1,33 
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393 PN048-2 Jun S73 Jun proto-oncogene-encoded 
AP1 transcription factor 
P05412 -1,30 
396 PN163 Jun T91 Jun proto-oncogene-encoded 
AP1 transcription factor 
P05412 -1,29 
638 PK132 PKR1 T446 Double-stranded RNA-
dependent protein-serine 
kinase (EIF2AK2) 
P19525 -1,29 
625 PK093-1 PKCm (PKD) S910 Protein-serine kinase C mu 
(Protein kinase D) 
Q15139 -1,29 
464 NK106-2 MEK7 (MAP2K7) Pan-specific MAPK/ERK protein-serine 
kinase 7 (MKK7) 
O14733 -1,28 
842 NK186 Yes Pan-specific Yamaguchi sarcoma proto-
oncogene-encoded tyrosine 
kinase 
P07947 -1,27 
398 NN153 KDEL receptor 1 Pan-specific ER lumen protein retaining 
receptor 1 
P24390 -1,27 
579 PK069 PKA R2a S99 cAMP-dependent protein-
serine kinase regulatory type 2 
subunit alpha 
P13861 -1,24 
211 PK013-1 ErbB2 (HER2) Y1248 ErbB2 (Neu) receptor-tyrosine 
kinase 
P04626 -1,21 
76 NN017 CASP7 Pan-specific Caspase 7 (ICE-like apoptotic 
protease 3 (ICE-LAP3), Mch3) 
P55210 -1,20 
486 NK113-3 MST1 Pan-specific Mammalian STE20-like protein-
serine kinase 1 (KRS2) 
Q13043 -1,20 
696 NN092-1 Rac1 Pan-specific Ras-related C3 botulinum toxin 
substrate 1 
P63000 1,20 
562 NN141-1 PDI Pan-specific Protein disulfide-isomerase P07237 1,22 
707 NN093 Rb Pan-specific Retinoblastoma-associated 
protein 1 
P06400 1,23 
144 NN026 Cofilin 1 Pan-specific Cofilin 1 P23528 1,24 
153 PN023 CREB1 S129+S133 cAMP response element 
binding protein 1 
P16220 1,25 
47 NK012 BMX (Etk) Pan-specific Bone marrow X protein-
tyrosine kinase 
P51813 1,26 
41 NN007 Bcl-xL Pan-specific Bcl2-like protein 1 Q07817 1,27 
700 NK155-3 Raf1 Pan-specific Raf1 proto-oncogene-encoded 
protein-serine kinase 
P04049 1,27 
795 NN107 STAT6 Pan-specific Signal transducer and activator 
of transcription 6 
P42226 1,28 
21 NN121 Arrestin b1 Pan-specific Arrestin beta 1 P49407 1,28 
811 PN091 Tau S717 Microtubule-associated protein 
tau 
P10636 1,31 
780 PN078-
PN135 
STAT1a S727 Signal transducer and activator 
of transcription 1 alpha 
P42224 1,35 
166 NN030-1 Cyclin D1 Pan-specific Cyclin D1 (PRAD1) P24385 1,36 
766 NN068-1 SOD (Mn) Pan-specific Superoxide dismutase [Mn] P04179 1,43 
733 PK100-2 RSK1/2 S363/S369 Ribosomal S6 protein-serine 
kinase 1/2 
Q15418 1,43 
796 NN108 STI1 Pan-specific Stress induced phosphoprotein 
1 (Hsc70/Hsp90 organizing 
protein (Hop)) 
P31948 1,43 
270 NN048 Grp78 Pan-specific Glucose regulated protein 78 P11021 1,47 
823 NN111 Trail Pan-specific Tumor necrosis factor-related 
apoptosis-inducing ligand 
P50591 1,48 
2 NN166 4E-BP1 Pan-specific Eukaryotic translation initiation 
factor 4E binding protein 1 
(PHAS1) 
Q13541 1,51 
682 PP003 PTEN S380+T382+
S385 
Phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase 
P60484 1,51 
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and protein phosphatase and 
tensin homolog deleted on 
chromosome 10 
57 NN136-2 Calnexin Pan-specific Calnexin P27824 1,52 
156 NN149-1 Crystallin aB Pan-specific Crystallin alpha B (heat-shock 
20 kDa like-protein) 
P02511 1,56 
58 NN137-1 Calreticulin Pan-specific Calreticulin P27797 1,58 
783 PN080 STAT2 Y690 Signal transducer and activator 
of transcription 2 
P52630 1,62 
776 PK108 Src Y530 Src proto-oncogene-encoded 
protein-tyrosine kinase 
P12931 1,67 
159 PN025 Crystallin aB S19 Crystallin alpha B (heat-shock 
20 kDa like-protein) 
P02511 1,74 
356 PN043 Integrin a4 S1027 Integrin alpha 4 (VLA4) P13612 1,76 
686 NP025 PTP1C Pan-specific Protein-tyrosine phosphatase 
1C (SHP1, SHPTP1, PTPN6) 
P29350 1,81 
138 NK037-1 CK1e Pan-specific Casein protein-serine kinase 1 
epsilon 
P49674 1,83 
685 NP024 PTP1B Pan-specific Protein-tyrosine phosphatase 
1B (PTPN1) 
P18031 1,84 
732 PK100 RSK1/2 S363/S369 Ribosomal S6 protein-serine 
kinase 1/2 
Q15418 1,86 
666 NP021 PP5C Pan-specific Protein-serine phosphatase 5  - 
catalytic subunit (PPT) 
P53041 1,87 
269 NN047 Grp75 Pan-specific Glucose regulated protein 75 P38646 1,89 
390 NN162 Jun Pan-specific Jun proto-oncogene-encoded 
AP1 transcription factor 
P05412 2,01 
788 PN082-1 STAT3 Y705 Signal transducer and activator 
of transcription 3 
P40763 2,02 
163 NN028 Cyclin A Pan-specific Cyclin A1 P78396 2,02 
721 NK159-1 ROCK2 Pan-specific RhoA protein-serine kinase 
alpha 
O75116 2,05 
662 NP018 PP2Cd Pan-specific Protein-serine phosphatase 2C 
- catalytic subunit - delta 
isoform 
O15297 2,08 
798 NN134 Striatin Pan-specific Striatin O43815 2,33 
777 NN102-
NN124 
STAT1a Pan-specific Signal transducer and activator 
of transcription 1 alpha 
P42224 2,75 
720 NK158 RIPK1 Pan-specific Receptor-interacting protein-
serine kinase 1 
Q13546 3,07 
782 NN103 STAT2 Pan-specific Signal transducer and activator 
of transcription 2 
P52630 3,29 
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Supplementary Table 2C - Antibody list of proteins down-regulated between shGRPR and 
scrambled in both LNCaP and VCaP. 
No. Antibody 
Codes 
Target 
Protein Name 
Phospho Site 
(Human) 
Full Target Protein Name Uniprot 
Link 
Average  
Z-ratio 
408 NK092-2 Lck Pan-specific Lymphocyte-specific protein-
tyrosine kinase 
Q07912 -1,95 
646 NK146-2 Plk2 Pan-specific Polo-like protein kinase 2 
(serum -inducible kinase (SNK)) 
P49407 -1,90 
612 NK136 PKCe Pan-specific Protein-serine kinase C epsilon P34932 -1,81 
828 NK181 Tyk2 Pan-specific Protein-tyrosine kinase 2 (Jak-
related) 
Q99683 -1,41 
584 PK072-3 PKBa (Akt1) S473 Protein-serine kinase B alpha O95757 -1,34 
464 NK106-2 MEK7 
(MAP2K7) 
Pan-specific MAPK/ERK protein-serine 
kinase 7 (MKK7) 
Q13131 -1,28 
398 NN153 KDEL receptor 
1 
Pan-specific ER lumen protein retaining 
receptor 1 
NA -1,27 
76 NN017 CASP7 Pan-specific Caspase 7 (ICE-like apoptotic 
protease 3 (ICE-LAP3), Mch3) 
Q13541 -1,20 
486 NK113-2 MST1 Pan-specific Mammalian STE20-like protein-
serine kinase 1 (KRS2) 
Q13043 -1,20 
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Abstract 
 
Gastrin-releasing peptide receptor (GRPR) is known to be overexpressed in several 
human malignancies, including prostate cancer (PCa), and has been implicated in multiple 
important neoplastic signaling pathways. Recently, we have identified GRPR as a target 
of overexpressed ETS transcription factors in PCa and showed that effective knockdown 
of GRPR in LNCaP and VCaP cells attenuates their malignant phenotype. Additionally, we 
identified TYK2, an important element for the enhancement of PCa invasiveness, as a 
downstream target of GRPR overexpression. In this work we aimed to evaluate the anti-
oncogenic potential of a therapy targeting GRPR and TYK2 signaling using in vitro models 
of PCa with ETS rearrangements. Our present work shows that a combination treatment 
targeting both GRPR and TYK2 with the specific inhibitors RC-3095 and Tyrphostin 1, 
respectively, was able to impair the malignant phenotype of LNCaP and VCaP cells, 
supporting a therapeutic potential of GRPR/TYK2 blockade for PCa harboring ETS 
rearrangements.  
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Introduction 
 
Prostate cancer (PCa) is a highly heterogeneous disease and radical prostatectomy 
is the only available treatment with curative intent. A significant proportion of the PCa are 
detected in advanced stage, where the treatment options are limited (1). Genomic 
rearrangements involving members of the ETS family of transcription factors are 
frequently found in PCa, with ERG and ETV1 being rearranged in around 50% and 10% of 
all PCa cases, respectively (2, 3). These aberrant alterations are also present in the 
HGPIN precursor lesions, suggesting a role in early events of prostate carcinogenesis (4-
8). Owing to the high frequency of PCa harboring ERG rearrangements, several studies 
have investigated their association with prognosis, but data are contradictory (2). In 
contrast, ETV1 rearrangements have been consistently associated with more aggressive 
PCa. In 2013, Baena and collaborators associated ETV1-regulated pathways with higher 
Gleason score and metastasis (9), supporting previous reports (10, 11). Considering the 
complexity of transcription factors in general, several groups have attempted to ascertain 
which genes are deregulated upon ERG and ETV1 overexpression, aiming to identify 
alternative downstream targets with therapeutic potential (12).  
In previously studies from our group, we found Gastrin-releasing peptide receptor 
(GRPR) as overexpressed in patients harboring ERG and ETV1 rearrangements (13) and 
further demonstrated the malignant role of GRPR in prostate carcinogenesis (14). GRPR 
is a member of the G-protein coupled receptor superfamily that is overexpressed in 
several human malignancies, being implicated in multiple neoplastic signaling pathways 
(15). In prostate cancer, GRPR overexpression has been identified in radical 
prostatectomy specimens at both mRNA and protein levels (16-19). Additionally, higher 
levels of this protein were also detected in high-grade prostatic intraepithelial neoplasias 
(HGPIN), considered precursor lesions of PCa (17). The discovery of GRPR 
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overexpression in several cancer types led to approaches to inhibit the autocrine growth 
effect of GRP on tumor growth, including receptor antagonists, and several studies have 
reported the antiproliferative effect of GRPR antagonists both in vitro and in vivo in distinct 
tumor models (20, 21).  
Moreover, we demonstrated that TYK2 (tyrosine kinase 2), a member of the Janus 
family of non-receptor tyrosine kinases (JAKs), is a target of the GRPR oncogenic 
pathway, being equally deregulated in ETS-positive PCa (14). Members of the JAK family 
play important roles in cellular growth, development, differentiation, survival and apoptosis 
of various cell types (22), and some reports have demonstrated that JAKs are expressed 
in prostate cancer tissues and cell lines (23, 24). The particular role of TYK2 in cancer has 
been extensively studied, with overexpression being described in several breast cancer 
cell lines, prostate cancers and squamous cervical carcinomas (25-27). Ide and 
collaborators further showed that blockade of TYK2 signaling by a small interfering RNA 
or by the JAK inhibitor tyrphostin A1 impaired the invasion capacity in human prostate 
cancer cells (25). The mechanism of how TYK2 contributes to the invasiveness of 
malignant cells is not completely understood, although reports have emerged implicating 
Jak/Stat signaling on tissue infiltration (28-30) and on regulation of metalloproteinases 
expression, important elements of metastasis (31-33). Considering the oncogenic role of 
TYK2 in prostate carcinogenesis and its overexpression in tumors harboring ETS 
rearrangements, a combined therapy of a GRPR antagonist and a TYK2 inhibitor may be 
a promising therapeutic approach for prostate carcinomas with ETS rearrangements. In 
this work, we aimed to evaluate the potential of an anti-oncogenic therapy targeting GRPR 
and TYK2 signaling using in vitro models of PCa with ETS rearrangements.  
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Methods 
 
Cell lines and reagents 
 The human prostate cell lines used in this study were LNCaP and VCaP, which 
were maintained in standard growth conditions, as previously described (14). Cultures 
were considered Mycoplasma-free by routine testing for Mycoplasma spp. contamination 
(PCR Mycoplasma Detection Set; Clontech Laboratories Inc., Mountain View, CA, USA). 
 The GRPR antagonist RC-3095 (R9653; Sigma-Aldrich, St. Louis, MO, USA) was 
dissolved in 0.1% dimethyl sulphoxide (DMSO; Sigma-Aldrich) in PBS and the TYK2 
antagonist Tyrphostin 1 (T7040-25MG; Sigma-Aldrich) was dissolved in dimethyl 
sulphoxide (DMSO; Sigma-Aldrich) to a concentration of 50 mM. 
 
IC50 assay 
 To establish the dose-response curve of Tyrphostin 1, the cell viability of VCaP 
and LNCaP cell lines was assessed using the MTT assay in the presence of different 
concentrations of Tyrphostin 1. The IC50 value was determined by the concentration of 
Tyrphostin 1 (Tyr1) that was required for 50% of cell inhibition at 24 hours of treatment 
(Figure 1). For the anti-GRPR treatment, cells were exposed to concentrations of RC-
3095 previously describe (1 and 10 µM) (34-36).   
 
Cell proliferation and apoptosis assays 
 The MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay 
and the apoptosis assay (Biocolor, Newtownabbey, Northern Ireland) were performed as 
previously described (14). LNCaP (1.0x104) and VCaP cells (2.5x104) were seeded in 96-
well plates (Sarstedt AG & Co, Nümbrecht, Germany) in 200 μL of serum-containing 
medium and incubated in normal growth conditions until cell adherence. For the anti-
GRPR treatment, cells were exposed to two concentrations of RC-3095 (1 and 10 µM) 
(34-36). For the anti-TYK2 treatment, cells were exposed to 300 nM of Tyrphostin 1, 
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following to the concentration determined by the IC50 assay for both cell lines. For the 
combined treatments, cells were exposed to two different combinations of RC-3095 (1 and 
10 µM) with 300 nM of Tyrphostin 1. Cells exposed to DMSO at 0.1% were used as 
control for both RC-3095 and/or Tyrphostin 1 treatments. At 24 hours after treatment the 
viability and apoptosis assays were performed. For viability measurement, treatment 
medium was replaced by medium containing MTT at 1mg/mL (Sigma-Aldrich, Schnelldorf, 
Germany) and incubated for 1 hour in regular growth conditions. The MTT solution was 
removed and formazan crystals were dissolved using DMSO (Sigma-Aldrich) in constant 
stirring for 15 minutes. Absorbance levels were measured using a microplate reader 
(Fluostar Omega, BMG Labtech, Offenburg, Germany) at a wavelength of 540 nm with 
background deduction at 630 nm. For quantification of apoptosis levels, cells were stained 
with APOPercentage dye for 1 hour and washed twice with PBS to remove non-cell bound 
dye. Dye Release Reagent was added to each well and the plate was shaked for 10 
minutes. The absorbance levels were measured using the microplate reader (Fluostar 
Omega) at a wavelength of 550nm. 
 
Invasion assay 
 Cell invasion through a three-dimensional extracellular matrix was evaluated by a 
Matrigel invasion assay using BD Matrigel Invasion Chambers (BD Biocoat, Bedford, MA, 
USA) with 8.0 µm pore, as previously described (14). Briefly, the matrigel-coated transwell 
chambers were rehydrated and 2.5x104 LNCaP cells and 5.0x104 VCaP cells, 
resuspended in 500 µL of serum-free medium, were plated in triplicate. For the anti-GRPR 
and anti-TYK2 treatments, cells were exposed to either 10 µM of RC-3095 or 300 nM of 
Tyrphostin 1, respectively. Cells exposed to DMSO at 0.1% were used as control for both 
treatments. After 48 or 72 hours (LNCaP and VCaP, respectively), cells in the upper 
surface of the transwell chambers were washed, and the invaded cells at the lower 
surface were fixed, stained with DAPI and counted under the microscope.  
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Statistical analysis 
 All in vitro data were carried out in triplicate and three independent experiments 
were performed. Statistical analyses were conducted using SPSS software (IBM-SPSS 
Inc., Chicago, IL, USA) and data analyzed by paired Student's t test. Graphs were built 
using GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). All p 
values are based on two-sided hypothesis testing and p<0.05 was considered statistically 
significant. 
 
 
Results 
 
Combinatory inhibition of GRPR and TYK2 signaling impairs cell viability and 
induces apoptosis 
 To evaluate the impact of inhibition of GRPR and TYK2 signaling in the early-stage 
characteristics of prostate cancer cells in the context of ERG and ETV1 rearrangements, 
proliferation and apoptosis were assessed. GRPR signaling inhibition by the specific 
antagonist RC-3095 at 10 µM was only effective in LNCaP cells, which displayed a 
significantly reduced cell viability of 17% comparing with control (Fig. 2A). Likewise, the 
TYK2 signaling inhibition by Tyrphostin 1 at 300 nM was only effective in the LNCaP cell 
line, leading to a significant 28% decrease of cell viability (Fig. 2A). When both drug 
dosages were used in combination, a significant decrease of cell viability was observed in 
both LNCaP and VCaP cell lines, showing 50% and 80% decrease, respectively (p<0.01; 
Fig. 2A). The lower dosage of RC-3095 (1 µM) in combination with 300 nM of Tyrphostin 1 
showed an equally significant decrease of cell viability in LNCaP cells, reaching around 
46% viability decrease (p<0.01), but had no significant impact in VCaP cells. Only the 
blockade of both GRPR and TYK2 in combination was significantly effective in inducing 
apoptosis. In fact, both dose combinations of RC-3095 (1 and 10 µM) with Tyrphostin 1 
led to significant increase in apoptosis levels in both prostate cell lines, reaching 3.0- and 
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5.8-fold increase for the higher RC-3095 dosage combination in LNCaP and VCaP, 
respectively (Fig. 2B). 
 
RC-3095 and Tyrphostin 1 combination treatment decreases the invasion capacity 
of prostate cancer cells 
 To evaluate whether the GRPR antagonist and the TYK2 inhibitor were efficient in 
inhibiting the phenotypic characteristics of advanced prostate carcinomas, we evaluated 
the impact of RC-3095 and Tyrphostin1 treatment, respectively, in the invasion potential. 
Comparing with control cells, in vitro treatment with RC-3095 at 10 µM in combination with 
300 nM of Tyrphostin 1 significantly decreased the invasion ability of both LNCaP and 
VCaP prostate cell lines (of around 62% and 30%, respectively; p<0.05) (Fig. 3). On the 
other hand, isolated treatment with RC-3095 or Tyrphostin 1 was ineffective on cell 
invasion inhibition in both cell lines (Fig. 3). 
  
 
Discussion 
Considering the relevance of ETS rearrangements in a significant proportion of 
prostate carcinomas, the identification and characterization of the downstream targets is 
crucial to define the signaling pathways that are deregulated by ETS overexpression and 
to define new therapeutic target options to this particular subset of PCa. Several studies 
have described GRPR as a therapeutic target and support the relevance of this receptor 
as an important activator of oncogenic signaling pathways in PCa cells. In our recent 
work, we reported for the first time the oncogenic role of GRPR in different biological 
processes of prostate cancer progression in an ETS-positive context, and identified TYK2 
as a GRPR target potentially involved in cancer-associated signaling pathways, namely 
invasion (14). Given the observed deregulation of these two oncogenic players in prostate 
cancers (14), we decided to test their potential as therapeutic targets by evaluating the 
phenotypic impact of GRPR and TYK2 blockade in vitro. Our present work shows that a 
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combined treatment targeting both GRPR and TYK2 with specific inhibitors is efficient in 
inhibiting both early-stage and more advanced phenotypic characteristics of prostate 
carcinomas in vitro, in the context of ERG and ETV1 rearrangements. In fact, the drug 
combination with 10 µM RC-3095 and 300 nM Tyrphostin 1 was able to decrease both 
proliferation and invasion, while increasing apoptosis.  
Several studies have demonstrated the strong inhibitory effect of GRPR 
antagonists on distinct tumors models, including prostate cancer cell lines (PC-3, DU-145, 
MDA-PCa-2b) (20, 37-39). The RC-3095 is a small molecule that binds to the extracellular 
domain of the receptor, leading to an inhibition of tumor growth in several experimental 
models, through a number of different mechanisms that are not completely understood 
(40). Nevertheless, and considering the preclinical antitumor activity of RC-3095, a phase 
I clinical trial was conducted in which RC-3095 was administered to 25 patients with 
different advanced solid malignancies, including six cases with PCa. In this initial study, 
no side effects were observed but tumor-reducing effects were also not convincing (41). 
Despite the inclusion of PCa individuals in this study cohort, no information was available 
regarding ETS status. According to our data, the pilot study could have benefited from a 
more accurate selection of the PCa patients based on the ETS rearrangement status of 
the prostate carcinomas, a molecular subtyping that is nowadays possible. 
TYK2 overexpression has been observed in several malignancies, such as breast 
cancer cell lines, prostate cancer and squamous cervical carcinomas (22), and some 
studies have described the involvement of this tyrosine kinase in enhancing prostate 
cancer invasion (25, 42). Ide and collaborators have demonstrated that TYK2 signaling 
blockade by the JAK inhibitor tyrphostin 1 at 100 µM impaired the invasion capacity in the 
DU-145 human prostate cancer cells (25), although the same drug dosage was not 
efficient to impair DU-145 cell proliferation. In the present study, the reported drug dosage 
was not able on its own to affect the phenotypic characteristics of any of the cell lines 
used (LNCaP and VCaP) (data not shown). 
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Considering the worst prognosis described for ETV1-positive PCa (Attard et al. 
2008, Shin et al. 2009, Baena et al. 2013) and our previous observations of a higher 
GRPR and TYK2 protein expression in prostate carcinomas harboring ETV1 
rearrangements (14), together with the fact that single treatments with RC-3095 or 
Tyrphostin 1 were only efficient in the LNCaP cell line that harbors an ETV1-
rearrangement, a combined therapy of RC3095 antagonist and a tyrosine kinase inhibitor 
targeting for TYK2 seems to be a promising and more effective approach to drive 
antitumor activity in prostate carcinomas with ETV1 rearrangements. Nevertheless, the 
elucidation of the application of the combined treatment approach in other prostate human 
cell lines, as well as in other human cancer cell line models, requires further investigation. 
Moreover, in vivo studies are also crucial to test the possible therapeutic application of this 
combined treatment in PCa. Furthermore, our data show that the dual GRPR/TYK2 
inhibition may be effective also in inducing apoptosis in PCa characterized by the common 
ERG rearrangements in addition to those involving ETV1, being a therapeutic strategy 
potentially applicable to about 60% of PCa. 
In conclusion, our data provides further evidence to support a therapeutic effect of 
GRPR/TYK2 blockade in PCa harboring ETS rearrangements by showing that combined 
treatment of RC-3095 and Tyrphostin 1 drastically impairs the in vitro tumorigenic 
behavior of PCa cell lines with these rearrangements.  
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Figure 1: Dose-response curve of Tyrphostin 1 in VCaP (left) and LNCaP (right) cell lines, 
assessed with the MTT assay. 
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Figure 2: Impact of GRPR and/or TYK2 inhibition in the cell viability and apoptosis of the 
LNCaP and VCaP cells at 24 hours after treatment. (A) Quantitative analysis of 
metabolically active cells by the MTT assay. (B) Quantitative analysis of the apoptotic 
levels. For both assays, results are shown for treated cell populations relative to the 
control cells, from three independent experiments. Statistically significant p values are 
showed by an asterisk (*p<0.05; **p<0.01). RC1, RC-3095 at 1 µM; RC10, RC-3095 at 10 
µM; Tyr300, Tyrphostin 1 at 300 nM. 
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Figure 3: Evaluation of the impact of GRPR and/or TYK2 inhibition in the invasive ability 
of LNCaP and VCaP cells, using Matrigel Invasion Chambers. Results are shown for 
treated cell population relative to the control cells, from three independent experiments. 
Statistically significant p values are showed by an asterisk (*p<0.05). RC10, RC-3095 at 
10 µM; Tyr300, Tyrphostin 1 at 300 nM. 
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PCa is still a major health concern worldwide, mainly due to insufficient biological 
knowledge about its onset and progression (Shen and Abate-Shen 2010). Considering the 
complexity and heterogeneity of PCa, there is no standard treatment for all patients. The 
selection of the optimal therapeutic approach is based on several individual features, and 
the therapeutic options available range from active surveillance, radical prostatectomy and 
radiation therapy to hormone and/or radiation therapy and chemotherapy. Nowadays, the 
challenge is to distinguish men with aggressive local disease for whom treatment might be 
useful from those with indolent disease for whom treatment would bring a decrease in life 
quality (DeVita et al. 2008). Concerning PCa therapeutic strategies, there is an urgent 
need to develop new and better therapeutic options. Increasing the knowledge on the 
molecular biology of PCa carcinogenesis is therefore crucial to identify efficient 
biomarkers for early detection, distinguish between indolent and aggressive PCa, and to 
develop new and more effective therapies.  
Genomic rearrangements involving members of the ETS family of transcription 
factors are frequently found in PCa, with ERG and ETV1 being rearranged in about 50% 
and 10% of all PCa cases, respectively (Kumar-Sinha et al. 2008, Clark and Cooper 
2009)(Cerveira et al. 2006, Perner et al. 2007, Clark et al. 2008, Park et al. 2010, van 
Leenders et al. 2011). Owing to the high frequency of PCa patients harboring ETS 
rearrangements, several studies have explored their association with prognosis, although 
the relevance of these rearrangements in prostate carcinogenesis is still poorly 
understood (Clark and Cooper 2009). Only ETV1 rearrangements have been regularly 
associated with a more aggressive PCa. However, therapeutic targeting of ETS and other 
transcription factors has been challenging due to their nuclear localization and molecular 
embedding in DNA–protein and protein–protein complexes. Consequently, it has been of 
utmost importance to identify and to characterize the downstream molecular targets of 
ETS rearrangements, as this knowledge might bring further insight on current 
understanding of prostate carcinogenesis, identify potential biomarkers, and ascertain 
potential targeted therapies.  
In a previous work in our group key players of the overexpressed ETS transcription 
factors in PCa were described using a genome-scale and gene-level expression 
microarray platform (Paulo et al. 2012). Specific and/or shared target genes were 
identified, which helped to clarify the signaling pathways deregulated in each molecular 
subtype of PCa. Because ERG and ETV1 belong to the same family of transcription 
factors, the existence of shared target genes was expected. In fact, in the study above 
mentioned, a list of 27 target genes shared by ERG and ETV1 rearrangements were 
reported, seven of which were validated by cell line models. Additionally, direct binding of 
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ERG to the promoter of some of these genes were also demonstrated by ERG-
immunoprecipitated chromatin from VCaP cells (Paulo et al. 2012). Among them the top 
most interesting gene was GRPR, which encodes for the gastrin-releasing peptide 
receptor and has been described as overexpressed in several cancer types, including 
PCa (Cornelio et al. 2007, Beer et al. 2012). Considering the overexpression of GRPR in 
a high proportion of PCa that harbor either ERG or ETV1 rearrangements, the cellular 
localization of its protein product, the relevance of its function, the availability of blocking 
agents and the previous reports of GRPR overexpression in several neoplasms, including 
PCa, make this an interesting downstream target.  
 
1. Overexpression of GRPR in prostate tumors and cell lines harboring ERG and 
ETV1 rearrangements  
As a first step, validation of the differential expression of GRPR between non-
malignant prostate samples and PCa with and without ETS rearrangements was 
performed in a partially independent series of 160 PCa and 15 morphologically normal 
prostate tissues (NPT) by real time RT-PCR (Paper I). Although GRPR overexpression 
was observed in all subtypes of PCa comparing with NPT samples, stratification of the 
samples by their ETS status showed that GRPR overexpression was particularly elevated 
in both ERG and ETV1 rearrangement positive PCa comparing with NPT samples and 
also with ETS-negative PCa. Additionally, the expression of GRPR, both at mRNA and 
protein levels, was detected in the ERG and ETV1 rearrangement positive prostate cancer 
cell lines VCaP and LNCaP, respectively.  
 
2. Stable knockdown of GRPR in LNCaP and VCaP cells attenuates their malignant 
phenotype 
To evaluate the oncogenic role of GRPR, two independent silenced populations 
(shGRPR#1 and shGRPR#2) were successfully established for each cell line model using 
the shRNA Lentiviral Particles Transdution System with specific short-hairpin RNAs and 
scrambled shRNA lentiviral particle as biological negative control.  
Although GRPR and its specific peptide have been associated with an oncogenic 
role in different tissues and models, Paper 1 is the first report ascertaining the malignant 
impact of this receptor in prostate carcinogenesis. In this work, the impact of GRPR 
silencing in the acquisition of early-stage characteristics, as well as in the phenotypic 
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characteristics of advanced prostate cancer cells, in the context of ERG and ETV1 
rearrangements, was clearly demonstrated. In fact, GRPR silenced cell populations 
(shGRPR) of both cell line models displayed a decline of early malignant features of PCa 
phenotype through reduction of cell viability and increment of apoptosis. Furthermore, the 
impact of GRPR silencing was evaluated in the phenotypic characteristics of advanced 
prostate cancer cells, namely invasion potential and in the capacity to grow without 
attachment. Using the in vitro Matrigel invasion assay, we were able to demonstrate that 
GRPR silencing in both cell lines significant reduces about 50% of their invasion ability. 
Similarly, looking at the capacity of cells to grow without attachment, cell populations with 
stable GRPR silencing developed about 50% fewer colonies than scrambled controls. 
 
3. Downstream pathway targets of GRPR   
The observed phenotypic effects of GRPR silencing prompted us to look for 
potential GRPR target proteins using the KAM-850 antibody microarray, which contains 
over 850 antibodies pan- and phospho site-specific, with wide coverage of cell signaling 
proteins and pathways frequently deregulated in tumorigenesis. This platform was used to 
compare the differential protein expression patterns between scrambled and shGRPR 
populations in both LNCaP and VCaP cell line models. In order to find potential 
oncogenes regulated by GRPR that could be interesting for targeted therapy of PCa with 
ETS rearrangements, focus was directed to down-regulated targets shared by both cell 
lines. Through this analysis, a list of nine proteins with decreased expression levels in 
both cell lines was found and, based on their cell pathway association, we concentrated 
our attention in five of them: PLK2, TYK2, MST1, p-AKT1 (Ser473) and p-PKCε (Ser729). 
We next evaluated by western blotting whether the in vitro association between the 
expression of GRPR and these potential targets, under an ETS-rearrangement context, 
was observed also in vivo. This approach showed that, overall, the expression of AKT1 
was higher in PCa samples when compared with NPT. Interestingly, tumors with ETV1 
rearrangement showed consistently higher expression of TYK2, MST1 and p-AKT1, when 
compared with both NPT and other PCa subgroups, in which the expression pattern of 
those proteins was shown to be highly heterogeneous. Regarding PKCε and p-PKCε 
expression, both ETV1 and ERG rearrangement-positive PCa samples showed 
consistently higher expression when compared with NPT, although high protein levels 
were also detected in some ETS-negative PCa. 
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Multiple molecular pathways are involved in proliferation and survival of prostate 
cancer cells during tumor progression. Among these survival signaling pathways, up-
regulation of the PI3K/Akt/mTOR pathway is particularly important, as it has been strongly 
implicated in tumor progression, mostly considering its role in survival enhancement and 
apoptosis inhibition (Morgan et al. 2009). Thus, the observed significant increase in 
apoptosis levels and the reduction of cell viability after GRPR knockdown could be related 
to a disturbance of the PI3K/Akt pathway via down-regulation of p-AKT1 (Ser473). 
Considering the increased levels of p-AKT1 (Ser473) observed in tumors harboring ETS 
rearrangements, these observations support the hypothesis that ETS overexpression up-
regulates the expression of GRPR and subsequently leads to up-regulation of p-AKT1 
(Ser473), placing ETS transcription factors as upstream regulators of GRPR 
overexpression in PCa. Concerning PKCε, a protein kinase described to be 
overexpressed in several solid tumors (including PCa), we also found its overexpression 
in ETS-positive tumors. However, PKCε seemed to be more dependent on the ETS 
context than on the GRPR overexpression, as no significant effect was observed on 
PKCε/p-PKCε expression upon silencing of GRPR in both cell line models (VCaP and 
LNCaP) and a significant decrease of p-PKCε was observed in LNCaP cells upon 
silencing of ETV1. In fact, p-PKCε was identified as the active kinase that phosphorylates 
AKT1 at serine 473, leading to full AKT activation (Zhang et al. 2005). We therefore 
suggest a link between ETS overexpression and increased PKCε/p-PKCε expression, as 
a GRPR alternative mediator of p-AKT1 (Ser473) activation. These findings are in 
agreement with studies proposing that high levels of ETS protein collaborate with 
constitutively activated AKT kinase, leading to the development of more aggressive PCa 
(Zong et al. 2009). 
Moreover, we have demonstrated that GRPR plays an important role in anchorage-
independent growth and invasion in prostate cancer, as GRPR silencing led to a 
significantly decrease in the invasive capacity of both LNCaP and VCaP cell lines. This 
observation could be a consequence of down-regulation of TYK2 and MST1 expression, 
as observed by immunoblotting of GRPR silenced populations from both cell lines. In fact, 
overexpression of TYK2 (a member of the Janus family of non-receptor tyrosine kinases, 
JAKs) has been described in several malignancies, such as breast cancer cell lines, 
prostate cancers and squamous cervical carcinomas (Ide et al. 2008, Song et al. 2008, 
Zhu et al. 2009), with some studies showing its involvement in enhancing prostate cancer 
invasion (Ide et al. 2008). Likewise, the signaling initiated by the binding of MST1 to its 
receptor (MST1R) is an important pathway for invasive growth in different neoplasias (Yao 
et al. 2013). However, we were only able to detect strong expression of both TYK2 and 
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MST1 proteins in ETV1-positive PCa, and silencing of ETV1 in LNCaP cells only showed 
a significant effect in the expression of TYK2, but not in MST1. These observations may 
indicate that both GRPR and ETV1 regulate the expression of TYK2 and MST1, which 
potentially act cumulatively when overexpression of both is present.  
A decrease in PLK2 expression was also observed in GRPR silenced cell 
populations, with higher impact in LNCaP cells, however the opposite effect was observed 
in response to ETV1 silencing in the LNCaP cell line. This suggests that PLK2 expression 
levels would be the result of a balance between the two factors, with ETV1/ETS 
transcription factors acting as repressors and GRPR as an activator. Nevertheless, no 
information was obtained from our series of prostate tissues, since PLK2 expression was 
not detected in any of the samples analyzed using two different antibodies. This 
observation, however, is in accordance to the low PLK2 expression levels described for 
normal and tumorous prostate tissues, suggesting that PLK2 expression levels in cell lines 
may result from adaptation to in vitro conditions, further illustrating the importance of 
looking into tumor samples to validate in vitro associations. 
 
 
4. Therapeutic potential of dual GRPR and TYK2 inhibition in prostate cancer 
harboring ETS rearrangements 
 
Several studies have described GRPR as a therapeutic target and support the 
relevance of this receptor as an important activator of oncogenic signaling pathways in 
PCa cells. In Paper I, we reported for the first time the oncogenic role of GRPR in different 
biological processes of prostate cancer progression in an ETS-positive context, and 
identified TYK2 as a GRPR target potentially involved in cancer-associated signaling 
pathways, namely invasion. Given the observed deregulation of these two oncogenic 
players in prostate cancers, we aimed to evaluate the anti-oncogenic potential of a 
therapy targeting GRPR and TYK2 signaling using in vitro models of PCa with ETS 
rearrangements (Paper II).  
To evaluate the impact of inhibition of GRPR and TYK2 signaling in the early-stage 
characteristics of prostate cancer cells in the context of ERG and ETV1 rearrangements, 
proliferation and apoptosis were assessed. GRPR signaling inhibition by RC-3095 or 
TYK2 signaling inhibition by Tyrphostin 1 were only effective in LNCaP cells. When both 
drugs were used in combination, a significant decrease of cell viability was observed in 
both LNCaP and VCaP cell lines, showing 50% and 80% decrease, respectively. 
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Concerning increasing apoptosis levels, only the dual blockade of GRPR and TYK2 was 
significantly effective. Additionally, to evaluate whether the GRPR antagonist and the 
TYK2 inhibitor were efficient in inhibiting the phenotypic characteristics of advanced 
prostate carcinomas, we evaluated the impact of RC-3095 and Tyrphostin1 treatment, 
respectively, in the invasion potential. Once again, the isolated treatment with RC-3095 or 
Tyrphostin 1 was ineffective on cell invasion inhibition in both cell lines, but the combined 
treatment with RC-3095 and Tyrphostin 1 significantly decreased the invasion ability of 
both LNCaP and VCaP prostate cell lines (of around 62% and 30%, respectively). We 
have therefore revealed that a combined treatment targeting both GRPR and TYK2 with 
specific inhibitors is efficient in inhibiting both early-stage and more advanced phenotypic 
characteristics of prostate carcinomas in vitro, in the context of ERG and ETV1 
rearrangements. In fact, the drug combination with 10 µM RC-3095 and 300 nM 
Tyrphostin 1 was able to decrease both proliferation and invasion, while increasing 
apoptosis.  
Several studies have demonstrated the strong inhibitory effect of GRPR antagonists 
on distinct tumors models, including prostate cancer cell lines (PC-3, DU-145, MDA-PCa-
2b) (Stangelberger et al. 2005a, Stangelberger et al. 2005b, Stangelberger et al. 2005c, 
Hohla and Schally 2010). Considering the preclinical antitumor activity of RC-3095, a 
phase I clinical trial was conducted in which RC-3095 was administered to 25 patients 
with different advanced solid malignancies, including six cases with PCa, in whom no side 
effects were observed but tumor-reducing effects were also not convincing 
(Schwartsmann et al. 2006). According to our present data, the pilot study could have 
benefited from a more accurate selection of the PCa patients based on the ETS 
rearrangement status of the prostate carcinomas, a molecular subtyping that is nowadays 
possible. 
Several studies have investigated the association between ETS rearrangements 
with prognosis. Concerning ERG rearrangements the data obtained is contradictory. In 
contrast, ETV1 rearrangements have been consistently associated with more aggressive 
PCa. ETV1-regulated pathways were effectively associated to higher Gleason score and 
metastasis (Baena et al. 2013). Considering the worst prognosis described for ETV1-
positive PCa and our previous observations of a higher GRPR and TYK2 protein 
expression in prostate carcinomas harboring ETV1 rearrangements (Paper I), together 
with the fact that single treatments with RC-3095 or Tyrphostin 1 were only efficient in the 
LNCaP cell line that harbors an ETV1-rearrangement, a combined therapy of GRPR 
antagonist and a tyrosine kinase inhibitor targeting TYK2 seems to be a promising and 
more effective approach to drive antitumor activity in prostate carcinomas with ETV1 
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rearrangements. Furthermore, our data show that the dual GRPR/TYK2 inhibition may be 
effective also in inducing apoptosis in PCa characterized by the common ERG 
rearrangements in addition to those involving ETV1, being a therapeutic strategy 
potentially applicable to about 60% of PCa. 
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The aims of this thesis were addressed in the included publications and the 
following conclusions can be presented: 
- The differential expression of GRPR between non-malignant prostate samples 
and PCa with and without ETS rearrangements was evaluated and this work has 
confirmed the striking GRPR overexpression in both ERG and ETV1 
rearrangement-positive PCa comparing with NPT samples and also with ETS-
negative PCa; 
 
- The oncogenic role of GRPR in different biological processes of prostate cancer 
progression was demonstrated through evaluation the phenotypic impact of 
GRPR silencing in prostate cancer cells in the context of ERG and ETV1 
rearrangements;  
 
- Downstream players of GRPR/ETS involved in cancer-associated signaling 
pathways, namely PLK2, TYK2, MST1, p-AKT1 (Ser473), and p-PKCε (Ser729), 
were identified; 
 
- A combination treatment targeting both GRPR and TYK2 with the specific 
inhibitors RC-3095 and Tyrphostin 1, respectively, was able to impair the 
malignant phenotype of LNCaP and VCaP cells, supporting a therapeutic 
potential of dual GRPR/TYK2 blockade for PCa harboring ETS rearrangements. 
 
 
 
 
 
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
 
Chapter 7 
 
 
 
FUTURE PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
 
The combination treatment targeting both GRPR and TYK2 with the specific 
inhibitors was able to impair the malignant phenotype of LNCaP and VCaP cells, 
supporting a therapeutic potential of dual GRPR/TYK2 blockade for PCa harboring ETS 
rearrangements. However, further in vitro and in vivo studies are crucial to test the 
possible therapeutic application of this combined treatment in PCa. There are already two 
ongoing studies on this issue: 
 
I. To ascertain the impact of inhibition of GRPR and TYK2 signaling in the early-
stage and advanced characteristics of prostate carcinomas in the context of de 
novo expression of ERG and ETV1 in the PNT2 benign prostate cell line, 
proliferation, apoptosis and invasion potential will be evaluated in the presence 
of specific inhibitors targeting GRPR and TYK2. 
 
II. To evaluate the impact of a therapy targeting GRPR and TYK2 signaling in in 
vivo models, subcutaneous mouse xenographs will be developed. 
Subcutaneous injection of LNCaP and VCaP cells will promote the development 
of a tumor xenograph, and the effect of the combination treatment targeting 
GRPR and TYK2 with the specific inhibitors will be assessed.  
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